    		                		            		                                                                                                                                          	    		   		   	  	       	            							    	    																																			    																	    	    	                             		       	                                                                                                   	        						    	    																																			    																	    	    	                             		       	                                                                                               									    	    																																			    																	    	    	                             		       	                                                                                               									    	    																																			    																	    	    	                             		       	                                                                                               	            			        	                            						    	    																																			    																	    	    	                             		       	                                                                                                                                                                                                                                                                                                                                                                                                                           	        	                                                                                                                                                                                                                                                     <!DOCTYPE html><html><head>        	<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" />    <meta charset="utf-8" />        	<title>DailyMed - XARELTO- rivaroxaban tablet, film coated  XARELTO- rivaroxaban    </title>                <!--[if lt IE 9]>        <script src="//html5shim.googlecode.com/svn/trunk/html5.js"></script>    <![endif]-->    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/skeleton.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/jquery.jqzoom.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/style.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/header-search.min.css" />    <link rel="stylesheet" type="text/css" media="all" href="dailymed/css/responsive.min.css" />    <link rel="stylesheet" type="text/css" media="print" href="dailymed/css/print.min.css" />    <!--[if !IE]><!-->    <link rel="stylesheet" type="text/css" media="all" href="dailymed/css/responsive-tables.min.css" />    <!--<![endif]-->    <link rel="icon" href="dailymed/images/favicons/favicon.ico" type="image/x-icon" />    <link rel="shortcut icon" href="dailymed/images/favicons/favicon.ico" type="image/x-icon"/>        <link rel="apple-touch-icon" sizes="57x57" href="dailymed/images/favicons/apple-touch-icon-57x57.png">    <link rel="apple-touch-icon" sizes="114x114" href="dailymed/images/favicons/apple-touch-icon-114x114.png">    <link rel="apple-touch-icon" sizes="72x72" href="dailymed/images/favicons/apple-touch-icon-72x72.png">    <link rel="apple-touch-icon" sizes="144x144" href="dailymed/images/favicons/apple-touch-icon-144x144.png">    <link rel="apple-touch-icon" sizes="60x60" href="dailymed/images/favicons/apple-touch-icon-60x60.png">    <link rel="apple-touch-icon" sizes="120x120" href="dailymed/images/favicons/apple-touch-icon-120x120.png">    <link rel="apple-touch-icon" sizes="76x76" href="dailymed/images/favicons/apple-touch-icon-76x76.png">    <link rel="apple-touch-icon" sizes="152x152" href="dailymed/images/favicons/apple-touch-icon-152x152.png">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-196x196.png" sizes="196x196">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-160x160.png" sizes="160x160">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-96x96.png" sizes="96x96">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-16x16.png" sizes="16x16">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-32x32.png" sizes="32x32">    <meta name="msapplication-config" content="/dailymed/images/favicons/browserconfig.xml" />    <meta name="msapplication-TileColor" content="#da532c">    <meta name="msapplication-TileImage" content="/dailymed/images/favicons/mstile-144x144.png">    <meta name="description" content="" />    <meta name="keywords" content="" />     <meta name="robots" content="noimageindex, noodp, noydir" />     <meta name="viewport" id="viewport" content="width=device-width,minimum-scale=1.0,maximum-scale=10.0,initial-scale=1.0" />    <script src="/dailymed/scripts/modernizr-2.0.6.min.js"></script>        <script type="text/javascript" src="//ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js"></script>        <script type="text/javascript">        if (typeof jQuery == 'undefined')        {              document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-1.10.2.min.js">\x3C/script>');        }    </script>                	                	            	    	<script type="text/javascript">		var basepath = "/dailymed";;		var availableClasses =  new Array();;		for(var i = 0; i < availableClasses.length; i++){			availableClasses[i] = availableClasses[i].replace(/"/g, '').trim();		}		var labeltitle = "XARELTO- rivaroxaban tablet, film coated <br>XARELTO- rivaroxaban   <br>";;		var emailLink = "";;		var emailrequest = "0";;	</script>    <script src="/dailymed/scripts/javascript-html-attribute-encoding.min.js"></script>	<script src="/dailymed/scripts/scripts.min.js"></script>        <script type='text/javascript' src="//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/jquery-ui.min.js"></script>    <script type="text/javascript">        if (typeof jQuery.ui == 'undefined')        {            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-ui-1.10.4.custom.min.js">\x3C/script>');            document.write('\x3Clink rel="stylesheet" type="text/css" media="all" href="dailymed/css/jquery-ui-1.10.4.custom.min.css">');        }        else{            document.write('<link rel="stylesheet" href="/ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/themes/smoothness/jquery-ui.min.css">');        }    </script>    <script type='text/javascript' src='/dailymed/scripts/jquery.elevateZoom-3.0.8.min.js'></script>      <script type="text/javascript" src="/dailymed/scripts/jquery.placeholder.min.js"></script>    <script src="//www.accessdata.fda.gov/spl/stylesheet/spl.js" type="text/javascript" charset="utf-8">/* */</script>    <!-- Magnific Popup core CSS file -->    <link rel="stylesheet" href="dailymed/css/magnific-popup.min.css">        <!-- Magnific Popup core JS file -->    <script src="/dailymed/scripts/jquery.magnific-popup.js"></script>        <meta name = "format-detection" content = "telephone=no"></head><body class="inner drug-info">	<div class="container_1000 bg_shadow">        <div style="width: 0; height: 0;"><a href="#" id="top-of-page"></a></div><header>	<div class="topHeader">				<ul id="skip">		<li><a href="#skip-main-content">Skip to Main Content</a></li></ul>		<nav class="topHeaderNav">        	<div class="topNIHLogo mobileview">        		<a href="http://www.nih.gov" class="top-logo" title="National Institutes of Health" target="_blank"><img src="/dailymed/images/nih-toplogo.png" alt="NIH Logo"/></a>            	<a href="/www.nlm.nih.gov" title="U.S. National Library of Medicine" target="_blank">U.S. National Library of Medicine</a></div>			<div class="container">				<div class="sixteen columns">                	<div class="topNIHLogo"><a href="http://www.nih.gov" title="National Institutes of Health" target="_blank"><img src="/dailymed/images/nih-toplogo.png" alt="NIH Logo"/></a>                    <a href="/www.nlm.nih.gov" title="U.S. National Library of Medicine" target="_blank">U.S. National Library of Medicine</a></div>					<ul>																		<li class="safety"><a title="Report Adverse Events" href="/www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report Adverse Events </a><span>|</span><a title="FDA Safety Reporting and Recalls" href="http://www.fda.gov/Safety/Recalls" target="_blank">Recalls</a></li>					</ul>				</div>			</div>		</nav>		<div class="divider"></div>	</div>	<div class="dailymedlogoprint"><img src="/dailymed/images/logo.png" alt="DailyMed" /></div>	<div class="bottomHeader">		<div class="header-image">						<div class="mobile-menu-btn closed hasjs" tabindex="0"></div><div class="mobile-menu">		<div class="mobile-menu-container">		<div class="pro-menu active">			<div class="first half">				<ul>					<li><a href="dailymed/index.cfm">Home</a></li>					<li>						News						<ul>							<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>							<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>						</ul>					</li>					<li><a href="dailymed/about-dailymed.cfm">About Dailymed</a></li>					<li><a href="dailymed/contact-us.cfm">Contact Us</a></li>					<li>						Safety Reporting &amp; Recalls						<ul>							<li><a href="/www.accessdata.fda.gov/scripts/medwatch/">Report Adverse Events</a></li>							<li><a href="http://www.fda.gov/Safety/Recalls">FDA Saftey Recalls</a></li>						</ul>					</li>					<li>						<a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a>											</li>				</ul>			</div>			<div class="last half">				<ul>					<li>						NLM SPL Resources						<ul>							<li>								<a href="dailymed/spl-resources.cfm">Download Data</a>								<ul>									<li><a href="dailymed/spl-resources-all-drug-labels.cfm">- All Drug Labels</a></li>									<li><a href="dailymed/spl-resources-all-indexing-files.cfm">- All Indexing Files</a></li>									<li><a href="dailymed/spl-resources-all-mapping-files.cfm">- All Mapping Files</a></li>								</ul>							</li>							<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>							<li><a href="dailymed/spl-resources-all-mapping-files.cfm">Articles &amp; Presentations</a></li>						</ul>					</li>					<li>						Application Development Support						<ul>							<li>								<a href="dailymed/app-support.cfm">Resources</a>								<ul>									<li><a href="dailymed/app-support-web-services.cfm">- Web Services</a></li>																		<li><a href="dailymed/app-support-mapping-files.cfm">- Mapping Files</a></li>								</ul>							</li>						</ul>					</li>					<li><a href="dailymed/help.cfm">Help</a></li>				</ul>			</div>		</div>			</div></div>			<a href="dailymed/index.cfm" class="logo" title="DailyMed">DailyMed</a>						<div class="header-search-container">				<div id="header-search">									    					    				    <form action="/dailymed/search.cfm">		<div class="searchNav">		<ul class="searchType">			<li class="all active">									<input type="radio" class="hidden" name="labeltype" id="labeltype-all" value="all" />					<label for="labeltype-all">All Drugs</label>							</li>			<li class="human">									<input type="radio" class="hidden" name="labeltype" id="labeltype-human" value="human"/>					<label for="labeltype-human">Human Drugs</label>							</li>			<li class="animal">									<input type="radio" class="hidden" name="labeltype" id="labeltype-animal" value="animal" />					<label for="labeltype-animal">Animal Drugs</label>							</li>							<li class="more-ways" id="header-search-more-ways">					<a href="#" id="more-ways-button" class="more-ways-label">More ways to search</a>					<ul id="more-ways-dropdown" class="dropdown" style="display:none;">						<li>							<a href="dailymed/advanced-search.cfm">Advanced Search</a>						</li>						<li>							<a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a>						</li>						<li>							<a href="dailymed/archives/index.cfm">Label Archives</a>						</li>						<li>							<a class="external-link" href="http://pillbox.nlm.nih.gov" target="_blank">Tablet/Capsule ID Tool</a>						</li>					</ul>				</li>								</ul>	</div>			<div class="searchForm">					<div class="searchInput">				<input id="searchQuery" name="query" tabindex="0" type="text" placeholder="Enter drug, NDC code, drug class, or Set ID" autocorrect="off" autocapitalize="off">									<button class="search-button">  </button>							</div>								<input class="search" tabindex="0" title="Search" type="submit" value="Search">	</div></form>									</div>			</div>			<div class="mobile-search-btn" tabindex="0"></div>												<div class="header-bg">																										</div>			<div class="divider"></div>		</div>		<div class="bottomHeaderContent">									<div class="search mobile-search">				<div class="divider_10 nomargin mobileview"></div>				<div class="searchTool mobileview"></div>															<form action="/dailymed/search.cfm">		<div class="searchNav">		<ul class="searchType">			<li class="all active">									<input type="radio" class="hidden" name="labeltype" id="labeltype-all-2" value="all" />					<label for="labeltype-all-2">All Drugs</label>							</li>			<li class="human">									<input type="radio" class="hidden" name="labeltype" id="labeltype-human-2" value="human"/>					<label for="labeltype-human-2">Human Drugs</label>							</li>			<li class="animal">									<input type="radio" class="hidden"  name="labeltype" id="labeltype-animal-2" value="animal" />					<label for="labeltype-animal-2">Animal Drugs</label>							</li>								</ul>	</div>			<div class="searchForm">					<div class="searchInput">				<input id="searchToolsQuery" name="query" tabindex="0" type="text" placeholder="Enter drug, NDC code, drug class, or Set ID" autocorrect="off" autocapitalize="off">			</div>								<input class="search" tabindex="0" title="Search" type="submit" value="Search">	</div></form>								<div class="divider"></div>								<nav class="bottomHeaderNav">                <noscript>                <div class="tabletnav no-js">                    <div class="col">                        <ul>                            <li><a href="dailymed/index.cfm">Home</a></li>                            <li>News                                <ul>                                    <li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>                                    <li><a href="dailymed/rss-updates.cfm">Get RSS News & Updates</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li>Search                                <ul>                                    <li><a href="dailymed/advanced-search.cfm">Advanced Search</a></li>                                    <li><a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>                                    <li><a href="dailymed/archives/index.cfm">Labels Archives</a></li>                                                                        <li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID Tool</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li><a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a></li>                            <li>NLM SPL Resources                                <ul>                                    <li><a href="dailymed/spl-resources.cfm">Download Data</a>                                        <ul>                                            <li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>                                            <li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Index Files</a></li>                                            <li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>                                        </ul>                                    </li>                                    <li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>                                    <li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li>Application Development Support                                <ul>                                    <li><a href="dailymed/app-support.cfm">Resources</a>                                        <ul>                                            <li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>                                            <li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>                                        </ul>                                    </li>                                </ul>                            </li>                            <li><a href="dailymed/help.cfm">Help</a></li>                        </ul>                    </div>                </div>           		</noscript>                					<ul class="webview hasjs">						<li><a href="dailymed/index.cfm" title="Home">Home</a></li>						<li>													<a href="#" title="News">												News</a>							<ul class="sub-menu">								<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>								<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>							</ul>						</li>						<li>																				<a href="dailymed/fda-drug-guidance.cfm" title="FDA Guidances &amp; Info">												FDA Guidances &amp; Info</a>													</li>						<li>													<a href="#" title="Structured Product Labeling (SPL) resources for industry professionals.">												NLM SPL Resources</a>														<ul class="sub-menu">								<li><a href="dailymed/spl-resources.cfm">Download Data</a>									<ul>										<li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>										<li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Indexing Files</a></li>										<li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>									</ul>								</li>								<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>								<li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>							</ul>						</li>						<li>													<a href="#" title="Application Development Support">												Application Development Support</a>							<ul class="sub-menu">								<li><a href="dailymed/app-support.cfm">Resources</a>									<ul>										<li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>																				<li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>									</ul>								</li>							</ul>						</li>									  						<li>													<a href="dailymed/help.cfm" title="Help">												Help</a></li>   					</ul>					<ul class="tabletview hasjs">						<li><a href="dailymed/advanced-search.cfm" title="Advanced Search">Advanced Search</a></li>						<li class="viewmore"><a href="#" title="View More">View More</a>							<ul>								<li><span>News</span>									<ul>										<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>										<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>									</ul>								</li>								<li><span>Safety Reporting and Recalls</span>									<ul>										<li><a href="/www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report Adverse Events</a></li>										<li><a href="/www.fda.gov/Safety/Recalls" target="_blank">FDA Saftey Recalls</a></li>									</ul>								</li>								<li>									<a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a>								</li>																<li><span>NLM SPL Resources</span>									<ul>										<li><a href="dailymed/spl-resources.cfm">Download Data</a>											<ul>												<li><a href="dailymed/spl-resources-all-drug-labels.cfm">- All Drug Labels</a></li>												<li><a href="dailymed/spl-resources-all-indexing-files.cfm">- All Indexing Files</a></li>												<li><a href="dailymed/spl-resources-all-mapping-files.cfm">- All Mapping Files</a></li>											</ul>										</li>										<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>										<li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>									</ul>								</li>   								<li><span>Application Development Support</span>									<ul>										<li><a href="dailymed/app-support.cfm">Resources</a>											<ul>												<li><a href="dailymed/app-support-web-services.cfm">- Web Services</a></li>																								<li><a href="dailymed/app-support-mapping-files.cfm">- Mapping Files</a></li>											</ul>										</li>									</ul>								</li>   								<li><a href="dailymed/help.cfm" title="Help">Help</a></li>   							</ul>						</li>						<li class="mobileview viewmore" tabindex="0"><a title="View More" href="#">More ways to search</a>							<ul>								<li tabindex="0"><a title="Browse Drug Classes" href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>								<li tabindex="0"><a title="Label Archives" href="dailymed/archives/index.cfm">Label Archives</a></li>																<li tabindex="0"><a target="_blank" title="Tablet/Capsule ID Tool" href="http://pillbox.nlm.nih.gov/">Tablet/Capsule ID Tool</a></li>   							</ul>						</li>					</ul>										<ul class="mobileview hasjs">						<li><a href="dailymed/advanced-search.cfm" title="Advanced Search">Advanced Search</a></li>						<li tabindex="0" class="viewmore"><a href="#" title="View More">View More</a>							<ul>								<li tabindex="0"><a href="dailymed/browse-drug-classes.cfm" title="Browse Drug Classes">Browse Drug Classes</a></li>								<li tabindex="0"><a href="dailymed/archives/index.cfm" title="Label Archives">Label Archives</a></li>																<li tabindex="0"><a href="http://pillbox.nlm.nih.gov/" title="Tablet/Capsule ID Tool" target="_blank">Tablet/Capsule ID Tool</a></li>   							</ul>						</li>					</ul>				</nav>				<div class="divider_10 nomargin"></div>			</div>					</div>				<div class="divider"></div>	</div></header><div id="skip-main-content"></div>        <div class="container">             <div class="main-content">                <div class="header long">                    <div class="header-top">                            <h1>Label: <span class="long-title">XARELTO- rivaroxaban tablet, film coated <br>XARELTO- rivaroxaban   <br></span></h1>                    </div>                                        <ul class="tools">                    	                        <li class="rss"><a href="#modal-label-rss" class="modal-open">Label RSS</a></li>                        <li class="share">Share                            <noscript>: JavaScript needed for Sharing tools</noscript>                            <!-- AddThis Button BEGIN -->                            <div class="addthis_toolbox addthis_default_style addthis_16x16_style">                                                                                                    	                                	            			        	                                                            <a class="email-share" href="mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AXARELTO%2D%20Rivaroxaban%20Tablet%2C%20Film%20Coated%20XARELTO%2D%20Rivaroxaban%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3D10db92f9%2D2300%2D4a80%2D836b%2D673e1ae91610%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E" title="Share by Email"></a>                                <a class="addthis_button_facebook"></a>                                <a class="addthis_button_twitter"></a>                                                                <a class="at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share" href="/www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed" target="_blank" style="display: block;">                                    <span style="left: -9999px; position: absolute;">Bookmark &amp; Share</span><img style="width:17px" src="/dailymed/images/addthis-image.jpg"></img>                                </a>                            </div>                            <script type="text/javascript">var addthis_config = {"data_track_addressbar":false};</script>                            <script type="text/javascript" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5" ></script>                             <!-- AddThis Button END -->                                                    </li>                    </ul>                  </div>                <div class="four columns sidebar" id="leftmenu">                    <section>                        <article>                                                        <div class="w-photos">                            	                                                                <div class="mod drug-photos">                                <h2><a>View Package Photos</a></h2>                                <ul>                                    <li>                                                                               <ul>                                                                                                                        	                                            	 <li class="img package-photo"><a href="image.cfm?type=img&name=xarelto-06.jpg&setid=10db92f9-2300-4a80-836b-673e1ae91610" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="0">                                                 	<img id="zoom_1" title="Package Photo" alt="Package Photo"                                                     data-zoom-image="image.cfm?type=img&name=xarelto-06.jpg&setid=10db92f9-2300-4a80-836b-673e1ae91610" src="image.cfm?type=img&name=xarelto-06.jpg&setid=10db92f9-2300-4a80-836b-673e1ae91610" data-photo-type="package">                                                 	<span class="enlarge"></span>                                                    </a></li>                                                                                             											                                                                                	                                            	 <li class="img package-photo"><a href="image.cfm?type=img&name=xarelto-07.jpg&setid=10db92f9-2300-4a80-836b-673e1ae91610" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="1">                                                 	<img id="zoom_2" title="Package Photo" alt="Package Photo"                                                     data-zoom-image="image.cfm?type=img&name=xarelto-07.jpg&setid=10db92f9-2300-4a80-836b-673e1ae91610" src="image.cfm?type=img&name=xarelto-07.jpg&setid=10db92f9-2300-4a80-836b-673e1ae91610" data-photo-type="package">                                                 	<span class="enlarge"></span>                                                    </a></li>                                                                                             											                                                                                </ul>                                    </li>                                </ul>								                                    <h4 class="more closed">VIEW MORE</h4>                                        <div class="show-more">                                            <ul>                                                                                                                        <li>                                                <ul>                                                                                    <li class="img package-photo">                                            	<a href="image.cfm?type=img&name=xarelto-08.jpg&setid=10db92f9-2300-4a80-836b-673e1ae91610" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="2">                                                <img id="zoom_3" title="Package Photo" alt="Package Photo"                                                 data-zoom-image="image.cfm?type=img&name=xarelto-08.jpg&setid=10db92f9-2300-4a80-836b-673e1ae91610" src="image.cfm?type=img&name=xarelto-08.jpg&setid=10db92f9-2300-4a80-836b-673e1ae91610" data-photo-type="package">                                                <span class="enlarge"></span>                                                </a></li>                                                                                                                                                                                                           <li class="img package-photo">                                            	<a href="image.cfm?type=img&name=xarelto-09.jpg&setid=10db92f9-2300-4a80-836b-673e1ae91610" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="3">                                                <img id="zoom_4" title="Package Photo" alt="Package Photo"                                                 data-zoom-image="image.cfm?type=img&name=xarelto-09.jpg&setid=10db92f9-2300-4a80-836b-673e1ae91610" src="image.cfm?type=img&name=xarelto-09.jpg&setid=10db92f9-2300-4a80-836b-673e1ae91610" data-photo-type="package">                                                <span class="enlarge"></span>                                                </a></li>                                                                                         </ul>                                             </li>                                                                                                                                                            </ul>                                     </div>                                                                 </div>            								                                                                                                <div class="mod drug-photos">                                <h2><a>View Drug Photos</a></h2>                                                                    <strong><a class="tip" rel="tooltip" title="NDC (National Drug Code) - Each drug product is assigned this unique number which can be found on the drug's outer packaging." href="#">NDC Codes:</a></strong>                                        <ul>                                        <li>                                            <ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        <li class="img drug-photo">                                                            	<p>50458-0579-30</p>                                                                                                                                                                                            	<a href="/rximage.nlm.nih.gov/image/images/gallery/original/50458-0579-30_NLMIMAGE10_8F1DC7FE.jpg"                                                                  class="thumbnail"                                                                  title="rivaroxaban&#x20;20&#x20;MG&#x20;Oral&#x20;Tablet&#x20;&#x5b;Xarelto&#x5d;"                                                                 data-slideorder="4"                                                                 data-ndccode="50458-0579-30"                                                                 data-standardname="rivaroxaban&#x20;20&#x20;MG&#x20;Oral&#x20;Tablet&#x20;&#x5b;Xarelto&#x5d;"                                                                 data-shape="TRIANGLE"                                                                 data-size="7mm"                                                                 data-color="RED"                                                                 data-scored="1"                                                                 data-imprint="20&#x3b;Xa"                                                                 data-photo-type="drug" >                                                                	<img id="zoom_5"                                                                         title="rivaroxaban&#x20;20&#x20;MG&#x20;Oral&#x20;Tablet&#x20;&#x5b;Xarelto&#x5d;"                                                                         alt="rivaroxaban&#x20;20&#x20;MG&#x20;Oral&#x20;Tablet&#x20;&#x5b;Xarelto&#x5d;"                                                                         data-zoom-image="//rximage.nlm.nih.gov/image/images/gallery/original/50458-0579-30_NLMIMAGE10_8F1DC7FE.jpg"                                                                         src="//rximage.nlm.nih.gov/image/images/gallery/original/50458-0579-30_NLMIMAGE10_8F1DC7FE.jpg"                                                                         />                                                                    <span class="enlarge"></span>                                                                </a>                                                             </li>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        <li class="img drug-photo">                                                            	<p>50458-0580-30</p>                                                                                                                                                                                            	<a href="/rximage.nlm.nih.gov/image/images/gallery/original/50458-0580-30_NLMIMAGE10_791DBCBD.jpg"                                                                  class="thumbnail"                                                                  title="rivaroxaban&#x20;10&#x20;MG&#x20;Oral&#x20;Tablet&#x20;&#x5b;Xarelto&#x5d;"                                                                 data-slideorder="5"                                                                 data-ndccode="50458-0580-30"                                                                 data-standardname="rivaroxaban&#x20;10&#x20;MG&#x20;Oral&#x20;Tablet&#x20;&#x5b;Xarelto&#x5d;"                                                                 data-shape="ROUND"                                                                 data-size="6mm"                                                                 data-color="RED"                                                                 data-scored="1"                                                                 data-imprint="10&#x3b;Xa"                                                                 data-photo-type="drug" >                                                                	<img id="zoom_6"                                                                         title="rivaroxaban&#x20;10&#x20;MG&#x20;Oral&#x20;Tablet&#x20;&#x5b;Xarelto&#x5d;"                                                                         alt="rivaroxaban&#x20;10&#x20;MG&#x20;Oral&#x20;Tablet&#x20;&#x5b;Xarelto&#x5d;"                                                                         data-zoom-image="//rximage.nlm.nih.gov/image/images/gallery/original/50458-0580-30_NLMIMAGE10_791DBCBD.jpg"                                                                         src="//rximage.nlm.nih.gov/image/images/gallery/original/50458-0580-30_NLMIMAGE10_791DBCBD.jpg"                                                                         />                                                                    <span class="enlarge"></span>                                                                </a>                                                             </li>                                                                                                                                                                                                                                                            </ul>                                        </li>                                    </ul>                                	                                </div>                                                            </div>                            <div class="mod-wrap">                                <div class="mod blue-list page-jump">                                    <h2><a href="#drug-information">Drug Label Info</a></h2>                                </div>                                                                <div class="mod blue-list orange">                                                                                                                                                                                                                                                                                                                                                                            <h2><a href="#">Safety</a></h2>                                    <ul>                                                                                    <li>                                                <a class="tip" rel="tooltip" title="A boxed warning is the strongest warning that the FDA requires, and signifies that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects." href="#boxedwarning">Boxed Warnings</a>                                            </li>                                                                                                                                                                    <li>                                                <a href="/www.accessdata.fda.gov/scripts/medwatch/ " target="_blank">Report Adverse Events</a>                                            </li>                                            <li><a href="http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety Recalls</a></li>                                            <li>                                                <a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22rivaroxaban%22+%29" target="_blank">Presence in Breast Milk</a>                                            </li>                                                                            </ul>                                </div>                                <div class="mod blue-list">                                    <h2><a href="#">Related Resources</a></h2>                                    <ul>                                                                                                                            <li>                                                <a href="/vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&query=rivaroxaban" target="_blank">Medline Plus</a>                                            </li>                                                                                <li>                                            <a href="/www.clinicaltrials.gov/ct/search?submit=Search&term=rivaroxaban" target="blank">Clinical Trials</a>                                        </li>                                                                                    <li>                                                <a href="#" id="pubmed-menu">PubMed</a>                                            	    											                                                                                                <ul>                                                    <li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=rivaroxaban[All Fields]" title="Link opens new window for All Citations" target="pubmed">All Citations</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=rivaroxaban/AE" title="Link opens new window for Adverse Effects" target="pubmed">Adverse Effects</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=rivaroxaban/TU"  title="Link opens new window for Therapeutic Use" target="pubmed">Therapeutic Use</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=rivaroxaban/PD" title="Link opens new window for Pharmacology" target="pubmed">Pharmacology</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=rivaroxaban[All Fields] AND Clinical Trial[ptyp]" title="Link opens new window for Clinical Trials" target="pubmed">Clinical Trials</a>                                                    </li>                                                </ul>                                            </li>                                            <li>                                                <a href="http://www.drugbank.ca/search?utf8=%E2%9C%93&query=rivaroxaban&search_type=drugs&button=" target="_blank">Biochemical Data Summary</a>                                            </li>                                                                            </ul>                                </div>                                <div class="mod blue-list">                                    <h2><a href="#">More Info For This Drug</a></h2>                                    <ul>                                    	                                        <li><a href="#modal-label-archives" class="modal-open">View Label Archives</a></li>                                        <li><a href="#modal-rx-norm" class="modal-open">RxNorm</a></li>                                                                                <li><a href="#modal-label-rss" class="modal-open">Get Label RSS Feed</a></li>                                    </ul>                                </div>                                                            </div>                        </article>                    </section>                </div>                               <div class="content-wide">                        <article>                            <ul class="drug-information">                            	                                                                <li>                                <strong><a class="tip" rel="tooltip" title="NDC (National Drug Code) - Each drug product is assigned this unique number which can be found on the drug's outer packaging." href="#">NDC Code(s):</a></strong> <span id="item-code-s">                                                                                                	                                    50458-578-10,                                                                                                                                        	                                    50458-578-14,                                                                                                                                        	                                    50458-578-30,                                                                                                                                        	                                    50458-578-90,                                                                        	<a class="view-more show-js" href="#">view more</a><div class="more-codes"><span>                                                                                                                                        	                                    50458-579-10,                                                                                                                                        	                                    50458-579-30,                                                                                                                                        	                                    50458-579-90,                                                                                                                                        	                                    50458-579-99,                                                                                                                                        	                                    50458-580-10,                                                                                                                                        	                                    50458-580-30,                                                                                                                                        	                                    50458-584-51                                                                                                                                                                        	</span>                                    </div>                                                                								</li>                                <li>                                                                                                                                                                <li><strong>Packager: </strong>Janssen Pharmaceuticals, Inc.</li>                                						    	    																																			    																	    	    	                             		       	                                                                                                                                                           </ul>                                                        <ul class="drug-information">                            	                                <li><strong>Category:</strong>                                 	                                    	<span id="category" class="orangetext">                                                                            	HUMAN PRESCRIPTION DRUG LABEL</span></li>                                                                    <li><strong>DEA Schedule:</strong> <span id="dea-schedule">                                                                        	None                                                                        </span></li>                                                                    <li><strong>Marketing Status:</strong> <span id="marketing-status">New Drug Application</span></li>								                            </ul>							                                    <div id="drug-information" class="toggle">                                                                                    <h2><a id="druglabel"></a>Drug Label Information</h2>                                                 <p class="date">Updated                                                  	                                                    	01/15                                                                                                     </p>                                                   <p class="orangetext">If you are a consumer or patient please visit <a href="dailymed/drugInfo.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610&audience=consumer">this version.</a></p>                                                                                                   <ul class="tools">                                                    <li class="download">Download DRUG LABEL INFO: <a class="pdf" href="dailymed/getFile.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610&amp;type=pdf&amp;name=10db92f9-2300-4a80-836b-673e1ae91610" target="_blank">PDF</a>                                                    	<a class="xml" href="dailymed/getFile.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610&amp;type=zip&amp;name=XARELTO">XML</a>                                                    </li>                                                                                                                                                            <li class="medguide">Medication Guide:                                                         <a href="dailymed/medguide.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610" target="_blank">HTML</a>                                                                                                            </li>                                                                                                        <li class="print">                                                        <a href="dailymed/fda/fdaDrugXsl.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610&amp;type=display" target="_blank">Print Drug Label Info</a>                                                    </li>                                                                                                    </ul>                                                                                                  <div class="drug-label-sections">                                                   <div class="control-nav show-js">                                            <a class="open-all" href="#">View All Sections</a><a class="close-all" href="#">Close All Sections</a>                                        </div>                                                                        <ul>                                                                                        	                                                <li id="boxedwarning"><a href="#">BOXED WARNING</a><a class=" tip" rel="tooltip" href="#" title="A boxed warning is the strongest warning that the FDA requires, and signifies that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects.">(What is this?)</a> <div class="Warning toggle-content open">   <a name="BOX"></a>  <a name="section-1"></a>   <p></p>   <h1> <span class="Emphasis">WARNING: (A) PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS,<br />(B) SPINAL/EPIDURAL HEMATOMA</span> </h1>   <p class="First"> <span class="Bold">A. PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS</span> </p>   <p> <span class="Bold">Premature discontinuation of any oral anticoagulant, including XARELTO, increases the risk of thrombotic events. If anticoagulation with XARELTO is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant <span class="Italics">[see <a href="#s2.2">Dosage and Administration (2.2</a>,<a href="#s2.6"> 2.6</a>), <a href="#s5.1">Warnings and Precautions (5.1)</a>, and <a href="#s14.1">Clinical Studies (14.1)</a>]</span>.</span> </p>   <p> <span class="Bold">B. SPINAL/EPIDURAL HEMATOMA</span> </p>   <p> <span class="Bold">Epidural or spinal hematomas have occurred in patients treated with XARELTO who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:</span> </p>   <ul class="Disc">    <li> <span class="Bold">use of indwelling epidural catheters</span> </li>    <li> <span class="Bold">concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants</span> </li>    <li> <span class="Bold">a history of traumatic or repeated epidural or spinal punctures</span> </li>    <li> <span class="Bold">a history of spinal deformity or spinal surgery</span> </li>    <li style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"> <span class="XmChange"><span class="Bold">optimal timing between the administration of XARELTO and neuraxial procedures is not known</span></span> </li>   </ul>   <p> <span class="Bold Italics">[see <a href="#s5.2">Warnings and Precautions (5.2</a>, <a href="#s5.3">5.3)</a> and <a href="#s6.2">Adverse Reactions (6.2)</a>].</span> </p>   <p> <span class="Bold">Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary <span class="Italics">[see <a href="#s5.3">Warnings and Precautions (5.3)</a>]</span>.</span> </p>   <p> <span class="Bold">Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis <span class="Italics">[see <a href="#s5.3">Warnings and Precautions (5.3)</a>]</span>.</span> </p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">HIGHLIGHTS OF PRESCRIBING INFORMATION</a> <div id="Highlights" class=" Highlights toggle-content closed">    <div class="HighlightsDisclaimer">   These highlights do not include all the information needed to use XARELTO   <span class="Sup">&reg;</span> (rivaroxaban) safely and effectively. See full prescribing information for XARELTO.   <br />&nbsp;   <br />XARELTO (rivaroxaban) tablets, for oral use   <br />Initial U.S. Approval: 2011  </div>   <div class="Warning">    <div>     <h1 class="Warning">WARNING: (A) PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS, and<br />(B) SPINAL/EPIDURAL HEMATOMA</h1>     <h1 class="Warning"> <span class="Italics">See full prescribing information for complete boxed warning</span> </h1>     <p class="Highlighta"> <span class="Bold">(A) PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS</span> </p>     <p class="Highlighta"> <span class="Bold">Premature discontinuation of any oral anticoagulant, including XARELTO, increases the risk of thrombotic events. To reduce this risk, consider coverage with another anticoagulant if XARELTO is discontinued for a reason other than pathological bleeding or completion of a course of therapy (<a href="#s2.2">2.2</a>, <a href="#s2.6">2.6</a>, <a href="#s5.1">5.1</a>, <a href="#s14.1">14.1</a>).</span> </p>     <p class="Highlighta"> <span class="Bold">(B) SPINAL/EPIDURAL HEMATOMA</span> </p>     <p class="Highlighta"> <span class="Bold">Epidural or spinal hematomas have occurred in patients treated with XARELTO who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis (<a href="#s5.2">5.2</a>, <a href="#s5.3">5.3</a>, <a href="#s6.2">6.2</a>).</span> </p>     <p class="Highlighta"> <span class="Bold">Monitor patients frequently for signs and symptoms of neurological impairment and if observed, treat urgently. Consider the benefits and risks before neuraxial intervention in patients who are or who need to be anticoagulated (<a href="#s5.3">5.3</a>).</span> </p>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>RECENT MAJOR CHANGES</span> </h1>    <div>     <table class="Noautorules" width="100%">      <colgroup>      <col align="left" valign="top" width="75%" />       <col align="right" valign="top" width="25%" />      </colgroup>     <tbody class="Headless">       <tr>        <td align="left"><a href="#BOX">Boxed Warning</a></td>       <td align="right">03/2014</td>       </tr>       <tr>        <td align="left">Dosage and Administration (<a href="#S2.8">2.8</a>)</td>       <td align="right">01/2015</td>       </tr>       <tr>        <td align="left">Warnings and Precautions (<a href="#S5.3">5.3</a>)</td>       <td align="right">03/2014</td>       </tr>      </tbody>     </table>    </div>   </div>   <div></div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>INDICATIONS AND USAGE</span> </h1>    <div>     <p class="Highlighta">XARELTO is a factor Xa inhibitor indicated: </p>     <ul class="Disc">      <li>to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (<a href="#s1.1">1.1</a>)</li>      <li>for the treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and for the reduction in the risk of recurrence of DVT and of PE (<a href="#s1.2">1.2</a>, <a href="#s1.3">1.3</a>, <a href="#s1.4">1.4</a>)</li>      <li>for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery (<a href="#s1.5">1.5</a>)</li>     </ul>    </div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DOSAGE AND ADMINISTRATION</span> </h1>    <div>     <ul class="Disc">      <li> Take 15 mg and 20 mg tablets with food; take 10 mg tablets with or without food (<a href="#s2.1">2.1</a>)</li>      <li> <span class="Underline">Nonvalvular Atrial Fibrillation</span>:       <ul class="Circle">        <li>For patients with CrCl &gt;50 mL/min: 20 mg orally, once daily <span class="Bold">with the evening meal </span>(<a href="#s2.3">2.3</a>)</li>        <li>For patients with CrCl 15 – 50 mL/min: 15 mg orally, once daily <span class="Bold">with the evening meal</span> (<a href="#s2.3">2.3</a>)</li>       </ul> </li>      <li> <span class="Underline">Treatment of DVT, PE, and Reduction in the Risk of Recurrence of DVT and of PE</span>: 15 mg orally twice daily with food for the first 21 days for the initial treatment of acute DVT or PE. After the initial treatment period, 20 mg orally once daily with food for the remaining treatment and the long-term reduction in the risk of recurrence of DVT and of PE. (<a href="#s2.4">2.4</a>)</li>      <li> <span class="Underline">Prophylaxis of DVT Following Hip or Knee Replacement Surgery</span>: 10 mg orally, once daily with or without food (<a href="#s2.5">2.5</a>)</li>     </ul>    </div>    <div></div>    <div>     <div></div>     <div></div>     <div></div>     <div></div>    </div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DOSAGE FORMS AND STRENGTHS</span> </h1>    <div>     <p class="Highlighta">Tablets: 10 mg, 15 mg, and 20 mg (<a href="#s3">3</a>) </p>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>CONTRAINDICATIONS</span> </h1>    <div>     <ul class="Disc">      <li> Active pathological bleeding (<a href="#s4">4</a>)</li>      <li> Severe hypersensitivity reaction to XARELTO (<a href="#s4">4</a>)</li>     </ul>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>WARNINGS AND PRECAUTIONS</span> </h1>    <div>     <ul>      <li> Risk of bleeding: XARELTO can cause serious and fatal bleeding. Promptly evaluate signs and symptoms of blood loss. (<a href="#s5.2">5.2</a>)</li>      <li> Pregnancy-related hemorrhage: Use XARELTO with caution in pregnant women due to the potential for obstetric hemorrhage and/or emergent delivery. Promptly evaluate signs and symptoms of blood loss. (<a href="#s5.7">5.7</a>)</li>      <li>Prosthetic heart valves: XARELTO use not recommended (<a href="#s5.8">5.8</a>)</li>     </ul>    </div>    <div></div>    <div>     <div></div>    </div>    <div></div>    <div>     <div></div>     <div></div>     <div></div>    </div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>ADVERSE REACTIONS</span> </h1>    <div>     <p class="Highlighta">The most common adverse reaction (&gt;5%) was bleeding. (<a href="#s6.1">6.1</a>)<br /> <br /> <span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Janssen Pharmaceuticals, Inc. at 1-800-526-7736 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch. </span></span> </p>    </div>    <div>     <div>      <div></div>      <div>       <div></div>       <div></div>      </div>      <div></div>     </div>     <div>      <div></div>     </div>    </div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DRUG INTERACTIONS</span> </h1>    <div>     <ul class="Disc">      <li> Combined P-gp and strong CYP3A4 inhibitors and inducers: Avoid concomitant use (<a href="#s7.1">7.1</a>, <a href="#s7.2">7.2</a>)</li>      <li> Anticoagulants: Avoid concomitant use (<a href="#s7.3">7.3</a>)</li>     </ul>    </div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>USE IN SPECIFIC POPULATIONS</span> </h1>    <div>     <ul class="Disc">      <li> Nursing mothers: discontinue drug or discontinue nursing (<a href="#s8.3">8.3</a>)</li>      <li> Renal impairment: Avoid or adjust dose based on CrCl (<a href="#s8.7">8.7</a>)</li>      <li> Hepatic impairment: Avoid use in patients with Child-Pugh B and C hepatic impairment or with any degree of hepatic disease associated with coagulopathy (<a href="#s8.8">8.8</a>)</li>     </ul>    </div>    <div>     <div></div>    </div>    <div></div>    <div></div>    <div></div>    <div></div>    <div>     <div></div>     <div></div>     <div></div>    </div>    <div></div>   </div>   <div></div>   <div></div>   <div>    <div></div>    <div></div>    <div>     <div></div>     <div></div>     <div></div>     <div></div>     <div>      <div></div>      <div></div>      <div></div>      <div></div>      <div></div>      <div></div>     </div>     <div>      <div></div>      <div></div>      <div></div>      <div></div>      <div></div>      <div></div>      <div></div>     </div>    </div>    <div></div>   </div>   <div>    <div></div>   </div>   <div>    <div></div>    <div>     <div></div>     <div></div>    </div>    <div></div>   </div>   <div>    <div></div>   </div>   <div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div></div>   <div></div>   <div></div>   <div></div>   <div></div>   <div></div>   <p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>   <p class="HighlightsRevision">Revised: 1/2015</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">FULL PRESCRIBING INFORMATION: CONTENTS*</a> <div id="Index" class=" Index toggle-content closed">    <h1> <a href="#section-1" class="toc"><span class="Emphasis">WARNING: (A) PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS,<br />(B) SPINAL/EPIDURAL HEMATOMA</span></a> </h1>   <h1> <a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a> </h1>   <h2> <a href="#section-1.1" class="toc">1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation</a> </h2>   <h2> <a href="#section-1.2" class="toc">1.2 Treatment of Deep Vein Thrombosis</a> </h2>   <h2> <a href="#section-1.3" class="toc">1.3 Treatment of Pulmonary Embolism</a> </h2>   <h2> <a href="#section-1.4" class="toc">1.4 Reduction in the Risk of Recurrence of Deep Vein Thrombosis and of Pulmonary Embolism</a> </h2>   <h2> <a href="#section-1.5" class="toc">1.5 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery</a> </h2>   <h1> <a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a> </h1>   <h2> <a href="#section-2.1" class="toc">2.1 Important Food Effect Information</a> </h2>   <h2> <a href="#section-2.2" class="toc">2.2 Switching to and from XARELTO</a> </h2>   <h2> <a href="#section-2.3" class="toc">2.3 Nonvalvular Atrial Fibrillation</a> </h2>   <h2> <a href="#section-2.4" class="toc">2.4 Treatment of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and Reduction in the Risk of Recurrence of DVT and of PE</a> </h2>   <h2> <a href="#section-2.5" class="toc">2.5 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery</a> </h2>   <h2> <a href="#section-2.6" class="toc">2.6 Discontinuation for Surgery and other Interventions</a> </h2>   <h2> <a href="#section-2.7" class="toc">2.7 Missed Dose</a> </h2>   <h2> <a href="#section-2.8" class="toc">2.8 Administration Options</a> </h2>   <h1> <a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a> </h1>   <h1> <a href="#section-4" class="toc">4 CONTRAINDICATIONS</a> </h1>   <h1> <a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a> </h1>   <h2> <a href="#section-5.1" class="toc">5.1 Increased Risk of Thrombotic Events after Premature Discontinuation</a> </h2>   <h2> <a href="#section-5.2" class="toc">5.2 Risk of Bleeding</a> </h2>   <h2> <a href="#section-5.3" class="toc">5.3 Spinal/Epidural Anesthesia or Puncture</a> </h2>   <h2> <a href="#section-5.4" class="toc">5.4 Use in Patients with Renal Impairment</a> </h2>   <h2> <a href="#section-5.5" class="toc">5.5 Use in Patients with Hepatic Impairment</a> </h2>   <h2> <a href="#section-5.6" class="toc">5.6 Use with P-gp and Strong CYP3A4 Inhibitors or Inducers</a> </h2>   <h2> <a href="#section-5.7" class="toc">5.7 Risk of Pregnancy-Related Hemorrhage</a> </h2>   <h2> <a href="#section-5.8" class="toc">5.8 Patients with Prosthetic Heart Valves</a> </h2>   <h2> <a href="#section-5.9" class="toc">5.9 Acute PE in Hemodynamically Unstable Patients or Patients Who Require Thrombolysis or Pulmonary Embolectomy</a> </h2>   <h1> <a href="#section-6" class="toc">6 ADVERSE REACTIONS</a> </h1>   <h2> <a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a> </h2>   <h2> <a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a> </h2>   <h1> <a href="#section-7" class="toc">7 DRUG INTERACTIONS</a> </h1>   <h2> <a href="#section-7.1" class="toc">7.1 Drugs that Inhibit Cytochrome P450 3A4 Enzymes and Drug Transport Systems</a> </h2>   <h2> <a href="#section-7.2" class="toc">7.2 Drugs that Induce Cytochrome P450 3A4 Enzymes and Drug Transport Systems</a> </h2>   <h2> <a href="#section-7.3" class="toc">7.3 Anticoagulants and NSAIDs/Aspirin</a> </h2>   <h2> <a href="#section-7.4" class="toc">7.4 Drug-Disease Interactions with Drugs that Inhibit Cytochrome P450 3A4 Enzymes and Drug Transport Systems</a> </h2>   <h1> <a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a> </h1>   <h2> <a href="#section-8.1" class="toc">8.1 Pregnancy</a> </h2>   <h2> <a href="#section-8.2" class="toc">8.2 Labor and Delivery</a> </h2>   <h2> <a href="#section-8.3" class="toc">8.3 Nursing Mothers</a> </h2>   <h2> <a href="#section-8.4" class="toc">8.4 Pediatric Use</a> </h2>   <h2> <a href="#section-8.5" class="toc">8.5 Geriatric Use</a> </h2>   <h2> <a href="#section-8.6" class="toc">8.6 Females of Reproductive Potential</a> </h2>   <h2> <a href="#section-8.7" class="toc">8.7 Renal Impairment</a> </h2>   <h2> <a href="#section-8.8" class="toc">8.8 Hepatic Impairment</a> </h2>   <h1> <a href="#section-9" class="toc">10 OVERDOSAGE</a> </h1>   <h1> <a href="#section-10" class="toc">11 DESCRIPTION</a> </h1>   <h1> <a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a> </h1>   <h2> <a href="#section-11.1" class="toc">12.1 Mechanism of Action</a> </h2>   <h2> <a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a> </h2>   <h2> <a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a> </h2>   <h2> <a href="#section-11.4" class="toc">12.6 QT/QTc Prolongation</a> </h2>   <h1> <a href="#section-12" class="toc">13 NON-CLINICAL TOXICOLOGY</a> </h1>   <h2> <a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a> </h2>   <h1> <a href="#section-13" class="toc">14 CLINICAL STUDIES</a> </h1>   <h2> <a href="#section-13.1" class="toc">14.1 Stroke Prevention in Nonvalvular Atrial Fibrillation</a> </h2>   <h2> <a href="#section-13.2" class="toc">14.2 Treatment of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and Reduction in the Risk of Recurrence of DVT and of PE</a> </h2>   <h2> <a href="#section-13.3" class="toc">14.3 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery</a> </h2>   <h1> <a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a> </h1>   <h1> <a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a> </h1>   <h2> <a href="#section-15.1" class="toc">17.1 Instructions for Patient Use</a> </h2>   <h2> <a href="#section-15.2" class="toc">17.2 Bleeding Risks</a> </h2>   <h2> <a href="#section-15.3" class="toc">17.3 Invasive or Surgical Procedures</a> </h2>   <h2> <a href="#section-15.4" class="toc">17.4 Concomitant Medication and Herbals</a> </h2>   <h2> <a href="#section-15.5" class="toc">17.5 Pregnancy and Pregnancy-Related Hemorrhage</a> </h2>   <h2> <a href="#section-15.6" class="toc">17.6 Nursing</a> </h2>   <h2> <a href="#section-15.7" class="toc">17.7 Females of Reproductive Potential</a> </h2>   <dl class="Footnote">    <dt>     <a name="footnote-content" href="#footnote-reference-content">*</a>    </dt>    <dd>    Sections or subsections omitted from the full prescribing information are not listed.   </dd>   </dl>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">1 INDICATIONS AND USAGE</a> <div class="Section toggle-content closed" data-sectioncode="34067-9">   <a name="S1"></a>  <a name="section-1"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="S1.1"></a>   <a name="section-1.1"></a>    <p></p>    <h2>1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation</h2>    <p class="First">XARELTO is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.</p>    <p>There are limited data on the relative effectiveness of XARELTO and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well-controlled<span class="Italics"> [see <a href="#s14.1">Clinical Studies (14.1)</a>].</span> </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S1.2"></a>   <a name="section-1.2"></a>    <p></p>    <h2>1.2 Treatment of Deep Vein Thrombosis</h2>    <p class="First">XARELTO is indicated for the treatment of deep vein thrombosis (DVT).</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S1.3"></a>   <a name="section-1.3"></a>    <p></p>    <h2>1.3 Treatment of Pulmonary Embolism</h2>    <p class="First">XARELTO is indicated for the treatment of pulmonary embolism (PE).</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S1.4"></a>   <a name="section-1.4"></a>    <p></p>    <h2>1.4 Reduction in the Risk of Recurrence of Deep Vein Thrombosis and of Pulmonary Embolism</h2>    <p class="First">XARELTO is indicated for the reduction in the risk of recurrence of deep vein thrombosis and of pulmonary embolism following initial 6 months treatment for DVT and/or PE.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S1.5"></a>   <a name="section-1.5"></a>    <p></p>    <h2>1.5 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery</h2>    <p class="First">XARELTO is indicated for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">2 DOSAGE AND ADMINISTRATION</a> <div class="Section toggle-content closed" data-sectioncode="34068-7">   <a name="S2"></a>  <a name="section-2"></a>   <p></p>    <div class="scrollingtable">   <table width="100%">     <colgroup>     <col align="left" valign="top" width="30%" />      <col align="left" valign="top" width="20%" />      <col align="left" valign="top" width="50%" />     </colgroup>    <thead>      <tr class="First Last">       <th class="Lrule" align="center">Indication</th>      <th class="Lrule Rrule" align="center" colspan="2">Dosage</th>      </tr>     </thead>     <tbody>      <tr class="Botrule First">       <td class="Rrule" align="left" rowspan="2"><span class="Bold">Reduction in Risk of Stroke in Nonvalvular Atrial Fibrillation (<a href="#s2.3">2.3</a>)</span></td>      <td align="left">CrCl &gt;50 mL/min:</td>      <td align="left">20 mg once daily <span class="Bold">with the evening meal</span></td>      </tr>      <tr class="Botrule">       <td align="left">CrCl 15 to 50 mL/min:</td>      <td align="left">15 mg once daily<span class="Bold"> with the evening meal</span></td>      </tr>      <tr>       <td class="Botrule Rrule" align="left" rowspan="3"><span class="Bold">Treatment of DVT (<a href="#s2.4">2.4</a>)<br />Treatment of PE (<a href="#s2.4">2.4</a>)</span></td>      <td align="left" colspan="2">15 mg <span class="Underline">twice daily</span> with food, for first 21 days</td>      </tr>      <tr>       <td align="left" colspan="2"><span class="Bold">&nbsp;&nbsp;▼after 21 days, transition to ▼</span></td>      </tr>      <tr class="Botrule">       <td align="left" colspan="2">20 mg once daily with food, for remaining treatment</td>      </tr>      <tr class="Botrule">       <td class="Rrule" align="left"><span class="Bold">Reduction in the Risk of Recurrence of DVT and of PE (<a href="#s2.4">2.4</a>)</span></td>      <td align="left" colspan="2" valign="middle">20 mg once daily with food</td>      </tr>      <tr class="Botrule">       <td class="Rrule" align="left" rowspan="2"><span class="Bold">Prophylaxis of DVT Following Hip or Knee Replacement Surgery (<a href="#s2.5">2.5</a>)</span></td>      <td align="left">Hip replacement:</td>      <td align="left">10 mg once daily for 35 days</td>      </tr>      <tr class="Last">       <td align="left">Knee replacement:</td>      <td align="left">10 mg once daily for 12 days</td>      </tr>     </tbody>    </table>  </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S2.1"></a>   <a name="section-2.1"></a>    <p></p>    <h2>2.1 Important Food Effect Information</h2>    <p class="First">The 15 mg and 20 mg XARELTO tablets should be taken with food, while the 10 mg tablet can be taken with or without food <span class="Italics">[see <a href="#s12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>    <p>In the nonvalvular atrial fibrillation efficacy study XARELTO was taken with the evening meal.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S2.2"></a>   <a name="section-2.2"></a>    <p></p>    <h2>2.2 Switching to and from XARELTO</h2>    <div class="Section" data-sectioncode="42229-5">     <a name="section-2.2.1"></a>     <p></p>     <p class="First"> <span class="Italics">Switching from Warfarin to XARELTO </span>- When switching patients from warfarin to XARELTO, discontinue warfarin and start XARELTO as soon as the International Normalized Ratio (INR) is below 3.0 to avoid periods of inadequate anticoagulation.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-2.2.2"></a>     <p></p>     <p class="First"> <span class="Italics">Switching from XARELTO to Warfarin - </span>No clinical trial data are available to guide converting patients from XARELTO to warfarin. XARELTO affects INR, so INR measurements made during coadministration with warfarin may not be useful for determining the appropriate dose of warfarin. One approach is to discontinue XARELTO and begin both a parenteral anticoagulant and warfarin at the time the next dose of XARELTO would have been taken.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-2.2.3"></a>     <p></p>     <p class="First"> <span class="Italics">Switching from XARELTO to Anticoagulants other than Warfarin</span> - For patients currently taking XARELTO and transitioning to an anticoagulant with rapid onset, discontinue XARELTO and give the first dose of the other anticoagulant (oral or parenteral) at the time that the next XARELTO dose would have been taken <span class="Italics">[see <a href="#s7.3">Drug Interactions (7.3)</a>]</span>.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-2.2.4"></a>     <p></p>     <p class="First"> <span class="Italics">Switching from Anticoagulants other than Warfarin to XARELTO -</span> For patients currently receiving an anticoagulant other than warfarin, start XARELTO 0 to 2 hours prior to the next scheduled evening administration of the drug (e.g., low molecular weight heparin or non-warfarin oral anticoagulant) and omit administration of the other anticoagulant. For unfractionated heparin being administered by continuous infusion, stop the infusion and start XARELTO at the same time.</p>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S2.3"></a>   <a name="section-2.3"></a>    <p></p>    <h2>2.3 Nonvalvular Atrial Fibrillation</h2>    <p class="First">For patients with creatinine clearance (CrCl) &gt;50 mL/min, the recommended dose of XARELTO is 20 mg taken orally once daily with the evening meal. For patients with CrCl 15 to 50 mL/min, the recommended dose is 15 mg once daily with the evening meal <span class="Italics">[see <a href="#s8.7">Use in Specific Populations (8.7)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S2.4"></a>   <a name="section-2.4"></a>    <p></p>    <h2>2.4 Treatment of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and Reduction in the Risk of Recurrence of DVT and of PE</h2>    <p class="First">The recommended dose of XARELTO for the initial treatment of acute DVT and/or PE is 15 mg taken orally twice daily with food for the first 21 days. After this initial treatment period, the recommended dose of XARELTO is 20 mg taken orally once daily with food, at approximately the same time each day. The recommended dose of XARELTO for reduction in the risk of recurrence of DVT or PE is 20 mg taken orally once daily with food at approximately the same time each day <span class="Italics">[see <a href="#s14.2">Clinical Studies (14.2)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S2.5"></a>   <a name="section-2.5"></a>    <p></p>    <h2>2.5 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery</h2>    <p class="First">The recommended dose of XARELTO is 10 mg taken orally once daily with or without food. The initial dose should be taken 6 to 10 hours after surgery provided that hemostasis has been established <span class="Italics">[see <a href="#s2.6">Dosage and Administration (2.6)</a>]</span>.</p>    <ul class="Disc">     <li>For patients undergoing hip replacement surgery, treatment duration of 35 days is recommended.</li>     <li>For patients undergoing knee replacement surgery, treatment duration of 12 days is recommended.</li>    </ul>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S2.6"></a>   <a name="section-2.6"></a>    <p></p>    <h2>2.6 Discontinuation for Surgery and other Interventions</h2>    <p class="First">If anticoagulation must be discontinued to reduce the risk of bleeding with surgical or other procedures, XARELTO should be stopped at least 24 hours before the procedure to reduce the risk of bleeding <span class="Italics">[see <a href="#s5.2">Warnings and Precautions (5.2)</a>]</span>. In deciding whether a procedure should be delayed until 24 hours after the last dose of XARELTO, the increased risk of bleeding should be weighed against the urgency of intervention. XARELTO should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established, noting that the time to onset of therapeutic effect is short <span class="Italics">[see <a href="#s5.1">Warnings and Precautions (5.1)</a>]</span>. If oral medication cannot be taken during or after surgical intervention, consider administering a parenteral anticoagulant.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S2.7"></a>   <a name="section-2.7"></a>    <p></p>    <h2>2.7 Missed Dose</h2>    <p class="First">If a dose of XARELTO is not taken at the scheduled time, administer the dose as soon as possible on the same day as follows:</p>    <ul class="Disc">     <li>For patients receiving 15 mg twice daily: The patient should take XARELTO immediately to ensure intake of 30 mg XARELTO per day. In this particular instance, two 15 mg tablets may be taken at once. The patient should continue with the regular 15 mg twice daily intake as recommended on the following day.</li>     <li>For patients receiving 20 mg, 15 mg or 10 mg once daily: The patient should take the missed XARELTO dose immediately.</li>    </ul>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S2.8"></a>   <a name="section-2.8"></a>    <p></p>    <h2>2.8 Administration Options</h2>    <p class="First" style="border-left:1px solid;"> <span class="XmChange">For patients who are unable to swallow whole tablets, 10 mg, 15 mg or 20 mg XARELTO tablets may be crushed and mixed with applesauce immediately prior to use and administered orally. After the administration of a crushed XARELTO 15 mg or 20 mg tablet, the dose should be immediately followed by food <span class="Italics">[see Dosage and Administration (<a href="#S2.1">2.1</a>, <a href="#S2.3">2.3</a>, <a href="#S2.4">2.4</a>) and <a href="#S12.3">Clinical Pharmacology (12.3</a>)]</span>.</span> </p>    <p style="border-left:1px solid;"> <span class="XmChange"><span class="Italics">Administration via nasogastric (NG) tube or gastric feeding tube:</span> After confirming gastric placement of the tube, 10 mg, 15 mg or 20 mg XARELTO tablets may be crushed and suspended in 50 mL of water and administered via an NG tube or gastric feeding tube. Since rivaroxaban absorption is dependent on the site of drug release, avoid administration of XARELTO distal to the stomach which can result in reduced absorption and thereby, reduced drug exposure. After the administration of a crushed XARELTO 15 mg or 20 mg tablet, the dose should then be immediately followed by enteral feeding <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</span> </p>    <p style="border-left:1px solid;"> <span class="XmChange">Crushed 10 mg, 15 mg or 20 mg XARELTO tablets are stable in water and in applesauce for up to 4 hours. An <span class="Italics">in vitro</span> compatibility study indicated that there is no adsorption of rivaroxaban from a water suspension of a crushed XARELTO tablet to PVC or silicone nasogastric (NG) tubing.</span> </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">3 DOSAGE FORMS AND STRENGTHS</a> <div class="Section toggle-content closed" data-sectioncode="43678-2">   <a name="S3"></a>  <a name="section-3"></a>   <p></p>    <ul class="Disc">    <li>10 mg tablets: Round, light red, biconvex and film-coated with a triangle pointing down above a &quot;10&quot; marked on one side and &quot;Xa&quot; on the other side</li>    <li>15 mg tablets: Round, red, biconvex, and film-coated with a triangle pointing down above a &quot;15&quot; marked on one side and &quot;Xa&quot; on the other side</li>    <li>20 mg tablets: Triangle-shaped, dark red, and film-coated with a triangle pointing down above a &quot;20&quot; marked on one side and &quot;Xa&quot; on the other side</li>   </ul>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">4 CONTRAINDICATIONS</a> <div class="Section toggle-content closed" data-sectioncode="34070-3">   <a name="S4"></a>  <a name="section-4"></a>   <p></p>    <p class="First">XARELTO is contraindicated in patients with:</p>   <ul class="Disc">    <li>active pathological bleeding <span class="Italics">[see <a href="#s5.2">Warnings and Precautions (5.2)</a>]</span> </li>    <li>severe hypersensitivity reaction to XARELTO (e.g., anaphylactic reactions) <span class="Italics">[see <a href="#s6.2">Adverse Reactions (6.2)</a>]</span> </li>   </ul>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">5 WARNINGS AND PRECAUTIONS</a> <div class="Section toggle-content closed" data-sectioncode="43685-7">   <a name="S5"></a>  <a name="section-5"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="S5.1"></a>   <a name="section-5.1"></a>    <p></p>    <h2>5.1 Increased Risk of Thrombotic Events after Premature Discontinuation</h2>    <p class="First">Premature discontinuation of any oral anticoagulant, including XARELTO, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from XARELTO to warfarin in clinical trials in atrial fibrillation patients. If XARELTO is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant <span class="Italics">[see <a href="#s2.2">Dosage and Administration (2.2</a>,<a href="#s2.6"> 2.6</a>) and <a href="#s14.1">Clinical Studies (14.1)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.2"></a>   <a name="section-5.2"></a>    <p></p>    <h2>5.2 Risk of Bleeding</h2>    <p class="First">XARELTO increases the risk of bleeding and can cause serious or fatal bleeding. In deciding whether to prescribe XARELTO to patients at increased risk of bleeding, the risk of thrombotic events should be weighed against the risk of bleeding.</p>    <p>Promptly evaluate any signs or symptoms of blood loss and consider the need for blood replacement. Discontinue XARELTO in patients with active pathological hemorrhage. The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.</p>    <p>Concomitant use of other drugs that impair hemostasis increases the risk of bleeding. These include aspirin, P2Y<span class="Sub">12</span> platelet inhibitors, other antithrombotic agents, fibrinolytic therapy, and non-steroidal anti-inflammatory drugs (NSAIDs) <span class="Italics">[see <a href="#s7.3">Drug Interactions (7.3)</a>].</span> </p>    <p>Concomitant use of drugs that are combined P-gp and CYP3A4 inhibitors (e.g., ketoconazole and ritonavir) increases rivaroxaban exposure and may increase bleeding risk <span class="Italics">[see <a href="#s7.1">Drug Interactions (7.1)</a>]</span>.</p>    <div class="Section" data-sectioncode="42229-5">     <a name="section-5.2.1"></a>     <p></p>     <p class="First"> <span class="Italics">Reversal of Anticoagulant Effect:</span> </p>     <p>A specific antidote for rivaroxaban is not available. Because of high plasma protein binding, rivaroxaban is not expected to be dialyzable <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of rivaroxaban. Partial reversal of prothrombin time prolongation has been seen after administration of prothrombin complex concentrates (PCCs) in healthy volunteers. The use of other procoagulant reversal agents like activated prothrombin complex concentrate (APCC) or recombinant factor VIIa (rFVIIa) has not been evaluated.</p>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.3"></a>   <a name="section-5.3"></a>    <p></p>    <h2>5.3 Spinal/Epidural Anesthesia or Puncture</h2>    <p class="First">When neuraxial anesthesia (spinal/epidural anesthesia) or spinal puncture is employed, patients treated with anticoagulant agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis <span class="Italics">[see <a href="#box">Boxed Warning</a>]</span>.</p>    <p style="border-left:1px solid;"> <span class="XmChange">To reduce the potential risk of bleeding associated with the concurrent use of rivaroxaban and epidural or spinal anesthesia/analgesia or spinal puncture, consider the pharmacokinetic profile of rivaroxaban <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of rivaroxaban is low; however, the exact timing to reach a sufficiently low anticoagulant effect in each patient is not known.</span> </p>    <p>An epidural catheter should not be removed earlier than 18 hours after the last administration of XARELTO. The next XARELTO dose is not to be administered earlier than 6 hours after the removal of the catheter. If traumatic puncture occurs, the administration of XARELTO is to be delayed for 24 hours.</p>    <p style="border-left:1px solid;"> <span class="XmChange">Should the physician decide to administer anticoagulation in the context of epidural or spinal anesthesia/analgesia or lumbar puncture, monitor frequently to detect any signs or symptoms of neurological impairment, such as midline back pain, sensory and motor deficits (numbness, tingling, or weakness in lower limbs), bowel and/or bladder dysfunction. Instruct patients to immediately report if they experience any of the above signs or symptoms. If signs or symptoms of spinal hematoma are suspected, initiate urgent diagnosis and treatment including consideration for spinal cord decompression even though such treatment may not prevent or reverse neurological sequelae.</span> </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.4"></a>   <a name="section-5.4"></a>    <p></p>    <h2>5.4 Use in Patients with Renal Impairment</h2>    <div class="Section" data-sectioncode="42229-5">     <a name="section-5.4.1"></a>     <p></p>     <p class="First">Nonvalvular Atrial Fibrillation</p>     <p>Avoid the use of XARELTO in patients with CrCl &lt;15 mL/min since drug exposure is increased. Periodically assess renal function as clinically indicated (i.e., more frequently in situations in which renal function may decline) and adjust therapy accordingly<span class="Italics">.</span> Discontinue XARELTO in patients who develop acute renal failure while on XARELTO <span class="Italics">[see <a href="#s8.7">Use in Specific Populations (8.7)</a>].</span> </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-5.4.2"></a>     <p></p>     <p class="First">Treatment of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and Reduction in the Risk of Recurrence of DVT and of PE</p>     <p>Avoid the use of XARELTO in patients with CrCl &lt;30 mL/min due to an expected increase in rivaroxaban exposure and pharmacodynamic effects in this patient population <span class="Italics">[see <a href="#s8.7">Use in Specific Populations (8.7)</a>]</span>.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-5.4.3"></a>     <p></p>     <p class="First">Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery</p>     <p>Avoid the use of XARELTO in patients with CrCl &lt;30 mL/min due to an expected increase in rivaroxaban exposure and pharmacodynamic effects in this patient population. Observe closely and promptly evaluate any signs or symptoms of blood loss in patients with CrCl 30 to 50 mL/min. Patients who develop acute renal failure while on XARELTO should discontinue the treatment <span class="Italics">[see <a href="#s8.7">Use in Specific Populations (8.7)</a>].</span> </p>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.5"></a>   <a name="section-5.5"></a>    <p></p>    <h2>5.5 Use in Patients with Hepatic Impairment</h2>    <p class="First">No clinical data are available for patients with severe hepatic impairment.</p>    <p>Avoid use of XARELTO in patients with moderate (Child-Pugh B) and severe (Child-Pugh C) hepatic impairment or with any hepatic disease associated with coagulopathy since drug exposure and bleeding risk may be increased <span class="Italics">[see <a href="#s8.8">Use in Specific Populations (8.8)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.6"></a>   <a name="section-5.6"></a>    <p></p>    <h2>5.6 Use with P-gp and Strong CYP3A4 Inhibitors or Inducers</h2>    <p class="First">Avoid concomitant use of XARELTO with combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, lopinavir/ritonavir, ritonavir, indinavir, and conivaptan) <span class="Italics">[see <a href="#s7.1">Drug Interactions (7.1)</a>]</span>.</p>    <p>Avoid concomitant use of XARELTO with drugs that are combined P-gp and strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin, St. John's wort) <span class="Italics">[see <a href="#s7.2">Drug Interactions (7.2)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s5.7"></a>   <a name="section-5.7"></a>    <p></p>    <h2>5.7 Risk of Pregnancy-Related Hemorrhage</h2>    <p class="First">In pregnant women, XARELTO should be used only if the potential benefit justifies the potential risk to the mother and fetus. XARELTO dosing in pregnancy has not been studied. The anticoagulant effect of XARELTO cannot be monitored with standard laboratory testing nor readily reversed. Promptly evaluate any signs or symptoms suggesting blood loss (e.g., a drop in hemoglobin and/or hematocrit, hypotension, or fetal distress).</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s5.8"></a>   <a name="section-5.8"></a>    <p></p>    <h2>5.8 Patients with Prosthetic Heart Valves</h2>    <p class="First">The safety and efficacy of XARELTO have not been studied in patients with prosthetic heart valves. Therefore, use of XARELTO is not recommended in these patients.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.9"></a>   <a name="section-5.9"></a>    <p></p>    <h2>5.9 Acute PE in Hemodynamically Unstable Patients or Patients Who Require Thrombolysis or Pulmonary Embolectomy</h2>    <p class="First">Initiation of XARELTO is not recommended acutely as an alternative to unfractionated heparin in patients with pulmonary embolism who present with hemodynamic instability or who may receive thrombolysis or pulmonary embolectomy.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">6 ADVERSE REACTIONS</a> <div class="Section toggle-content closed" data-sectioncode="34084-4">   <a name="S6"></a>  <a name="section-6"></a>   <p></p>    <p class="First">The following adverse reactions are also discussed in other sections of the labeling:</p>   <ul class="Disc">    <li>Increased risk of stroke after discontinuation in nonvalvular atrial fibrillation <span class="Italics">[see <a href="#box">Boxed Warning</a></span> and <span class="Italics"><a href="#s5.1">Warnings and Precautions (5.1)</a>]</span> </li>    <li>Bleeding risk <span class="Italics">[see <a href="#s5.2">Warnings and Precautions (5.2</a>, <a href="#s5.4">5.4</a>, <a href="#s5.5">5.5</a>, <a href="#s5.6">5.6</a>, <a href="#s5.7">5.7)</a>]</span> </li>    <li>Spinal/epidural hematoma <span class="Italics">[see <a href="#box">Boxed Warning</a></span> and <span class="Italics"><a href="#s5.3">Warnings and Precautions (5.3)</a>]</span> </li>   </ul>   <div class="Section" data-sectioncode="42229-5">    <a name="S6.1"></a>   <a name="section-6.1"></a>    <p></p>    <h2>6.1 Clinical Trials Experience</h2>    <p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>    <p>During clinical development for the approved indications, 16326 patients were exposed to XARELTO. These included 7111 patients who received XARELTO 15 mg or 20 mg orally once daily for a mean of 19 months (5558 for 12 months and 2512 for 24 months) to reduce the risk of stroke and systemic embolism in nonvalvular atrial fibrillation (ROCKET AF); 4728 patients who received either XARELTO 15 mg orally twice daily for three weeks followed by 20 mg orally once daily (EINSTEIN DVT, EINSTEIN PE) or 20 mg orally once daily (EINSTEIN Extension) to treat DVT, PE, and to reduce the risk of recurrence of DVT and of PE; and 4487 patients who received XARELTO 10 mg orally once daily for prophylaxis of DVT following hip or knee replacement surgery (RECORD 1–3).</p>    <div class="Section" data-sectioncode="42229-5">     <a name="section-6.1.1"></a>     <p></p>     <p class="First">Hemorrhage</p>     <p>The most common adverse reactions with XARELTO were bleeding complications <span class="Italics">[see <a href="#s5.2">Warnings and Precautions (5.2)</a>]</span>.</p>     <div class="Section" data-sectioncode="42229-5">      <a name="section-6.1.1.1"></a>      <p></p>      <p class="First"> <span class="Italics Underline">Nonvalvular Atrial Fibrillation</span> </p>      <p>In the ROCKET AF trial, the most frequent adverse reactions associated with permanent drug discontinuation were bleeding events, with incidence rates of 4.3% for XARELTO vs. 3.1% for warfarin. The incidence of discontinuations for non-bleeding adverse events was similar in both treatment groups.</p>      <p>Table 1 shows the number of patients experiencing various types of bleeding events in the ROCKET AF trial.</p>      <a name="t1"></a>      <div class="scrollingtable">      <table width="100%">        <caption>         <span>Table 1: Bleeding Events in ROCKET AF<a class="Sup" href="#footnote-1" name="footnote-reference-1">*</a></span>        </caption>        <colgroup>        <col align="left" valign="top" width="30%" />         <col align="center" valign="top" width="15%" />         <col align="center" valign="top" width="20%" />         <col align="center" valign="top" width="15%" />         <col align="center" valign="top" width="20%" />        </colgroup>       <thead>         <tr class="First Last">          <th class="Lrule" align="center">Parameter</th>         <th align="center">XARELTO<br />N = 7111<br />n (%)</th>         <th align="center">Event Rate<br />(per 100 Pt-yrs)</th>         <th align="center">Warfarin<br />N = 7125<br />n (%)</th>         <th class="Rrule" align="center">Event Rate<br />(per 100 Pt-yrs)</th>         </tr>        </thead>        <tfoot>         <tr>          <td align="left" colspan="5">           <dl class="Footnote">            <dt>             <a href="#footnote-reference-1" name="footnote-1">*</a>            </dt>            <dd>            For all sub-types of major bleeding, single events may be represented in more than one row, and individual patients may have more than one event.           </dd>            <dt>             <a href="#footnote-reference-2" name="footnote-2">†</a>            </dt>            <dd>            Defined as clinically overt bleeding associated with a decrease in hemoglobin of ≥2 g/dL, transfusion of ≥2 units of packed red blood cells or whole blood, bleeding at a critical site, or with a fatal outcome. Hemorrhagic strokes are counted as both bleeding and efficacy events. Major bleeding rates excluding strokes are 3.3 per 100 Pt-yrs for XARELTO vs. 2.9 per 100 Pt-yrs for warfarin.           </dd>            <dt>             <a href="#footnote-reference-3" name="footnote-3">‡</a>            </dt>            <dd>            The majority of the events were intracranial, and also included intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, or retroperitoneal.           </dd>           </dl> </td>         </tr>        </tfoot>        <tbody>         <tr class="Botrule First">          <td class="Lrule" align="left">Major bleeding<a class="Sup" href="#footnote-2" name="footnote-reference-2">†</a></td>         <td align="center">395 (5.6)</td>         <td align="center">3.6</td>         <td align="center">386 (5.4)</td>         <td class="Rrule" align="center">3.5</td>         </tr>         <tr class="Botrule">          <td class="Lrule" align="left">&nbsp;&nbsp;Bleeding into a critical organ<a class="Sup" href="#footnote-3" name="footnote-reference-3">‡</a></td>         <td align="center">91 (1.3)</td>         <td align="center">0.8</td>         <td align="center">133 (1.9)</td>         <td class="Rrule" align="center">1.2</td>         </tr>         <tr class="Botrule">          <td class="Lrule" align="left">&nbsp;&nbsp;Fatal bleeding</td>         <td align="center">27 (0.4)</td>         <td align="center">0.2</td>         <td align="center">55 (0.8)</td>         <td class="Rrule" align="center">0.5</td>         </tr>         <tr class="Botrule">          <td class="Lrule" align="left">&nbsp;&nbsp;Bleeding resulting in transfusion of ≥2 units of whole blood or packed red blood cells</td>         <td align="center">183 (2.6)</td>         <td align="center">1.7</td>         <td align="center">149 (2.1)</td>         <td class="Rrule" align="center">1.3</td>         </tr>         <tr class="Last">          <td class="Lrule" align="left">Gastrointestinal bleeding</td>         <td align="center">221 (3.1)</td>         <td align="center">2.0</td>         <td align="center">140 (2.0)</td>         <td class="Rrule" align="center">1.2</td>         </tr>        </tbody>       </table>     </div>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="section-6.1.1.2"></a>      <p></p>      <p class="First"> <span class="Italics Underline">Treatment of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and to Reduce the Risk of Recurrence of DVT and of PE</span> </p>      <div class="Section" data-sectioncode="42229-5">       <a name="section-6.1.1.2.1"></a>       <p></p>       <p class="First">EINSTEIN DVT and EINSTEIN PE Studies</p>       <p>In the pooled analysis of the EINSTEIN DVT and EINSTEIN PE clinical studies, the most frequent adverse reactions leading to permanent drug discontinuation were bleeding events, with XARELTO vs. enoxaparin/Vitamin K antagonist (VKA) incidence rates of 1.7% vs. 1.5%, respectively. The mean duration of treatment was 208 days for XARELTO-treated patients and 204 days for enoxaparin/VKA-treated patients.</p>       <p>Table 2 shows the number of patients experiencing major bleeding events in the pooled analysis of the EINSTEIN DVT and EINSTEIN PE studies.</p>       <div class="scrollingtable">       <table width="100%">         <caption>          <span>Table 2: Bleeding Events<a class="Sup" href="#footnote-4" name="footnote-reference-4">*</a> in the Pooled Analysis of EINSTEIN DVT and EINSTEIN PE Studies</span>         </caption>         <colgroup>         <col align="left" valign="top" width="60%" />          <col align="center" valign="top" width="20%" />          <col align="center" valign="top" width="20%" />         </colgroup>        <thead>          <tr class="First Last">           <th class="Lrule" align="center">Parameter</th>          <th class="Lrule" align="center">XARELTO<a class="Sup" href="#footnote-5" name="footnote-reference-5">†</a> <br />N = 4130<br />n (%)</th>          <th class="Lrule Rrule" align="center">Enoxaparin/<br />VKA<a class="Sup" href="#footnote-5">†</a> <br />N = 4116<br />n (%)</th>          </tr>         </thead>         <tfoot>          <tr>           <td align="left" colspan="3">            <dl class="Footnote">             <dt>              <a href="#footnote-reference-4" name="footnote-4">*</a>             </dt>             <dd>             Bleeding event occurred after randomization and up to 2 days after the last dose of study drug. Although a patient may have had 2 or more events, the patient is counted only once in a category.            </dd>             <dt>              <a href="#footnote-reference-5" name="footnote-5">†</a>             </dt>             <dd>             Treatment schedule in EINSTEIN DVT and EINSTEIN PE studies: XARELTO 15 mg twice daily for 3 weeks followed by 20 mg once daily; enoxaparin/VKA [enoxaparin: 1 mg/kg twice daily, VKA: individually titrated doses to achieve a target INR of 2.5 (range: 2.0–3.0)]            </dd>             <dt>              <a href="#footnote-reference-6" name="footnote-6">‡</a>             </dt>             <dd>             Treatment-emergent major bleeding events with at least &gt;2 subjects in any pooled treatment group            </dd>             <dt>              <a href="#footnote-reference-7" name="footnote-7">&sect;</a>             </dt>             <dd>             Major bleeding which is not fatal or in a critical organ, but resulting in a decrease in Hb ≥ 2 g/dL and/or transfusion of ≥2 units of whole blood or packed red blood cells            </dd>            </dl> </td>          </tr>         </tfoot>         <tbody>          <tr class="First">           <td class="Botrule Lrule Rrule" align="left">Major bleeding event</td>          <td class="Botrule Rrule" align="center">40 (1.0)</td>          <td class="Botrule Rrule" align="center">72 (1.7)</td>          </tr>          <tr>           <td class="Botrule Lrule Rrule" align="left">&nbsp;&nbsp;Fatal bleeding</td>          <td class="Botrule Rrule" align="center">3 (&lt;0.1)</td>          <td class="Botrule Rrule" align="center">8 (0.2)</td>          </tr>          <tr>           <td class="Botrule Lrule Rrule" align="left">&nbsp;&nbsp;&nbsp;&nbsp;Intracranial</td>          <td class="Botrule Rrule" align="center">2 (&lt;0.1)</td>          <td class="Botrule Rrule" align="center">4 (&lt;0.1)</td>          </tr>          <tr>           <td class="Botrule Lrule Rrule" align="left">&nbsp;&nbsp;Non-fatal critical organ bleeding</td>          <td class="Botrule Rrule" align="center">10 (0.2)</td>          <td class="Botrule Rrule" align="center">29 (0.7)</td>          </tr>          <tr>           <td class="Botrule Lrule Rrule" align="left">&nbsp;&nbsp;&nbsp;&nbsp;Intracranial<a class="Sup" href="#footnote-6" name="footnote-reference-6">‡</a></td>          <td class="Botrule Rrule" align="center">3 (&lt;0.1)</td>          <td class="Botrule Rrule" align="center">10 (0.2)</td>          </tr>          <tr>           <td class="Botrule Lrule Rrule" align="left">&nbsp;&nbsp;&nbsp;&nbsp;Retroperitoneal<a class="Sup" href="#footnote-6">‡</a></td>          <td class="Botrule Rrule" align="center">1 (&lt;0.1)</td>          <td class="Botrule Rrule" align="center">8 (0.2)</td>          </tr>          <tr>           <td class="Botrule Lrule Rrule" align="left">&nbsp;&nbsp;&nbsp;&nbsp;Intraocular<a class="Sup" href="#footnote-6">‡</a></td>          <td class="Botrule Rrule" align="center">3 (&lt;0.1)</td>          <td class="Botrule Rrule" align="center">2 (&lt;0.1)</td>          </tr>          <tr>           <td class="Botrule Lrule Rrule" align="left">&nbsp;&nbsp;&nbsp;&nbsp;Intra-articular<a class="Sup" href="#footnote-6">‡</a></td>          <td class="Botrule Rrule" align="center">0</td>          <td class="Botrule Rrule" align="center">4 (&lt;0.1)</td>          </tr>          <tr>           <td class="Botrule Lrule Rrule" align="left">&nbsp;&nbsp;Non-fatal non-critical organ bleeding<a class="Sup" href="#footnote-7" name="footnote-reference-7">&sect;</a></td>          <td class="Botrule Rrule" align="center">27 (0.7)</td>          <td class="Botrule Rrule" align="center">37 (0.9)</td>          </tr>          <tr>           <td class="Botrule Lrule Rrule" align="left">&nbsp;&nbsp;Decrease in Hb ≥ 2g/dL</td>          <td class="Botrule Rrule" align="center">28 (0.7)</td>          <td class="Botrule Rrule" align="center">42 (1.0)</td>          </tr>          <tr>           <td class="Botrule Lrule Rrule" align="left">&nbsp;&nbsp;Transfusion of ≥2 units of whole blood or packed red blood cells</td>          <td class="Botrule Rrule" align="center">18 (0.4)</td>          <td class="Botrule Rrule" align="center">25 (0.6)</td>          </tr>          <tr>           <td class="Botrule Lrule Rrule" align="left">Clinically relevant non-major bleeding</td>          <td class="Botrule Rrule" align="center">357 (8.6)</td>          <td class="Botrule Rrule" align="center">357 (8.7)</td>          </tr>          <tr class="Botrule Last">           <td class="Lrule Rrule" align="left">Any bleeding</td>          <td class="Rrule" align="center">1169 (28.3)</td>          <td class="Rrule" align="center">1153 (28.0)</td>          </tr>         </tbody>        </table>      </div>      </div>      <div class="Section" data-sectioncode="42229-5">       <a name="section-6.1.1.2.2"></a>       <p></p>       <p class="First">EINSTEIN Extension Study</p>       <p>In the EINSTEIN Extension clinical study, the most frequent adverse reactions associated with permanent drug discontinuation were bleeding events, with incidence rates of 1.8% for XARELTO vs. 0.2% for placebo treatment groups. The mean duration of treatment was 190 days for both XARELTO and placebo treatment groups.</p>       <p>Table 3 shows the number of patients experiencing bleeding events in the EINSTEIN Extension study.</p>       <div class="scrollingtable">       <table width="100%">         <caption>          <span>Table 3: Bleeding Events<a class="Sup" href="#footnote-8" name="footnote-reference-8">*</a> in EINSTEIN Extension Study</span>         </caption>         <colgroup>         <col align="left" valign="top" width="60%" />          <col align="center" valign="top" width="20%" />          <col align="center" valign="top" width="20%" />         </colgroup>        <thead>          <tr class="Botrule First Last">           <th class="Lrule" align="center">Parameter</th>          <th class="Lrule" align="center">XARELTO<a class="Sup" href="#footnote-9" name="footnote-reference-9">†</a> <br />20 mg<br />N = 598<br />n (%)</th>          <th class="Lrule Rrule" align="center">Placebo<a class="Sup" href="#footnote-9">†</a> <br />N = 590<br />n (%)</th>          </tr>         </thead>         <tfoot>          <tr>           <td align="left" colspan="3">            <dl class="Footnote">             <dt>              <a href="#footnote-reference-8" name="footnote-8">*</a>             </dt>             <dd>             Bleeding event occurred after the first dose and up to 2 days after the last dose of study drug. Although a patient may have had 2 or more events, the patient is counted only once in a category.            </dd>             <dt>              <a href="#footnote-reference-9" name="footnote-9">†</a>             </dt>             <dd>             Treatment schedule: XARELTO 20 mg once daily; matched placebo once daily            </dd>             <dt>              <a href="#footnote-reference-10" name="footnote-10">‡</a>             </dt>             <dd>             There were no fatal or critical organ bleeding events.            </dd>            </dl> </td>          </tr>         </tfoot>         <tbody>          <tr class="Botrule First">           <td class="Lrule Rrule" align="left">Major bleeding event<a class="Sup" href="#footnote-10" name="footnote-reference-10">‡</a></td>          <td class="Rrule" align="center">4 (0.7)</td>          <td class="Rrule" align="center">0</td>          </tr>          <tr class="Botrule">           <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Decrease in Hb ≥2 g/dL</td>          <td class="Rrule" align="center">4 (0.7)</td>          <td class="Rrule" align="center">0</td>          </tr>          <tr class="Botrule">           <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Transfusion of ≥2 units of whole blood or packed red blood cells</td>          <td class="Rrule" align="center">2 (0.3)</td>          <td class="Rrule" align="center">0</td>          </tr>          <tr class="Botrule">           <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Gastrointestinal</td>          <td class="Rrule" align="center">3 (0.5)</td>          <td class="Rrule" align="center">0</td>          </tr>          <tr class="Botrule">           <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Menorrhagia</td>          <td class="Rrule" align="center">1 (0.2)</td>          <td class="Rrule" align="center">0</td>          </tr>          <tr class="Botrule">           <td class="Lrule Rrule" align="left">Clinically relevant non-major bleeding</td>          <td class="Rrule" align="center">32 (5.4)</td>          <td class="Rrule" align="center">7 (1.2)</td>          </tr>          <tr class="Last">           <td class="Lrule Rrule" align="left">Any bleeding</td>          <td class="Rrule" align="center">104 (17.4)</td>          <td class="Rrule" align="center">63 (10.7)</td>          </tr>         </tbody>        </table>      </div>      </div>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="section-6.1.1.3"></a>      <p></p>      <p class="First"> <span class="Italics Underline">Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery</span> </p>      <p>In the RECORD clinical trials, the overall incidence rate of adverse reactions leading to permanent treatment discontinuation was 3.7% with XARELTO.</p>      <p>The rates of major bleeding events and any bleeding events observed in patients in the RECORD clinical trials are shown in Table 4.</p>      <div class="scrollingtable">      <table width="100%">        <caption>         <span>Table 4: Bleeding Events<a class="Sup" href="#footnote-11" name="footnote-reference-11">*</a> in Patients Undergoing Hip or Knee Replacement Surgeries (RECORD 1–3)</span>        </caption>        <colgroup>        <col align="left" valign="top" width="40%" />         <col align="center" valign="top" width="30%" />         <col align="center" valign="top" width="30%" />        </colgroup>       <thead>         <tr class="Botrule First Last">          <th class="Lrule" align="left"></th>         <th class="Lrule" align="center">XARELTO 10 mg</th>         <th class="Lrule Rrule" align="center">Enoxaparin<a class="Sup" href="#footnote-12" name="footnote-reference-12">†</a></th>         </tr>        </thead>        <tfoot>         <tr>          <td align="left" colspan="3">           <dl class="Footnote">            <dt>             <a href="#footnote-reference-11" name="footnote-11">*</a>            </dt>            <dd>            Bleeding events occurring any time following the first dose of double-blind study medication (which may have been prior to administration of active drug) until two days after the last dose of double-blind study medication. Patients may have more than one event.           </dd>            <dt>             <a href="#footnote-reference-12" name="footnote-12">†</a>            </dt>            <dd>            Includes the placebo-controlled period for RECORD 2, enoxaparin dosing was 40 mg once daily (RECORD 1–3)           </dd>            <dt>             <a href="#footnote-reference-13" name="footnote-13">‡</a>            </dt>            <dd>            Includes major bleeding events           </dd>           </dl> </td>         </tr>        </tfoot>        <tbody>         <tr class="Botrule First">          <td class="Lrule Rrule" align="left"><span class="Bold">Total treated patients</span></td>         <td class="Rrule" align="center"><span class="Bold">N = 4487<br />n (%)</span></td>         <td class="Rrule" align="center"><span class="Bold">N = 4524<br />n (%)</span></td>         </tr>         <tr class="Botrule">          <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Major bleeding event</td>         <td class="Rrule" align="center">14 (0.3)</td>         <td class="Rrule" align="center">9 (0.2)</td>         </tr>         <tr class="Botrule">          <td class="Lrule Rrule" align="left">&nbsp;&nbsp;&nbsp;&nbsp;Fatal bleeding</td>         <td class="Rrule" align="center">1 (&lt;0.1)</td>         <td class="Rrule" align="center">0</td>         </tr>         <tr class="Botrule">          <td class="Lrule Rrule" align="left">&nbsp;&nbsp;&nbsp;&nbsp;Bleeding into a critical organ</td>         <td class="Rrule" align="center">2 (&lt;0.1)</td>         <td class="Rrule" align="center">3 (0.1)</td>         </tr>         <tr class="Botrule">          <td class="Lrule Rrule" align="left">&nbsp;&nbsp;&nbsp;&nbsp;Bleeding that required re-operation</td>         <td class="Rrule" align="center">7 (0.2)</td>         <td class="Rrule" align="center">5 (0.1)</td>         </tr>         <tr class="Botrule">          <td class="Lrule Rrule" align="left">&nbsp;&nbsp;&nbsp;&nbsp;Extra-surgical site bleeding requiring transfusion of &gt;2 units of whole blood or packed cells</td>         <td class="Rrule" align="center">4 (0.1)</td>         <td class="Rrule" align="center">1 (&lt;0.1)</td>         </tr>         <tr class="Botrule">          <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Any bleeding event<a class="Sup" href="#footnote-13" name="footnote-reference-13">‡</a></td>         <td class="Rrule" align="center">261 (5.8)</td>         <td class="Rrule" align="center">251 (5.6)</td>         </tr>         <tr class="Botrule">          <td class="Lrule Rrule" align="left"><span class="Bold">Hip Surgery Studies</span></td>         <td class="Rrule" align="center"><span class="Bold">N = 3281<br />n (%)</span></td>         <td class="Rrule" align="center"><span class="Bold">N = 3298<br />n (%)</span></td>         </tr>         <tr class="Botrule">          <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Major bleeding event</td>         <td class="Rrule" align="center">7 (0.2)</td>         <td class="Rrule" align="center">3 (0.1)</td>         </tr>         <tr class="Botrule">          <td class="Lrule Rrule" align="left">&nbsp;&nbsp;&nbsp;&nbsp;Fatal bleeding</td>         <td class="Rrule" align="center">1 (&lt;0.1)</td>         <td class="Rrule" align="center">0</td>         </tr>         <tr class="Botrule">          <td class="Lrule Rrule" align="left">&nbsp;&nbsp;&nbsp;&nbsp;Bleeding into a critical organ</td>         <td class="Rrule" align="center">1 (&lt;0.1)</td>         <td class="Rrule" align="center">1 (&lt;0.1)</td>         </tr>         <tr class="Botrule">          <td class="Lrule Rrule" align="left">&nbsp;&nbsp;&nbsp;&nbsp;Bleeding that required re-operation</td>         <td class="Rrule" align="center">2 (0.1)</td>         <td class="Rrule" align="center">1 (&lt;0.1)</td>         </tr>         <tr class="Botrule">          <td class="Lrule Rrule" align="left">&nbsp;&nbsp;&nbsp;&nbsp;Extra-surgical site bleeding requiring transfusion of &gt;2 units of whole blood or packed cells</td>         <td class="Rrule" align="center">3 (0.1)</td>         <td class="Rrule" align="center">1 (&lt;0.1)</td>         </tr>         <tr class="Botrule">          <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Any bleeding event<a class="Sup" href="#footnote-13">‡</a></td>         <td class="Rrule" align="center">201 (6.1)</td>         <td class="Rrule" align="center">191 (5.8)</td>         </tr>         <tr class="Botrule">          <td class="Lrule Rrule" align="left"><span class="Bold">Knee Surgery Study</span></td>         <td class="Rrule" align="center"><span class="Bold">N = 1206<br />n (%)</span></td>         <td class="Rrule" align="center"><span class="Bold">N = 1226<br />n (%)</span></td>         </tr>         <tr class="Botrule">          <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Major bleeding event</td>         <td class="Rrule" align="center">7 (0.6)</td>         <td class="Rrule" align="center">6 (0.5)</td>         </tr>         <tr class="Botrule">          <td class="Lrule Rrule" align="left">&nbsp;&nbsp;&nbsp;&nbsp;Fatal bleeding</td>         <td class="Rrule" align="center">0</td>         <td class="Rrule" align="center">0</td>         </tr>         <tr class="Botrule">          <td class="Lrule Rrule" align="left">&nbsp;&nbsp;&nbsp;&nbsp;Bleeding into a critical organ</td>         <td class="Rrule" align="center">1 (0.1)</td>         <td class="Rrule" align="center">2 (0.2)</td>         </tr>         <tr class="Botrule">          <td class="Lrule Rrule" align="left">&nbsp;&nbsp;&nbsp;&nbsp;Bleeding that required re-operation</td>         <td class="Rrule" align="center">5 (0.4)</td>         <td class="Rrule" align="center">4 (0.3)</td>         </tr>         <tr class="Botrule">          <td class="Lrule Rrule" align="left">&nbsp;&nbsp;&nbsp;&nbsp;Extra-surgical site bleeding requiring transfusion of &gt;2 units of whole blood or packed cells</td>         <td class="Rrule" align="center">1 (0.1)</td>         <td class="Rrule" align="center">0</td>         </tr>         <tr class="Last">          <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Any bleeding event<a class="Sup" href="#footnote-13">‡</a></td>         <td class="Rrule" align="center">60 (5.0)</td>         <td class="Rrule" align="center">60 (4.9)</td>         </tr>        </tbody>       </table>     </div>      <p>Following XARELTO treatment, the majority of major bleeding complications (≥60%) occurred during the first week after surgery.</p>     </div>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-6.1.2"></a>     <p></p>     <p class="First">Other Adverse Reactions</p>     <p>Non-hemorrhagic adverse reactions reported in ≥1% of XARELTO-treated patients in the EINSTEIN Extension study are shown in Table 5.</p>     <div class="scrollingtable">     <table width="100%">       <caption>        <span>Table 5: Other Adverse Reactions<a class="Sup" href="#footnote-14" name="footnote-reference-14">*</a> Reported by ≥1% of XARELTO-Treated Patients in EINSTEIN Extension Study</span>       </caption>       <colgroup>       <col align="left" valign="top" width="60%" />        <col align="center" valign="top" width="20%" />        <col align="center" valign="top" width="20%" />       </colgroup>      <thead>        <tr class="First Last">         <th class="Lrule" align="left">System Organ Class<br />&nbsp;&nbsp;Preferred Term</th>        <th class="Lrule" align="center">XARELTO<br />N = 598<br />n (%)</th>        <th class="Lrule Rrule" align="center">Placebo<br />N = 590<br />n (%)</th>        </tr>       </thead>       <tfoot>        <tr>         <td align="left" colspan="3">          <dl class="Footnote">           <dt>            <a href="#footnote-reference-14" name="footnote-14">*</a>           </dt>           <dd>           Adverse reaction (with Relative Risk &gt;1.5 for XARELTO versus placebo) occurred after the first dose and up to 2 days after the last dose of study drug. Incidences are based on the number of patients, not the number of events. Although a patient may have had 2 or more clinical adverse reactions, the patient is counted only once in a category. The same patient may appear in different categories.          </dd>          </dl> </td>        </tr>       </tfoot>       <tbody>        <tr class="Botrule First">         <td class="Lrule Rrule" align="left"><span class="Bold">Gastrointestinal disorders</span></td>        <td class="Rrule" align="center"></td>        <td class="Rrule" align="center"></td>        </tr>        <tr class="Botrule">         <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Abdominal pain upper</td>        <td class="Rrule" align="center">10 (1.7)</td>        <td class="Rrule" align="center">1 (0.2)</td>        </tr>        <tr class="Botrule">         <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Dyspepsia</td>        <td class="Rrule" align="center">8 (1.3)</td>        <td class="Rrule" align="center">4 (0.7)</td>        </tr>        <tr class="Botrule">         <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Toothache</td>        <td class="Rrule" align="center">6 (1.0)</td>        <td class="Rrule" align="center">0</td>        </tr>        <tr class="Botrule">         <td class="Lrule Rrule" align="left"><span class="Bold">General disorders and administration site conditions</span></td>        <td class="Rrule" align="center"></td>        <td class="Rrule" align="center"></td>        </tr>        <tr class="Botrule">         <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Fatigue</td>        <td class="Rrule" align="center">6 (1.0)</td>        <td class="Rrule" align="center">3 (0.5)</td>        </tr>        <tr class="Botrule">         <td class="Lrule Rrule" align="left"><span class="Bold">Infections and infestations</span></td>        <td class="Rrule" align="center"></td>        <td class="Rrule" align="center"></td>        </tr>        <tr class="Botrule">         <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Sinusitis</td>        <td class="Rrule" align="center">7 (1.2)</td>        <td class="Rrule" align="center">3 (0.5)</td>        </tr>        <tr class="Botrule">         <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Urinary tract infection</td>        <td class="Rrule" align="center">7 (1.2)</td>        <td class="Rrule" align="center">3 (0.5)</td>        </tr>        <tr class="Botrule">         <td class="Lrule Rrule" align="left"><span class="Bold">Musculoskeletal and connective tissue disorders</span></td>        <td class="Rrule" align="center"></td>        <td class="Rrule" align="center"></td>        </tr>        <tr class="Botrule">         <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Back pain</td>        <td class="Rrule" align="center">22 (3.7)</td>        <td class="Rrule" align="center">7 (1.2)</td>        </tr>        <tr class="Botrule">         <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Osteoarthritis</td>        <td class="Rrule" align="center">10 (1.7)</td>        <td class="Rrule" align="center">5 (0.8)</td>        </tr>        <tr class="Botrule">         <td class="Lrule Rrule" align="left"><span class="Bold">Respiratory, thoracic and mediastinal disorders</span></td>        <td class="Rrule" align="center"></td>        <td class="Rrule" align="center"></td>        </tr>        <tr class="Last">         <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Oropharyngeal pain</td>        <td class="Rrule" align="center">6 (1.0)</td>        <td class="Rrule" align="center">2 (0.3)</td>        </tr>       </tbody>      </table>    </div>     <p>Non-hemorrhagic adverse reactions reported in ≥1% of XARELTO-treated patients in RECORD 1–3 studies are shown in Table 6.</p>     <div class="scrollingtable">     <table width="100%">       <caption>        <span>Table 6: Other Adverse Drug Reactions<a class="Sup" href="#footnote-15" name="footnote-reference-15">*</a> Reported by ≥1% of XARELTO-Treated Patients in RECORD 1–3 Studies</span>       </caption>       <colgroup>       <col align="left" valign="top" width="40%" />        <col align="center" valign="top" width="30%" />        <col align="center" valign="top" width="30%" />       </colgroup>      <thead>        <tr class="First">         <th class="Lrule" align="left">System/Organ Class<br />&nbsp;&nbsp;Adverse Reaction<br /> </th>        <th class="Lrule" align="center">XARELTO<br />10 mg</th>        <th class="Lrule Rrule" align="center">Enoxaparin<a class="Sup" href="#footnote-16" name="footnote-reference-16">†</a></th>        </tr>        <tr class="Last">         <th class="Lrule" align="left"></th>        <th class="Lrule" align="center">N = 4487<br />n (%)</th>        <th class="Lrule Rrule" align="center">N = 4524<br />n (%)</th>        </tr>       </thead>       <tfoot>        <tr>         <td align="left" colspan="3">          <dl class="Footnote">           <dt>            <a href="#footnote-reference-15" name="footnote-15">*</a>           </dt>           <dd>           Adverse reaction occurring any time following the first dose of double-blind medication, which may have been prior to administration of active drug, until two days after the last dose of double-blind study medication          </dd>           <dt>            <a href="#footnote-reference-16" name="footnote-16">†</a>           </dt>           <dd>           Includes the placebo-controlled period of RECORD 2, enoxaparin dosing was 40 mg once daily (RECORD 1–3)          </dd>          </dl> </td>        </tr>       </tfoot>       <tbody>        <tr class="Botrule First">         <td class="Lrule Rrule" align="left"><span class="Bold">Injury, poisoning and procedural complications</span></td>        <td class="Rrule" align="center"></td>        <td class="Rrule" align="center"></td>        </tr>        <tr class="Botrule">         <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Wound secretion</td>        <td class="Rrule" align="center">125 (2.8)</td>        <td class="Rrule" align="center">89 (2.0)</td>        </tr>        <tr class="Botrule">         <td class="Lrule Rrule" align="left"><span class="Bold">Musculoskeletal and connective tissue disorders</span></td>        <td class="Rrule" align="center"></td>        <td class="Rrule" align="center"></td>        </tr>        <tr class="Botrule">         <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Pain in extremity</td>        <td class="Rrule" align="center">74 (1.7)</td>        <td class="Rrule" align="center">55 (1.2)</td>        </tr>        <tr class="Botrule">         <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Muscle spasm</td>        <td class="Rrule" align="center">52 (1.2)</td>        <td class="Rrule" align="center">32 (0.7)</td>        </tr>        <tr class="Botrule">         <td class="Lrule Rrule" align="left"><span class="Bold">Nervous system disorders</span></td>        <td class="Rrule" align="center"></td>        <td class="Rrule" align="center"></td>        </tr>        <tr class="Botrule">         <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Syncope</td>        <td class="Rrule" align="center">55 (1.2)</td>        <td class="Rrule" align="center">32 (0.7)</td>        </tr>        <tr class="Botrule">         <td class="Lrule Rrule" align="left"><span class="Bold">Skin and subcutaneous tissue disorders</span></td>        <td class="Rrule" align="center"></td>        <td class="Rrule" align="center"></td>        </tr>        <tr class="Botrule">         <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Pruritus</td>        <td class="Rrule" align="center">96 (2.1)</td>        <td class="Rrule" align="center">79 (1.8)</td>        </tr>        <tr class="Last">         <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Blister</td>        <td class="Rrule" align="center">63 (1.4)</td>        <td class="Rrule" align="center">40 (0.9)</td>        </tr>       </tbody>      </table>    </div>     <div class="Section" data-sectioncode="42229-5">      <a name="section-6.1.2.1"></a>      <p></p>      <p class="First"> <span class="Italics">Other clinical trial experience: </span>In an investigational study of acute medically ill patients being treated with XARELTO 10 mg tablets, cases of pulmonary hemorrhage and pulmonary hemorrhage with bronchiectasis were observed.</p>     </div>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S6.2"></a>   <a name="section-6.2"></a>    <p></p>    <h2>6.2 Postmarketing Experience</h2>    <p class="First">The following adverse reactions have been identified during post-approval use of rivaroxaban. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>    <p> <span class="Italics">Blood and lymphatic system disorders:</span> agranulocytosis, thrombocytopenia</p>    <p> <span class="Italics">Gastrointestinal disorders:</span> retroperitoneal hemorrhage</p>    <p> <span class="Italics">Hepatobiliary disorders:</span> jaundice, cholestasis, hepatitis (including hepatocellular injury)</p>    <p> <span class="Italics">Immune system disorders:</span> hypersensitivity, anaphylactic reaction, anaphylactic shock, angioedema</p>    <p> <span class="Italics">Nervous system disorders:</span> cerebral hemorrhage, subdural hematoma, epidural hematoma, hemiparesis</p>    <p> <span class="Italics">Skin and subcutaneous tissue disorders:</span> Stevens-Johnson syndrome</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">7 DRUG INTERACTIONS</a> <div class="Section toggle-content closed" data-sectioncode="34073-7">   <a name="S7"></a>  <a name="section-7"></a>   <p></p>    <p class="First">Rivaroxaban is a substrate of CYP3A4/5, CYP2J2, and the P-gp and ATP-binding cassette G2 (ABCG2) transporters. Inhibitors and inducers of these CYP450 enzymes or transporters (e.g., P-gp) may result in changes in rivaroxaban exposure.</p>   <div class="Section" data-sectioncode="42229-5">    <a name="S7.1"></a>   <a name="section-7.1"></a>    <p></p>    <h2>7.1 Drugs that Inhibit Cytochrome P450 3A4 Enzymes and Drug Transport Systems</h2>    <p class="First">In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin and fluconazole), increases in rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation) were observed. The increases in exposure ranged from 30% to 160%. Significant increases in rivaroxaban exposure may increase bleeding risk <span class="Italics">[see <a href="#s12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>    <p>When data suggest a change in exposure is unlikely to affect bleeding risk (e.g., clarithromycin, erythromycin), no precautions are necessary during coadministration with drugs that are combined P-gp and CYP3A4 inhibitors.</p>    <p>Avoid concomitant administration of XARELTO with combined P-gp and strong CYP3A4 inhibitors <span class="Italics">[see <a href="#s5.6">Warnings and Precautions (5.6)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S7.2"></a>   <a name="section-7.2"></a>    <p></p>    <h2>7.2 Drugs that Induce Cytochrome P450 3A4 Enzymes and Drug Transport Systems</h2>    <p class="First">Results from drug interaction studies and population PK analyses from clinical studies indicate coadministration of XARELTO with a combined P-gp and strong CYP3A4 inducer (e.g., rifampicin, phenytoin) decreased rivaroxaban exposure by up to 50%. Similar decreases in pharmacodynamic effects were also observed. These decreases in exposure to rivaroxaban may decrease efficacy <span class="Italics">[see <a href="#s12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>    <p>Avoid concomitant use of XARELTO with drugs that are combined P-gp and strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin, St. John's wort) <span class="Italics">[see <a href="#s5.6">Warnings and Precautions (5.6)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S7.3"></a>   <a name="section-7.3"></a>    <p></p>    <h2>7.3 Anticoagulants and NSAIDs/Aspirin</h2>    <p class="First">Single doses of enoxaparin and XARELTO given concomitantly resulted in an additive effect on anti-factor Xa activity. Single doses of warfarin and XARELTO resulted in an additive effect on factor Xa (FXa) inhibition and PT. Concomitant aspirin use has been identified as an independent risk factor for major bleeding in efficacy trials. NSAIDs are known to increase bleeding, and bleeding risk may be increased when NSAIDs are used concomitantly with XARELTO. Coadministration of the platelet aggregation inhibitor clopidogrel and XARELTO resulted in an increase in bleeding time for some subjects <span class="Italics">[see <a href="#s12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>    <p>Avoid concurrent use of XARELTO with other anticoagulants due to increased bleeding risk unless benefit outweighs risk. Promptly evaluate any signs or symptoms of blood loss if patients are treated concomitantly with aspirin, other platelet aggregation inhibitors, or NSAIDs <span class="Italics">[see <a href="#s5.2">Warnings and Precautions (5.2)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S7.4"></a>   <a name="section-7.4"></a>    <p></p>    <h2>7.4 Drug-Disease Interactions with Drugs that Inhibit Cytochrome P450 3A4 Enzymes and Drug Transport Systems</h2>    <p class="First">Results from a pharmacokinetic trial with erythromycin indicated that patients with renal impairment coadministered XARELTO with drugs classified as combined P-gp and moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, dronedarone, and erythromycin) have increased exposure compared with patients with normal renal function and no inhibitor use. Significant increases in rivaroxaban exposure may increase bleeding risk.</p>    <p>While increases in rivaroxaban exposure can be expected under such conditions, results from an analysis in the ROCKET AF trial, which allowed concomitant use with combined P-gp and weak or moderate CYP3A4 inhibitors (e.g., amiodarone, diltiazem, verapamil, chloramphenicol, cimetidine, and erythromycin), did not show an increase in bleeding in patients with CrCl 30 to &lt;50 mL/min [Hazard Ratio (95% CI): 1.05 (0.77, 1.42)] <span class="Italics">[see <a href="#S8.7">Use in Specific Populations (8.7)</a>]</span>.</p>    <p>XARELTO should not be used in patients with CrCl 15 to 80 mL/min who are receiving concomitant combined P-gp and moderate CYP3A4 inhibitors unless the potential benefit justifies the potential risk <span class="Italics">[see <a href="#s12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">8 USE IN SPECIFIC POPULATIONS</a> <div class="Section toggle-content closed" data-sectioncode="43684-0">   <a name="S8"></a>  <a name="section-8"></a>   <p></p>    <div class="Section" data-sectioncode="42228-7">    <a name="S8.1"></a>   <a name="section-8.1"></a>    <p></p>    <h2>8.1 Pregnancy</h2>    <div class="Section" data-sectioncode="34077-8">     <a name="section-8.1.1"></a>     <p></p>     <p class="First">Pregnancy Category C</p>     <p>There are no adequate or well-controlled studies of XARELTO in pregnant women, and dosing for pregnant women has not been established. Use XARELTO with caution in pregnant patients because of the potential for pregnancy related hemorrhage and/or emergent delivery with an anticoagulant that is not readily reversible. The anticoagulant effect of XARELTO cannot be reliably monitored with standard laboratory testing. Animal reproduction studies showed no increased risk of structural malformations, but increased post-implantation pregnancy loss occurred in rabbits. XARELTO should be used during pregnancy only if the potential benefit justifies the potential risk to mother and fetus <span class="Italics">[see <a href="#s5.7">Warnings and Precautions (5.7)</a>]</span>.</p>     <p>Rivaroxaban crosses the placenta in animals. Animal reproduction studies have shown pronounced maternal hemorrhagic complications in rats and an increased incidence of post‑implantation pregnancy loss in rabbits. Rivaroxaban increased fetal toxicity (increased resorptions, decreased number of live fetuses, and decreased fetal body weight) when pregnant rabbits were given oral doses of ≥10 mg/kg rivaroxaban during the period of organogenesis. This dose corresponds to about 4 times the human exposure of unbound drug, based on AUC comparisons at the highest recommended human dose of 20 mg/day. Fetal body weights decreased when pregnant rats were given oral doses of 120 mg/kg. This dose corresponds to about 14 times the human exposure of unbound drug.</p>    </div>   </div>   <div class="Section" data-sectioncode="34079-4">    <a name="S8.2"></a>   <a name="section-8.2"></a>    <p></p>    <h2>8.2 Labor and Delivery</h2>    <p class="First">Safety and effectiveness of XARELTO during labor and delivery have not been studied in clinical trials. However, in animal studies maternal bleeding and maternal and fetal death occurred at the rivaroxaban dose of 40 mg/kg (about 6 times maximum human exposure of the unbound drug at the human dose of 20 mg/day).</p>   </div>   <div class="Section" data-sectioncode="34080-2">    <a name="S8.3"></a>   <a name="section-8.3"></a>    <p></p>    <h2>8.3 Nursing Mothers</h2>    <p class="First">It is not known if rivaroxaban is excreted in human milk. Rivaroxaban and/or its metabolites were excreted into the milk of rats. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from rivaroxaban, a decision should be made whether to discontinue nursing or discontinue XARELTO, taking into account the importance of the drug to the mother.</p>   </div>   <div class="Section" data-sectioncode="34081-0">    <a name="S8.4"></a>   <a name="section-8.4"></a>    <p></p>    <h2>8.4 Pediatric Use</h2>    <p class="First">Safety and effectiveness in pediatric patients have not been established.</p>   </div>   <div class="Section" data-sectioncode="34082-8">    <a name="S8.5"></a>   <a name="section-8.5"></a>    <p></p>    <h2>8.5 Geriatric Use</h2>    <p class="First">Of the total number of patients in the RECORD 1–3 clinical studies evaluating XARELTO, about 54% were 65 years and over, while about 15% were &gt;75 years. In ROCKET AF, approximately 77% were 65 years and over and about 38% were &gt;75 years. In the EINSTEIN DVT, PE and Extension clinical studies approximately 37% were 65 years and over and about 16% were &gt;75 years. In clinical trials the efficacy of XARELTO in the elderly (65 years or older) was similar to that seen in patients younger than 65 years. Both thrombotic and bleeding event rates were higher in these older patients, but the risk-benefit profile was favorable in all age groups <span class="Italics">[see <a href="#s12.3">Clinical Pharmacology (12.3)</a> and <a href="#s14">Clinical Studies (14)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S8.6"></a>   <a name="section-8.6"></a>    <p></p>    <h2>8.6 Females of Reproductive Potential</h2>    <p class="First">Females of reproductive potential requiring anticoagulation should discuss pregnancy planning with their physician.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S8.7"></a>   <a name="section-8.7"></a>    <p></p>    <h2>8.7 Renal Impairment</h2>    <p class="First">In a pharmacokinetic study, compared to healthy subjects with normal creatinine clearance, rivaroxaban exposure increased by approximately 44 to 64% in subjects with renal impairment. Increases in pharmacodynamic effects were also observed <span class="Italics">[see <a href="#s12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>    <div class="Section" data-sectioncode="42229-5">     <a name="section-8.7.1"></a>     <p></p>     <p class="First"> <span class="Underline">Nonvalvular Atrial Fibrillation</span> </p>     <p>In the ROCKET AF trial, patients with CrCl 30 to 50 mL/min were administered XARELTO 15 mg once daily resulting in serum concentrations of rivaroxaban and clinical outcomes similar to those in patients with better renal function administered XARELTO 20 mg once daily. Patients with CrCl 15 to 30 mL/min were not studied, but administration of XARELTO 15 mg once daily is also expected to result in serum concentrations of rivaroxaban similar to those in patients with normal renal function <span class="Italics">[see <a href="#s2.3">Dosage and Administration (2.3)</a>]</span>.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-8.7.2"></a>     <p></p>     <p class="First"> <span class="Underline">Treatment of DVT and/or PE, and Reduction in the Risk of Recurrence of DVT and of PE</span> </p>     <p>In the EINSTEIN trials, patients with CrCl values &lt;30 mL/min at screening were excluded from the studies. Avoid the use of XARELTO in patients with CrCl &lt;30 mL/min.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-8.7.3"></a>     <p></p>     <p class="First"> <span class="Underline">Prophylaxis of DVT Following Hip or Knee Replacement Surgery</span> </p>     <p>The combined analysis of the RECORD 1–3 clinical efficacy studies did not show an increase in bleeding risk for patients with CrCl 30 to 50 mL/min and reported a possible increase in total venous thromboemboli in this population. Observe closely and promptly evaluate any signs or symptoms of blood loss in patients with CrCl 30 to 50 mL/min. Avoid the use of XARELTO in patients with CrCl &lt;30 mL/min.</p>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S8.8"></a>   <a name="section-8.8"></a>    <p></p>    <h2>8.8 Hepatic Impairment</h2>    <p class="First">In a pharmacokinetic study, compared to healthy subjects with normal liver function, AUC increases of 127% were observed in subjects with moderate hepatic impairment (Child-Pugh B).</p>    <p>The safety or PK of XARELTO in patients with severe hepatic impairment (Child-Pugh C) has not been evaluated <span class="Italics">[see <a href="#s12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>    <p>Avoid the use of XARELTO in patients with moderate (Child-Pugh B) and severe (Child-Pugh C) hepatic impairment or with any hepatic disease associated with coagulopathy.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">10 OVERDOSAGE</a> <div class="Section toggle-content closed" data-sectioncode="34088-5">   <a name="S10"></a>  <a name="section-9"></a>   <p></p>    <p class="First">Overdose of XARELTO may lead to hemorrhage. Discontinue XARELTO and initiate appropriate therapy if bleeding complications associated with overdosage occur. A specific antidote for rivaroxaban is not available. Rivaroxaban systemic exposure is not further increased at single doses &gt;50 mg due to limited absorption. The use of activated charcoal to reduce absorption in case of XARELTO overdose may be considered. Due to the high plasma protein binding, rivaroxaban is not expected to be dialyzable <span class="Italics">[see <a href="#s5.2">Warnings and Precautions (5.2)</a> and <a href="#s12.3">Clinical Pharmacology (12.3)</a>]</span>. Partial reversal of laboratory anticoagulation parameters may be achieved with use of plasma products.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">11 DESCRIPTION</a> <div class="Section toggle-content closed" data-sectioncode="34089-3">   <a name="S11"></a>  <a name="section-10"></a>   <p></p>    <p class="First">Rivaroxaban, a FXa inhibitor, is the active ingredient in XARELTO Tablets with the chemical name 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide. The molecular formula of rivaroxaban is C<span class="Sub">19</span>H<span class="Sub">18</span>ClN<span class="Sub">3</span>O<span class="Sub">5</span>S and the molecular weight is 435.89. The structural formula is:</p>   <div class="Figure">    <img src="image.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610&name=xarelto%2D01%2Ejpg" alt="Chemical Structure" />  </div>   <p>Rivaroxaban is a pure (<span class="Italics">S</span>)-enantiomer. It is an odorless, non-hygroscopic, white to yellowish powder. Rivaroxaban is only slightly soluble in organic solvents (e.g., acetone, polyethylene glycol 400) and is practically insoluble in water and aqueous media.</p>   <p>Each XARELTO tablet contains 10 mg, 15 mg, or 20 mg of rivaroxaban. The inactive ingredients of XARELTO are: croscarmellose sodium, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. Additionally, the proprietary film coating mixture used for XARELTO 10 mg tablets is Opadry<span class="Sup">&reg;</span> Pink and for XARELTO 15 mg tablets is Opadry<span class="Sup">&reg;</span> Red, both containing ferric oxide red, hypromellose, polyethylene glycol 3350, and titanium dioxide, and for XARELTO 20 mg tablets is Opadry<span class="Sup">&reg;</span> II Dark Red, containing ferric oxide red, polyethylene glycol 3350, polyvinyl alcohol (partially hydrolyzed), talc, and titanium dioxide.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">12 CLINICAL PHARMACOLOGY</a> <div class="Section toggle-content closed" data-sectioncode="34090-1">   <a name="S12"></a>  <a name="section-11"></a>   <p></p>    <div class="Section" data-sectioncode="43679-0">    <a name="S12.1"></a>   <a name="section-11.1"></a>    <p></p>    <h2>12.1 Mechanism of Action</h2>    <p class="First">XARELTO is a selective inhibitor of FXa. It does not require a cofactor (such as Anti-thrombin III) for activity. Rivaroxaban inhibits free FXa and prothrombinase activity. Rivaroxaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, rivaroxaban decreases thrombin generation.</p>   </div>   <div class="Section" data-sectioncode="43681-6">    <a name="S12.2"></a>   <a name="section-11.2"></a>    <p></p>    <h2>12.2 Pharmacodynamics</h2>    <p class="First">Dose-dependent inhibition of FXa activity was observed in humans and the Neoplastin<span class="Sup">&reg;</span> prothrombin time (PT), activated partial thromboplastin time (aPTT) and HepTest<span class="Sup">&reg;</span> are prolonged dose-dependently. Anti-factor Xa activity is also influenced by rivaroxaban.</p>   </div>   <div class="Section" data-sectioncode="43682-4">    <a name="S12.3"></a>   <a name="section-11.3"></a>    <p></p>    <h2>12.3 Pharmacokinetics</h2>    <div class="Section" data-sectioncode="42229-5">     <a name="section-11.3.1"></a>     <p></p>     <p class="First">Absorption</p>     <p>The absolute bioavailability of rivaroxaban is dose-dependent. For the 10 mg dose, it is estimated to be 80% to 100% and is not affected by food. XARELTO 10 mg tablets can be taken with or without food. For the 20 mg dose in the fasted state, the absolute bioavailability is approximately 66%. Coadministration of XARELTO with food increases the bioavailability of the 20 mg dose (mean AUC and C<span class="Sub">max</span> increasing by 39% and 76% respectively with food). XARELTO 15 mg and 20 mg tablets should be taken with food <span class="Italics">[see <a href="#s2.1">Dosage and Administration (2.1)</a>]</span>.</p>     <p>The maximum concentrations (C<span class="Sub">max</span>) of rivaroxaban appear 2 to 4 hours after tablet intake. The pharmacokinetics of rivaroxaban were not affected by drugs altering gastric pH. Coadministration of XARELTO (30 mg single dose) with the H<span class="Sub">2</span>-receptor antagonist ranitidine (150 mg twice daily), the antacid aluminum hydroxide/magnesium hydroxide (10 mL) or XARELTO (20 mg single dose) with the PPI omeprazole (40 mg once daily) did not show an effect on the bioavailability and exposure of rivaroxaban.</p>     <p>Absorption of rivaroxaban is dependent on the site of drug release in the GI tract. A 29% and 56% decrease in AUC and C<span class="Sub">max</span> compared to tablet was reported when rivaroxaban granulate is released in the proximal small intestine. Exposure is further reduced when drug is released in the distal small intestine, or ascending colon. Avoid administration of rivaroxaban distal to the stomach which can result in reduced absorption and related drug exposure.</p>     <p>In a study with 44 healthy subjects, both mean AUC and C<span class="Sub">max</span> values for 20 mg rivaroxaban administered orally as a crushed tablet mixed in applesauce were comparable to that after the whole tablet. However, for the crushed tablet suspended in water and administered via an NG tube followed by a liquid meal, only mean AUC was comparable to that after the whole tablet, and C<span class="Sub">max</span> was 18% lower.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-11.3.2"></a>     <p></p>     <p class="First">Distribution</p>     <p>Plasma protein binding of rivaroxaban in human plasma is approximately 92% to 95%, with albumin being the main binding component. The steady-state volume of distribution in healthy subjects is approximately 50 L.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-11.3.3"></a>     <p></p>     <p class="First">Metabolism</p>     <p>Approximately 51% of an orally administered [<span class="Sup">14</span>C]-rivaroxaban dose was recovered as inactive metabolites in urine (30%) and feces (21%). Oxidative degradation catalyzed by CYP3A4/5 and CYP2J2 and hydrolysis are the major sites of biotransformation. Unchanged rivaroxaban was the predominant moiety in plasma with no major or active circulating metabolites.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-11.3.4"></a>     <p></p>     <p class="First">Excretion</p>     <p>Following oral administration, approximately one-third of the absorbed dose is excreted unchanged in the urine, with the remaining two-thirds excreted as inactive metabolites in both the urine and feces. In a Phase 1 study, following the administration of a [<span class="Sup">14</span>C]-rivaroxaban dose, 66% of the radioactive dose was recovered in urine (36% as unchanged drug) and 28% was recovered in feces (7% as unchanged drug). Unchanged drug is excreted into urine, mainly via active tubular secretion and to a lesser extent via glomerular filtration (approximate 5:1 ratio). Rivaroxaban is a substrate of the efflux transporter proteins P-gp and ABCG2 (also abbreviated Bcrp). Rivaroxaban's affinity for influx transporter proteins is unknown.</p>     <p>Rivaroxaban is a low-clearance drug, with a systemic clearance of approximately 10 L/hr in healthy volunteers following intravenous administration. The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.</p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-11.3.5"></a>     <p></p>     <p class="First">Specific Populations</p>     <div class="Section" data-sectioncode="42229-5">      <a name="section-11.3.5.1"></a>      <p></p>      <p class="First"> <span class="Italics">Gender</span> </p>      <p>Gender did not influence the pharmacokinetics or pharmacodynamics of XARELTO.</p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="section-11.3.5.2"></a>      <p></p>      <p class="First"> <span class="Italics">Race</span> </p>      <p>Healthy Japanese subjects were found to have 20 to 40% on average higher exposures compared to other ethnicities including Chinese. However, these differences in exposure are reduced when values are corrected for body weight.</p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="section-11.3.5.3"></a>      <p></p>      <p class="First"> <span class="Italics">Elderly</span> </p>      <p>In clinical studies, elderly subjects exhibited higher rivaroxaban plasma concentrations than younger subjects with mean AUC values being approximately 50% higher, mainly due to reduced (apparent) total body and renal clearance. Age related changes in renal function may play a role in this age effect. The terminal elimination half-life is 11 to 13 hours in the elderly <span class="Italics">[see <a href="#s8.5">Use in Specific Populations (8.5)</a>]</span>.</p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="section-11.3.5.4"></a>      <p></p>      <p class="First"> <span class="Italics">Body Weight</span> </p>      <p>Extremes in body weight (&lt;50 kg or &gt;120 kg) did not influence (less than 25%) rivaroxaban exposure.</p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="section-11.3.5.5"></a>      <p></p>      <p class="First"> <span class="Italics">Renal Impairment</span> </p>      <p>The safety and pharmacokinetics of single-dose XARELTO (10 mg) were evaluated in a study in healthy subjects [CrCl ≥80 mL/min (n=8)] and in subjects with varying degrees of renal impairment (see <a href="#table7">Table 7</a>). Compared to healthy subjects with normal creatinine clearance, rivaroxaban exposure increased in subjects with renal impairment. Increases in pharmacodynamic effects were also observed.</p>      <a name="table7"></a>      <div class="scrollingtable">      <table width="100%">        <caption>         <span>Table 7: Percent Increase of Rivaroxaban PK and PD Parameters from Normal in Subjects with Renal Insufficiency from a Dedicated Renal Impairment Study</span>        </caption>        <colgroup>        <col align="center" valign="top" width="33%" />         <col align="center" valign="top" width="7%" />         <col align="center" valign="top" width="20%" />         <col align="center" valign="top" width="20%" />         <col align="center" valign="top" width="20%" />        </colgroup>       <thead>         <tr class="First">          <th align="center" colspan="2"></th>         <th class="Botrule" align="center" colspan="3">CrCl (mL/min)</th>         </tr>         <tr class="Last">          <th align="center" colspan="2">Parameter</th>         <th align="center">50 to 79<br />N = 8</th>         <th align="center">30 to 49<br />N = 8</th>         <th align="center">15 to 29<br />N = 8</th>         </tr>        </thead>        <tfoot>         <tr class="First Last">          <td align="left" colspan="5" valign="top">PT = Prothrombin time; FXa = Coagulation factor Xa; AUC = Area under the concentration or effect curve; C<span class="Sub">max </span>= maximum concentration; E<span class="Sub">max </span>= maximum effect; and CrCl = creatinine clearance</td>         </tr>        </tfoot>        <tbody>         <tr class="First">          <td align="center"><span class="Bold">Exposure</span></td>         <td align="center"><span class="Bold">AUC</span></td>         <td align="center">44</td>         <td align="center">52</td>         <td align="center">64</td>         </tr>         <tr>          <td align="center"><span class="Bold">(% increase relative to normal)</span></td>         <td align="center"><span class="Bold">C<span class="Sub">max</span></span></td>         <td align="center">28</td>         <td align="center">12</td>         <td align="center">26</td>         </tr>         <tr>          <td align="center"><span class="Bold">FXa Inhibition</span></td>         <td align="center"><span class="Bold">AUC</span></td>         <td align="center">50</td>         <td align="center">86</td>         <td align="center">100</td>         </tr>         <tr>          <td align="center"><span class="Bold">(% increase relative to normal)</span></td>         <td align="center"><span class="Bold">E<span class="Sub">max</span></span></td>         <td align="center">9</td>         <td align="center">10</td>         <td align="center">12</td>         </tr>         <tr>          <td align="center"><span class="Bold">PT Prolongation</span></td>         <td align="center"><span class="Bold">AUC</span></td>         <td align="center">33</td>         <td align="center">116</td>         <td align="center">144</td>         </tr>         <tr class="Botrule Last">          <td align="center"><span class="Bold">(% increase relative to normal)</span></td>         <td align="center"><span class="Bold">E<span class="Sub">max</span></span></td>         <td align="center">4</td>         <td align="center">17</td>         <td align="center">20</td>         </tr>        </tbody>       </table>     </div>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="section-11.3.5.6"></a>      <p></p>      <p class="First">Hepatic Impairment</p>      <p>The safety and pharmacokinetics of single-dose XARELTO (10 mg) were evaluated in a study in healthy subjects (n=16) and subjects with varying degrees of hepatic impairment (see <a href="#table8">Table 8</a>). No patients with severe hepatic impairment (Child-Pugh C) were studied. Compared to healthy subjects with normal liver function, significant increases in rivaroxaban exposure were observed in subjects with moderate hepatic impairment (Child-Pugh B). Increases in pharmacodynamic effects were also observed.</p>      <a name="table8"></a>      <div class="scrollingtable">      <table width="100%">        <caption>         <span>Table 8: Percent Increase of Rivaroxaban PK and PD Parameters from Normal in Subjects with Hepatic Insufficiency from a Dedicated Hepatic Impairment Study</span>        </caption>        <colgroup>        <col align="center" valign="top" width="33%" />         <col align="center" valign="top" width="7%" />         <col align="center" valign="top" width="30%" />         <col align="center" valign="top" width="30%" />        </colgroup>       <thead>         <tr class="First">          <th align="center" colspan="2"></th>         <th class="Botrule" align="center" colspan="2">Hepatic Impairment Class<br />(Child-Pugh Class)</th>         </tr>         <tr class="Last">          <th align="center" colspan="2">Parameter</th>         <th align="center">Mild<br />(Child-Pugh A)<br />N = 8</th>         <th align="center">Moderate<br />(Child-Pugh B)<br />N = 8</th>         </tr>        </thead>        <tfoot>         <tr class="First Last">          <td align="left" colspan="4" valign="top">PT = Prothrombin time; FXa = Coagulation factor Xa; AUC = Area under the concentration or effect curve; C<span class="Sub">max </span>= maximum concentration; E<span class="Sub">max </span>= maximum effect</td>         </tr>        </tfoot>        <tbody>         <tr class="First">          <td align="center"><span class="Bold">Exposure</span></td>         <td align="center"><span class="Bold">AUC</span></td>         <td align="center">15</td>         <td align="center">127</td>         </tr>         <tr>          <td align="center"><span class="Bold">(% increase relative to normal)</span></td>         <td align="center"><span class="Bold">C<span class="Sub">max</span></span></td>         <td align="center">0</td>         <td align="center">27</td>         </tr>         <tr>          <td align="center"><span class="Bold">FXa Inhibition</span></td>         <td align="center"><span class="Bold">AUC</span></td>         <td align="center">8</td>         <td align="center">159</td>         </tr>         <tr>          <td align="center"><span class="Bold">(% increase relative to normal)</span></td>         <td align="center"><span class="Bold">E<span class="Sub">max</span></span></td>         <td align="center">0</td>         <td align="center">24</td>         </tr>         <tr>          <td align="center"><span class="Bold">PT Prolongation</span></td>         <td align="center"><span class="Bold">AUC</span></td>         <td align="center">6</td>         <td align="center">114</td>         </tr>         <tr class="Botrule Last">          <td align="center"><span class="Bold">(% increase relative to normal)</span></td>         <td align="center"><span class="Bold">E<span class="Sub">max</span></span></td>         <td align="center">2</td>         <td align="center">41</td>         </tr>        </tbody>       </table>     </div>     </div>    </div>    <div class="Section" data-sectioncode="34073-7">     <a name="section-11.3.6"></a>     <p></p>     <p class="First">Drug Interactions</p>     <p> <span class="Italics">In vitro</span> studies indicate that rivaroxaban neither inhibits the major cytochrome P450 enzymes CYP1A2, 2C8, 2C9, 2C19, 2D6, 2J2, and 3A4 nor induces CYP1A2, 2B6, 2C19, or 3A4.<span class="Italics"> In vitro</span> data also indicates a low rivaroxaban inhibitory potential for P-gp and ABCG2 transporters.</p>     <div class="Section" data-sectioncode="42229-5">      <a name="section-11.3.6.1"></a>      <p></p>      <p class="First"> <span class="Italics">Drugs that Inhibit Cytochrome P450 3A4 Enzymes and Drug Transport Systems</span> </p>      <p>In drug interaction studies evaluating the concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors the following increases in rivaroxaban exposure were observed. Similar increases in pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation) were also observed. Significant increases in rivaroxaban exposure may increase bleeding risk.</p>      <ul class="Disc">       <li> <span class="Italics">Ketoconazole (combined P-gp and strong CYP3A4 inhibitor):</span> Steady-state rivaroxaban AUC and C<span class="Sub">max</span> increased by 160% and 70%, respectively. Similar increases in pharmacodynamic effects were also observed.</li>       <li> <span class="Italics">Ritonavir (combined P-gp and strong CYP3A4 inhibitor): </span>Single-dose rivaroxaban AUC and C<span class="Sub">max</span> increased by 150% and 60%, respectively. Similar increases in pharmacodynamic effects were also observed.</li>       <li> <span class="Italics">Clarithromycin (combined P-gp and strong CYP3A4 inhibitor):</span> Single-dose rivaroxaban AUC and C<span class="Sub">max</span> increased by 50% and 40%, respectively. The smaller increases in exposure observed for clarithromycin compared to ketoconazole or ritonavir may be due to the relative difference in P-gp inhibition.</li>       <li> <span class="Italics">Erythromycin (combined P-gp and moderate CYP3A4 inhibitor):</span> Both the single-dose rivaroxaban AUC and C<span class="Sub">max</span> increased by 30%.</li>       <li> <span class="Italics">Fluconazole (moderate CYP3A4 inhibitor):</span> Single-dose rivaroxaban AUC and C<span class="Sub">max</span> increased by 40% and 30%, respectively.</li>      </ul>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="section-11.3.6.2"></a>      <p></p>      <p class="First"> <span class="Italics">Drugs that Induce Cytochrome P450 3A4 Enzymes and Drug Transport Systems</span> </p>      <p>In a drug interaction study, coadministration of XARELTO (20 mg single dose with food) with a drug that is a combined P-gp and strong CYP3A4 inducer (rifampicin titrated up to 600 mg once daily) led to an approximate decrease of 50% and 22% in AUC and C<span class="Sub">max</span>, respectively. Similar decreases in pharmacodynamic effects were also observed. These decreases in exposure to rivaroxaban may decrease efficacy.</p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="section-11.3.6.3"></a>      <p></p>      <p class="First"> <span class="Italics">Anticoagulants</span> </p>      <p>In a drug interaction study, single doses of enoxaparin (40 mg subcutaneous) and XARELTO (10 mg) given concomitantly resulted in an additive effect on anti-factor Xa activity. Enoxaparin did not affect the pharmacokinetics of rivaroxaban. In another study, single doses of warfarin (15 mg) and XARELTO (5 mg) resulted in an additive effect on factor Xa inhibition and PT. Warfarin did not affect the pharmacokinetics of rivaroxaban.</p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="section-11.3.6.4"></a>      <p></p>      <p class="First"> <span class="Italics">NSAIDs/Aspirin</span> </p>      <p>In ROCKET AF, concomitant aspirin use (almost exclusively at a dose of 100 mg or less) during the double-blind phase was identified as an independent risk factor for major bleeding. NSAIDs are known to increase bleeding, and bleeding risk may be increased when NSAIDs are used concomitantly with XARELTO. In a single-dose drug interaction study there were no pharmacokinetic or pharmacodynamic interactions observed after concomitant administration of naproxen or aspirin (acetylsalicylic acid) with XARELTO.</p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="section-11.3.6.5"></a>      <p></p>      <p class="First"> <span class="Italics">Clopidogrel</span> </p>      <p>In two drug interaction studies where clopidogrel (300 mg loading dose followed by 75 mg daily maintenance dose) and XARELTO (15 mg single dose) were coadministered in healthy subjects, an increase in bleeding time to 45 minutes was observed in approximately 45% and 30% of subjects in these studies, respectively. The change in bleeding time was approximately twice the maximum increase seen with either drug alone. There was no change in the pharmacokinetics of either drug.</p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="section-11.3.6.6"></a>      <p></p>      <p class="First"> <span class="Italics">Drug-Disease Interactions with Drugs that Inhibit Cytochrome P450 3A4 Enzymes and Drug Transport Systems</span> </p>      <p>In a pharmacokinetic trial, XARELTO was administered as a single dose in subjects with mild (CrCl = 50 to 79 mL/min) or moderate renal impairment (CrCl = 30 to 49 mL/min) receiving multiple doses of erythromycin (a combined P-gp and moderate CYP3A4 inhibitor). Compared to XARELTO administered alone in subjects with normal renal function (CrCl &gt;80 mL/min), subjects with mild and moderate renal impairment concomitantly receiving erythromycin reported a 76% and 99% increase in AUC<span class="Sub">inf</span> and a 56% and 64% increase in C<span class="Sub">max</span>, respectively. Similar trends in pharmacodynamic effects were also observed.</p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="section-11.3.6.7"></a>      <p></p>      <p class="First"> <span class="Italics">Drugs that are Substrates of CYP3A4 and/or Drug Transport Systems</span> </p>      <p>In addition, there were no significant pharmacokinetic interactions observed in studies comparing concomitant rivaroxaban 20 mg and 7.5 mg single dose of midazolam (substrate of CYP3A4), 0.375 mg once-daily dose of digoxin (substrate of P-gp), or 20 mg once daily dose of atorvastatin (substrate of CYP3A4 and P-gp) in healthy volunteers.</p>     </div>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S12.6"></a>   <a name="section-11.4"></a>    <p></p>    <h2>12.6 QT/QTc Prolongation</h2>    <p class="First">In a thorough QT study in healthy men and women aged 50 years and older, no QTc prolonging effects were observed for XARELTO (15 mg and 45 mg, single-dose).</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">13 NON-CLINICAL TOXICOLOGY</a> <div class="Section toggle-content closed" data-sectioncode="43680-8">   <a name="S13"></a>  <a name="section-12"></a>   <p></p>    <div class="Section" data-sectioncode="34083-6">    <a name="S13.1"></a>   <a name="section-12.1"></a>    <p></p>    <h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>    <p class="First">Rivaroxaban was not carcinogenic when administered by oral gavage to mice or rats for up to 2 years. The systemic exposures (AUCs) of unbound rivaroxaban in male and female mice at the highest dose tested (60 mg/kg/day) were 1- and 2-times, respectively, the human exposure of unbound drug at the human dose of 20 mg/day. Systemic exposures of unbound drug in male and female rats at the highest dose tested (60 mg/kg/day) were 2- and 4-times, respectively, the human exposure.</p>    <p>Rivaroxaban was not mutagenic in bacteria (Ames-Test) or clastogenic in V79 Chinese hamster lung cells <span class="Italics">in vitro</span> or in the mouse micronucleus test<span class="Italics"> in vivo</span>.</p>    <p>No impairment of fertility was observed in male or female rats when given up to 200 mg/kg/day of rivaroxaban orally. This dose resulted in exposure levels, based on the unbound AUC, at least 13 times the exposure in humans given 20 mg rivaroxaban daily.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">14 CLINICAL STUDIES</a> <div class="Section toggle-content closed" data-sectioncode="34092-7">   <a name="S14"></a>  <a name="section-13"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="S14.1"></a>   <a name="section-13.1"></a>    <p></p>    <h2>14.1 Stroke Prevention in Nonvalvular Atrial Fibrillation</h2>    <p class="First">The evidence for the efficacy and safety of XARELTO was derived from ROCKET AF, a multi-national, double-blind study comparing XARELTO (at a dose of 20 mg once daily with the evening meal in patients with CrCl &gt;50 mL/min and 15 mg once daily with the evening meal in patients with CrCl 30 to &lt;50 mL/min) to warfarin (titrated to INR 2.0 to 3.0) to reduce the risk of stroke and non-central nervous system (CNS) systemic embolism in patients with nonvalvular atrial fibrillation (AF). Patients had to have one or more of the following additional risk factors for stroke:</p>    <ul class="Disc">     <li>a prior stroke (ischemic or unknown type), transient ischemic attack (TIA) or non‑CNS systemic embolism, or</li>     <li>2 or more of the following risk factors:      <ul class="Circle">       <li>age ≥75 years,</li>       <li>hypertension,</li>       <li>heart failure or left ventricular ejection fraction ≤35%, or</li>       <li>diabetes mellitus</li>      </ul> </li>    </ul>    <p>ROCKET AF was a non-inferiority study designed to demonstrate that XARELTO preserved more than 50% of warfarin's effect on stroke and non-CNS systemic embolism as established by previous placebo-controlled studies of warfarin in atrial fibrillation.</p>    <p>A total of 14264 patients were randomized and followed on study treatment for a median of 590 days. The mean age was 71 years and the mean CHADS<span class="Sub">2</span> score was 3.5. The population was 60% male, 83% Caucasian, 13% Asian and 1.3% Black. There was a history of stroke, TIA, or non-CNS systemic embolism in 55% of patients, and 38% of patients had not taken a vitamin K antagonist (VKA) within 6 weeks at time of screening. Concomitant diseases of patients in this study included hypertension 91%, diabetes 40%, congestive heart failure 63%, and prior myocardial infarction 17%. At baseline, 37% of patients were on aspirin (almost exclusively at a dose of 100 mg or less) and few patients were on clopidogrel. Patients were enrolled in Eastern Europe (39%); North America (19%); Asia, Australia, and New Zealand (15%); Western Europe (15%); and Latin America (13%). Patients randomized to warfarin had a mean percentage of time in the INR target range of 2.0 to 3.0 of 55%, lower during the first few months of the study.</p>    <p>In ROCKET AF, XARELTO was demonstrated non-inferior to warfarin for the primary composite endpoint of time to first occurrence of stroke (any type) or non-CNS systemic embolism [HR (95% CI): 0.88 (0.74, 1.03)], but superiority to warfarin was not demonstrated. There is insufficient experience to determine how XARELTO and warfarin compare when warfarin therapy is well-controlled.</p>    <p>Table 9 displays the overall results for the primary composite endpoint and its components.</p>    <a name="table9"></a>    <div class="scrollingtable">    <table width="100%">      <caption>       <span>Table 9: Primary Composite Endpoint Results in ROCKET AF Study</span>      </caption>      <colgroup>      <col align="left" valign="middle" width="20%" />       <col align="center" valign="middle" width="15%" />       <col align="center" valign="middle" width="15%" />       <col align="center" valign="middle" width="15%" />       <col align="center" valign="middle" width="15%" />       <col align="center" valign="middle" width="20%" />      </colgroup>     <thead>       <tr class="Botrule First">        <th align="left"></th>       <th align="center" colspan="2" valign="top">XARELTO</th>       <th align="center" colspan="2" valign="top">Warfarin</th>       <th align="center" valign="top">XARELTO vs. Warfarin</th>       </tr>       <tr class="Botrule Last">        <th align="left">Event</th>       <th align="center" valign="top">N = 7081<br />n (%)</th>       <th align="center" valign="top">Event Rate<br />(per 100 Pt-yrs)</th>       <th align="center" valign="top">N = 7090<br />n (%)</th>       <th align="center" valign="top">Event Rate<br />(per 100 Pt-yrs)</th>       <th align="center" valign="top">Hazard Ratio<br />(95% CI)</th>       </tr>      </thead>      <tfoot>       <tr>        <td align="left" colspan="6">         <dl class="Footnote">          <dt>           <a href="#footnote-reference-17" name="footnote-17">*</a>          </dt>          <dd>          The primary endpoint was the time to first occurrence of stroke (any type) or non-CNS systemic embolism. Data are shown for all randomized patients followed to site notification that the study would end.         </dd>         </dl> </td>       </tr>      </tfoot>      <tbody>       <tr class="Botrule First">        <td align="left">Primary Composite Endpoint<a class="Sup" href="#footnote-17" name="footnote-reference-17">*</a></td>       <td align="center">269 (3.8)</td>       <td align="center">2.1</td>       <td align="center">306 (4.3)</td>       <td align="center">2.4</td>       <td align="center">0.88 (0.74, 1.03)</td>       </tr>       <tr class="Botrule">        <td align="left">Stroke</td>       <td align="center">253 (3.6)</td>       <td align="center">2.0</td>       <td align="center">281 (4.0)</td>       <td align="center">2.2</td>       <td align="center"></td>       </tr>       <tr class="Botrule">        <td align="left">&nbsp;&nbsp;Hemorrhagic Stroke</td>       <td align="center">33 (0.5)</td>       <td align="center">0.3</td>       <td align="center">57 (0.8)</td>       <td align="center">0.4</td>       <td align="center"></td>       </tr>       <tr class="Botrule">        <td align="left">&nbsp;&nbsp;Ischemic Stroke</td>       <td align="center">206 (2.9)</td>       <td align="center">1.6</td>       <td align="center">208 (2.9)</td>       <td align="center">1.6</td>       <td align="center"></td>       </tr>       <tr class="Botrule">        <td align="left">&nbsp;&nbsp;Unknown Stroke Type</td>       <td align="center">19 (0.3)</td>       <td align="center">0.2</td>       <td align="center">18 (0.3)</td>       <td align="center">0.1</td>       <td align="center"></td>       </tr>       <tr class="Botrule Last">        <td align="left">Non-CNS Systemic Embolism</td>       <td align="center">20 (0.3)</td>       <td align="center">0.2</td>       <td align="center">27 (0.4)</td>       <td align="center">0.2</td>       <td align="center"></td>       </tr>      </tbody>     </table>   </div>    <p>Figure 1 is a plot of the time from randomization to the occurrence of the first primary endpoint event in the two treatment arms.</p>    <p> <a name="fig1"></a><span class="Bold">Figure 1: Time to First Occurrence of Stroke (any type) or Non-CNS Systemic Embolism by Treatment Group</span> </p>    <div class="Figure">     <img src="image.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610&name=xarelto%2D02%2Ejpg" alt="Figure 1" />   </div>    <p>The efficacy of XARELTO was generally consistent across major subgroups.</p>    <p>The protocol for ROCKET AF did not stipulate anticoagulation after study drug discontinuation, but warfarin patients who completed the study were generally maintained on warfarin. XARELTO patients were generally switched to warfarin without a period of coadministration of warfarin and XARELTO, so that they were not adequately anticoagulated after stopping XARELTO until attaining a therapeutic INR. During the 28 days following the end of the study, there were 22 strokes in the 4637 patients taking XARELTO vs. 6 in the 4691 patients taking warfarin.</p>    <p>Few patients in ROCKET AF underwent electrical cardioversion for atrial fibrillation. The utility of XARELTO for preventing post-cardioversion stroke and systemic embolism is unknown.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S14.2"></a>   <a name="section-13.2"></a>    <p></p>    <h2>14.2 Treatment of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and Reduction in the Risk of Recurrence of DVT and of PE</h2>    <div class="Section" data-sectioncode="42229-5">     <a name="section-13.2.1"></a>     <p></p>     <p class="First"> <span class="Underline">EINSTEIN Deep Vein Thrombosis and EINSTEIN Pulmonary Embolism Studies</span> </p>     <p>XARELTO for the treatment of DVT and/or PE and for the reduction in the risk of recurrence of DVT and of PE was studied in EINSTEIN DVT and EINSTEIN PE, multi-national, open-label, non-inferiority studies comparing XARELTO (at an initial dose of 15 mg twice daily with food for the first three weeks, followed by XARELTO 20 mg once daily with food) to enoxaparin 1 mg/kg twice daily for at least five days with VKA and then continued with VKA only after the target INR (2.0–3.0) was reached. Patients who required thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent and patients with creatinine clearance &lt;30 mL/min, significant liver disease, or active bleeding were excluded from the studies. The intended treatment duration was 3, 6, or 12 months based on investigator's assessment prior to randomization.</p>     <p>A total of 8281 (3449 in EINSTEIN DVT and 4832 in EINSTEIN PE) patients were randomized and followed on study treatment for a mean of 208 days in the XARELTO group and 204 days in the enoxaparin/VKA group. The mean age was approximately 57 years. The population was 55% male, 70% Caucasian, 9% Asian and about 3% Black. About 73% and 92% of XARELTO-treated patients in the EINSTEIN DVT and EINSTEIN PE studies, respectively, received initial parenteral anticoagulant treatment for a median duration of 2 days. Enoxaparin/VKA-treated patients in the EINSTEIN DVT and EINSTEIN PE studies received initial parenteral anticoagulant treatment for a median duration of 8 days. Aspirin was taken as on treatment concomitant antithrombotic medication by approximately 12% of patients in both treatment groups. Patients randomized to VKA had an unadjusted mean percentage of time in the INR target range of 2.0 to 3.0 of 58% in EINSTEIN DVT study and 60% in EINSTEIN PE study, with the lower values occurring during the first month of the study.</p>     <p>In the EINSTEIN DVT and EINSTEIN PE studies, 49% of patients had an idiopathic DVT/PE at baseline. Other risk factors included previous episode of DVT/PE (19%), recent surgery or trauma (18%), immobilization (16%), use of estrogen-containing drug (8%), known thrombophilic conditions (6%), or active cancer (5%).</p>     <p>In the EINSTEIN DVT and EINSTEIN PE studies, XARELTO was demonstrated to be non-inferior to enoxaparin/VKA for the primary composite endpoint of time to first occurrence of recurrent DVT or non-fatal or fatal PE [EINSTEIN DVT HR (95% CI): 0.68 (0.44, 1.04); EINSTEIN PE HR (95% CI): 1.12 (0.75, 1.68)]. In each study the conclusion of non-inferiority was based on the upper limit of the 95% confidence interval for the hazard ratio being less than 2.0.</p>     <p>Table 10 displays the overall results for the primary composite endpoint and its components for EINSTEIN DVT and EINSTEIN PE studies.</p>     <a name="table10"></a>     <div class="scrollingtable">     <table width="100%">       <caption>        <span>Table 10: Primary Composite Endpoint Results<a class="Sup" href="#footnote-18" name="footnote-reference-18">*</a> in EINSTEIN DVT and EINSTEIN PE Studies – Intent-to-Treat Population</span>       </caption>       <colgroup>       <col align="left" valign="middle" width="40%" />        <col align="center" valign="middle" width="20%" />        <col align="center" valign="middle" width="20%" />        <col align="center" valign="middle" width="20%" />       </colgroup>      <thead>        <tr class="First Last">         <th class="Lrule" align="left">Event</th>        <th align="center" valign="top">XARELTO 20 mg<a class="Sup" href="#footnote-19" name="footnote-reference-19">†</a></th>        <th align="center" valign="top">Enoxaparin/VKA<a class="Sup" href="#footnote-19">†</a></th>        <th class="Rrule" align="center" valign="top">XARELTO vs. Enoxaparin/VKA Hazard Ratio<br />(95% CI)</th>        </tr>       </thead>       <tfoot>        <tr>         <td align="left" colspan="4">          <dl class="Footnote">           <dt>            <a href="#footnote-reference-18" name="footnote-18">*</a>           </dt>           <dd>           For the primary efficacy analysis, all confirmed events were considered from randomization up to the end of intended treatment duration (3, 6 or 12 months) irrespective of the actual treatment duration. If the same patient had several events, the patient may have been counted for several components.          </dd>           <dt>            <a href="#footnote-reference-19" name="footnote-19">†</a>           </dt>           <dd>           Treatment schedule in EINSTEIN DVT and EINSTEIN PE studies: XARELTO 15 mg twice daily for 3 weeks followed by 20 mg once daily; enoxaparin/VKA [enoxaparin: 1 mg/kg twice daily, VKA: individually titrated doses to achieve a target INR of 2.5 (range: 2.0–3.0)]          </dd>          </dl> </td>        </tr>       </tfoot>       <tbody>        <tr class="Botrule First">         <td class="Lrule" align="left"><span class="Bold">EINSTEIN DVT Study</span></td>        <td align="center"><span class="Bold">N = 1731<br />n (%)</span></td>        <td align="center"><span class="Bold">N = 1718<br />n (%)</span></td>        <td class="Rrule" align="center"></td>        </tr>        <tr class="Botrule">         <td class="Lrule" align="left">Primary Composite Endpoint</td>        <td align="center">36 (2.1)</td>        <td align="center">51 (3.0)</td>        <td class="Rrule" align="center">0.68 (0.44, 1.04)</td>        </tr>        <tr class="Botrule">         <td class="Lrule" align="left">&nbsp;&nbsp;Death (PE)</td>        <td align="center">1 (&lt;0.1)</td>        <td align="center">0</td>        <td class="Rrule" align="center"></td>        </tr>        <tr class="Botrule">         <td class="Lrule" align="left">&nbsp;&nbsp;Death (PE cannot be excluded)</td>        <td align="center">3 (0.2)</td>        <td align="center">6 (0.3)</td>        <td class="Rrule" align="center"></td>        </tr>        <tr class="Botrule">         <td class="Lrule" align="left">&nbsp;&nbsp;Symptomatic PE and DVT</td>        <td align="center">1 (&lt;0.1)</td>        <td align="center">0</td>        <td class="Rrule" align="center"></td>        </tr>        <tr class="Botrule">         <td class="Lrule" align="left">&nbsp;&nbsp;Symptomatic recurrent PE only</td>        <td align="center">20 (1.2)</td>        <td align="center">18 (1.0)</td>        <td class="Rrule" align="center"></td>        </tr>        <tr class="Botrule">         <td class="Lrule" align="left">&nbsp;&nbsp;Symptomatic recurrent DVT only</td>        <td align="center">14 (0.8)</td>        <td align="center">28 (1.6)</td>        <td class="Rrule" align="center"></td>        </tr>        <tr class="Botrule">         <td class="Lrule" align="left"><span class="Bold">EINSTEIN PE Study</span></td>        <td align="center"><span class="Bold">N = 2419<br />n (%)</span></td>        <td align="center"><span class="Bold">N = 2413<br />n (%)</span></td>        <td class="Rrule" align="center"></td>        </tr>        <tr class="Botrule">         <td class="Lrule" align="left">Primary Composite Endpoint</td>        <td align="center">50 (2.1)</td>        <td align="center">44 (1.8)</td>        <td class="Rrule" align="center">1.12 (0.75, 1.68)</td>        </tr>        <tr class="Botrule">         <td class="Lrule" align="left">&nbsp;&nbsp;Death (PE)</td>        <td align="center">3 (0.1)</td>        <td align="center">1 (&lt;0.1)</td>        <td class="Rrule" align="center"></td>        </tr>        <tr class="Botrule">         <td class="Lrule" align="left">&nbsp;&nbsp;Death (PE cannot be excluded)</td>        <td align="center">8 (0.3)</td>        <td align="center">6 (0.2)</td>        <td class="Rrule" align="center"></td>        </tr>        <tr class="Botrule">         <td class="Lrule" align="left">&nbsp;&nbsp;Symptomatic PE and DVT</td>        <td align="center">0</td>        <td align="center">2 (&lt;0.1)</td>        <td class="Rrule" align="center"></td>        </tr>        <tr class="Botrule">         <td class="Lrule" align="left">&nbsp;&nbsp;Symptomatic recurrent PE only</td>        <td align="center">23 (1.0)</td>        <td align="center">20 (0.8)</td>        <td class="Rrule" align="center"></td>        </tr>        <tr class="Last">         <td class="Lrule" align="left">&nbsp;&nbsp;Symptomatic recurrent DVT only</td>        <td align="center">18 (0.7)</td>        <td align="center">17 (0.7)</td>        <td class="Rrule" align="center"></td>        </tr>       </tbody>      </table>    </div>     <p>Figures 2 and 3 are plots of the time from randomization to the occurrence of the first primary efficacy endpoint event in the two treatment groups in EINSTEIN DVT and EINSTEIN PE studies, respectively.</p>     <p> <span class="Bold">Figure 2: Time to First Occurrence of the Composite of Recurrent DVT or Non-fatal or Fatal PE by Treatment Group (Intent-to-Treat Population) – EINSTEIN DVT Study</span> </p>     <div class="Figure">      <img src="image.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610&name=xarelto%2D03%2Ejpg" alt="Figure 2" />    </div>     <p> <span class="Bold">Figure 3: Time to First Occurrence of the Composite of Recurrent DVT or Non-fatal or Fatal PE by Treatment Group (Intent-to-Treat Population) – EINSTEIN PE Study</span> </p>     <div class="Figure">      <img src="image.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610&name=xarelto%2D04%2Ejpg" alt="Figure 3" />    </div>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="section-13.2.2"></a>     <p></p>     <p class="First"> <span class="Underline">EINSTEIN Extension Study</span> </p>     <p>XARELTO for reduction in the risk of recurrence of DVT and of PE was studied in the EINSTEIN Extension study, a multi-national, double-blind, superiority study comparing XARELTO (20 mg once daily with food) to placebo in patients who had completed 6 to 14 months of treatment for DVT and/or PE following the acute event. The intended treatment duration was 6 or 12 months based on investigator's assessment prior to randomization.</p>     <p>A total of 1196 patients were randomized and followed on study treatment for a mean of 190 days for both XARELTO and placebo treatment groups. The mean age was approximately 58 years. The population was 58% male, 78% Caucasian, 8% Asian and about 2% Black. Aspirin was taken as on-treatment concomitant antithrombotic medication by approximately 12% of patients in both treatment groups. In the EINSTEIN Extension study about 60% of patients had a history of proximal index DVT without PE event and 29% of patients had a PE without symptomatic DVT event. About 59% of patients had an idiopathic DVT/PE. Other risk factors included previous episode of DVT/PE (16%), immobilization (14%), known thrombophilic conditions (8%), or active cancer (5%).</p>     <p>In the EINSTEIN Extension study XARELTO was demonstrated to be superior to placebo for the primary composite endpoint of time to first occurrence of recurrent DVT or non-fatal or fatal PE [HR (95% CI): 0.18 (0.09, 0.39)].</p>     <p>Table 11 displays the overall results for the primary composite endpoint and its components.</p>     <a name="table11"></a>     <div class="scrollingtable">     <table width="100%">       <caption>        <span>Table 11: Primary Composite Endpoint Results<a class="Sup" href="#footnote-20" name="footnote-reference-20">*</a> in EINSTEIN Extension Study – Intent-to-Treat Population</span>       </caption>       <colgroup>       <col align="left" valign="middle" width="40%" />        <col align="center" valign="middle" width="20%" />        <col align="center" valign="middle" width="15%" />        <col align="center" valign="middle" width="25%" />       </colgroup>      <thead>        <tr class="First Last">         <th align="left">Event</th>        <th align="center">XARELTO 20 mg<br />N = 602<br />n (%)</th>        <th align="center">Placebo<br />N = 594<br />n (%)</th>        <th align="center">XARELTO vs. Placebo<br />Hazard Ratio<br />(95% CI)</th>        </tr>       </thead>       <tfoot>        <tr>         <td align="left" colspan="4">          <dl class="Footnote">           <dt>            <a href="#footnote-reference-20" name="footnote-20">*</a>           </dt>           <dd>           For the primary efficacy analysis, all confirmed events were considered from randomization up to the end of intended treatment duration (6 or 12 months) irrespective of the actual treatment duration.          </dd>          </dl> </td>        </tr>       </tfoot>       <tbody>        <tr class="Botrule First">         <td align="left">Primary Composite Endpoint</td>        <td align="center">8 (1.3)</td>        <td align="center">42 (7.1)</td>        <td align="center">0.18 (0.09, 0.39)<br />p-value = &lt;0.0001</td>        </tr>        <tr class="Botrule">         <td align="left">&nbsp;&nbsp;Death (PE)</td>        <td align="center">0</td>        <td align="center">1 (0.2)</td>        <td align="center"></td>        </tr>        <tr class="Botrule">         <td align="left">&nbsp;&nbsp;Death (PE cannot be excluded)</td>        <td align="center">1 (0.2)</td>        <td align="center">0</td>        <td align="center"></td>        </tr>        <tr class="Botrule">         <td align="left">&nbsp;&nbsp;Symptomatic recurrent PE</td>        <td align="center">2 (0.3)</td>        <td align="center">13 (2.2)</td>        <td align="center"></td>        </tr>        <tr class="Botrule Last">         <td align="left">&nbsp;&nbsp;Symptomatic recurrent DVT</td>        <td align="center">5 (0.8)</td>        <td align="center">31 (5.2)</td>        <td align="center"></td>        </tr>       </tbody>      </table>    </div>     <p>Figure 4 is a plot of the time from randomization to the occurrence of the first primary efficacy endpoint event in the two treatment groups.</p>     <p> <span class="Bold">Figure 4: Time to First Occurrence of the Composite of Recurrent DVT or Non-fatal or Fatal PE by Treatment Group (Intent-to-Treat Population) – EINSTEIN Extension Study</span> </p>     <div class="Figure">      <img src="image.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610&name=xarelto%2D05%2Ejpg" alt="Figure 4" />    </div>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="s14.3"></a>   <a name="section-13.3"></a>    <p></p>    <h2>14.3 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery</h2>    <p class="First">XARELTO was studied in 9011 patients (4487 XARELTO-treated, 4524 enoxaparin-treated patients) in the RECORD 1, 2, and 3 studies.</p>    <p>The two randomized, double-blind, clinical studies (RECORD 1 and 2) in patients undergoing elective total hip replacement surgery compared XARELTO 10 mg once daily starting at least 6 to 8 hours (about 90% of patients dosed 6 to 10 hours) after wound closure versus enoxaparin 40 mg once daily started 12 hours preoperatively. In RECORD 1 and 2, a total of 6727 patients were randomized and 6579 received study drug. The mean age [&plusmn; standard deviation (SD)] was 63 &plusmn; 12.2 (range 18 to 93) years with 49% of patients ≥65 years and 55% of patients were female. More than 82% of patients were White, 7% were Asian, and less than 2% were Black. The studies excluded patients undergoing staged bilateral total hip replacement, patients with severe renal impairment defined as an estimated creatinine clearance &lt;30 mL/min, or patients with significant liver disease (hepatitis or cirrhosis). In RECORD 1, the mean exposure duration (&plusmn; SD) to active XARELTO and enoxaparin was 33.3 &plusmn; 7.0 and 33.6 &plusmn; 8.3 days, respectively. In RECORD 2, the mean exposure duration to active XARELTO and enoxaparin was 33.5 &plusmn; 6.9 and 12.4 &plusmn; 2.9 days, respectively. After Day 13, oral placebo was continued in the enoxaparin group for the remainder of the double-blind study duration. The efficacy data for RECORD 1 and 2 are provided in Table 12.</p>    <a name="table12"></a>    <div class="scrollingtable">    <table width="100%">      <caption>       <span>Table 12: Summary of Key Efficacy Analysis Results for Patients Undergoing Total Hip Replacement Surgery - Modified Intent-to-Treat Population</span>      </caption>      <colgroup>      <col align="left" valign="top" width="22%" />       <col align="center" valign="top" width="13%" />       <col align="center" valign="top" width="13%" />       <col align="center" valign="top" width="13%" />       <col align="center" valign="top" width="13%" />       <col align="center" valign="top" width="13%" />       <col align="center" valign="top" width="13%" />      </colgroup>     <thead>       <tr class="Botrule First">        <th class="Lrule Rrule" align="left"></th>       <th class="Rrule" align="center" colspan="3">RECORD 1</th>       <th class="Rrule" align="center" colspan="3">RECORD 2</th>       </tr>       <tr class="Botrule Last">        <th class="Lrule Rrule" align="left">Treatment Dosage and Duration</th>       <th class="Rrule" align="center">XARELTO<br />10 mg once daily</th>       <th class="Rrule" align="center">Enoxaparin<br />40 mg once daily</th>       <th class="Rrule" align="center" valign="middle">RRR<a class="Sup" href="#footnote-21" name="footnote-reference-21">*</a>,<br />p-value</th>       <th class="Rrule" align="center">XARELTO<br />10 mg once daily</th>       <th class="Rrule" align="center">Enoxaparin<a class="Sup" href="#footnote-22" name="footnote-reference-22">†</a> <br />40 mg once daily</th>       <th class="Rrule" align="center" valign="middle">RRR<a class="Sup" href="#footnote-21">*</a>,<br />p-value</th>       </tr>      </thead>      <tfoot>       <tr>        <td align="left" colspan="7">         <dl class="Footnote">          <dt>           <a href="#footnote-reference-21" name="footnote-21">*</a>          </dt>          <dd>          Relative Risk Reduction; CI = confidence interval         </dd>          <dt>           <a href="#footnote-reference-22" name="footnote-22">†</a>          </dt>          <dd>          Includes the placebo-controlled period of RECORD 2         </dd>          <dt>           <a href="#footnote-reference-23" name="footnote-23">‡</a>          </dt>          <dd>          Proximal DVT, nonfatal PE or VTE-related death         </dd>         </dl> </td>       </tr>      </tfoot>      <tbody>       <tr class="Botrule First">        <td class="Lrule Rrule" align="left"><span class="Bold">Number of Patients</span></td>       <td class="Rrule" align="center"><span class="Bold">N = 1513</span></td>       <td class="Rrule" align="center"><span class="Bold">N = 1473</span></td>       <td class="Rrule" align="center"></td>       <td class="Rrule" align="center"><span class="Bold">N = 834</span></td>       <td class="Rrule" align="center"><span class="Bold">N = 835</span></td>       <td class="Rrule" align="center"></td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Total VTE </span></td>       <td class="Rrule" align="center">17 (1.1%)</td>       <td class="Rrule" align="center">57 (3.9%)</td>       <td class="Rrule" align="center">71%<br />(95% CI: 50, 83),<br />p&lt;0.001</td>       <td class="Rrule" align="center">17 (2.0%)</td>       <td class="Rrule" align="center">70 (8.4%)</td>       <td class="Rrule" align="center">76%<br />(95% CI: 59, 86),<br />p&lt;0.001</td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left" colspan="7"><span class="Bold">Components of Total VTE </span></td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Proximal DVT</td>       <td class="Rrule" align="center">1 (0.1%)</td>       <td class="Rrule" align="center">31 (2.1%)</td>       <td class="Rrule" align="center"></td>       <td class="Rrule" align="center">5 (0.6%)</td>       <td class="Rrule" align="center">40 (4.8%)</td>       <td class="Rrule" align="center"></td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Distal DVT</td>       <td class="Rrule" align="center">12 (0.8%)</td>       <td class="Rrule" align="center">26 (1.8%)</td>       <td class="Rrule" align="center"></td>       <td class="Rrule" align="center">11 (1.3%)</td>       <td class="Rrule" align="center">43 (5.2%)</td>       <td class="Rrule" align="center"></td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Non-fatal PE</td>       <td class="Rrule" align="center">3 (0.2%)</td>       <td class="Rrule" align="center">1 (0.1%)</td>       <td class="Rrule" align="center"></td>       <td class="Rrule" align="center">1 (0.1%)</td>       <td class="Rrule" align="center">4 (0.5%)</td>       <td class="Rrule" align="center"></td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Death (any cause)</td>       <td class="Rrule" align="center">4 (0.3%)</td>       <td class="Rrule" align="center">4 (0.3%)</td>       <td class="Rrule" align="center"></td>       <td class="Rrule" align="center">2 (0.2%)</td>       <td class="Rrule" align="center">4 (0.5%)</td>       <td class="Rrule" align="center"></td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Number of Patients</span></td>       <td class="Rrule" align="center"><span class="Bold">N = 1600</span></td>       <td class="Rrule" align="center"><span class="Bold">N = 1587</span></td>       <td class="Rrule" align="center"></td>       <td class="Rrule" align="center"><span class="Bold">N = 928</span></td>       <td class="Rrule" align="center"><span class="Bold">N = 929</span></td>       <td class="Rrule" align="center"></td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Major VTE</span><a class="Sup" href="#footnote-23" name="footnote-reference-23">‡</a></td>       <td class="Rrule" align="center">3 (0.2%)</td>       <td class="Rrule" align="center">33 (2.1%)</td>       <td class="Rrule" align="center">91% (95% CI: 71, 97), p&lt;0.001</td>       <td class="Rrule" align="center">6 (0.7%)</td>       <td class="Rrule" align="center">45 (4.8%)</td>       <td class="Rrule" align="center">87% (95% CI: 69, 94), p&lt;0.001</td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Number of Patients</span></td>       <td class="Rrule" align="center"><span class="Bold">N = 2103</span></td>       <td class="Rrule" align="center"><span class="Bold">N = 2119</span></td>       <td class="Rrule" align="center"></td>       <td class="Rrule" align="center"><span class="Bold">N = 1178</span></td>       <td class="Rrule" align="center"><span class="Bold">N = 1179</span></td>       <td class="Rrule" align="center"></td>       </tr>       <tr class="Last">        <td class="Lrule Rrule" align="left"><span class="Bold">Symptomatic VTE</span></td>       <td class="Rrule" align="center">5 (0.2%)</td>       <td class="Rrule" align="center">11 (0.5%)</td>       <td class="Rrule" align="center"></td>       <td class="Rrule" align="center">3 (0.3%)</td>       <td class="Rrule" align="center">15 (1.3%)</td>       <td class="Rrule" align="center"></td>       </tr>      </tbody>     </table>   </div>    <p>One randomized, double-blind, clinical study (RECORD 3) in patients undergoing elective total knee replacement surgery compared XARELTO 10 mg once daily started at least 6 to 8 hours (about 90% of patients dosed 6 to 10 hours) after wound closure versus enoxaparin. In RECORD 3, the enoxaparin regimen was 40 mg once daily started 12 hours preoperatively. The mean age (&plusmn; SD) of patients in the study was 68 &plusmn; 9.0 (range 28 to 91) years with 66% of patients ≥65 years. Sixty-eight percent (68%) of patients were female. Eighty-one percent (81%) of patients were White, less than 7% were Asian, and less than 2% were Black. The study excluded patients with severe renal impairment defined as an estimated creatinine clearance &lt;30 mL/min or patients with significant liver disease (hepatitis or cirrhosis). The mean exposure duration (&plusmn; SD) to active XARELTO and enoxaparin was 11.9 &plusmn; 2.3 and 12.5 &plusmn; 3.0 days, respectively. The efficacy data are provided in Table 13.</p>    <a name="table13"></a>    <div class="scrollingtable">    <table width="100%">      <caption>       <span>Table 13: Summary of Key Efficacy Analysis Results for Patients Undergoing Total Knee Replacement Surgery - Modified Intent-to-Treat Population</span>      </caption>      <colgroup>      <col align="left" valign="top" width="25%" />       <col align="center" valign="top" width="25%" />       <col align="center" valign="top" width="25%" />       <col align="center" valign="top" width="25%" />      </colgroup>     <thead>       <tr class="Botrule First">        <th class="Lrule" align="left"></th>       <th class="Lrule Rrule" align="center" colspan="3">RECORD 3</th>       </tr>       <tr class="Botrule Last">        <th class="Lrule" align="left">Treatment Dosage and Duration</th>       <th class="Lrule" align="center">XARELTO<br />10 mg once daily</th>       <th class="Lrule" align="center">Enoxaparin<br />40 mg once daily</th>       <th class="Lrule Rrule" align="center" valign="middle">RRR<a class="Sup" href="#footnote-24" name="footnote-reference-24">*</a>,<br />p-value</th>       </tr>      </thead>      <tfoot>       <tr>        <td align="left" colspan="4">         <dl class="Footnote">          <dt>           <a href="#footnote-reference-24" name="footnote-24">*</a>          </dt>          <dd>          Relative Risk Reduction; CI = confidence interval         </dd>          <dt>           <a href="#footnote-reference-25" name="footnote-25">†</a>          </dt>          <dd>          Proximal DVT, nonfatal PE or VTE-related death         </dd>         </dl> </td>       </tr>      </tfoot>      <tbody>       <tr class="Botrule First">        <td class="Lrule Rrule" align="left"><span class="Bold">Number of Patients</span></td>       <td class="Rrule" align="center"><span class="Bold">N = 813</span></td>       <td class="Rrule" align="center"><span class="Bold">N = 871</span></td>       <td class="Rrule" align="center"></td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Total VTE </span></td>       <td class="Rrule" align="center">79 (9.7%)</td>       <td class="Rrule" align="center">164 (18.8%)</td>       <td class="Rrule" align="center">48%<br />(95% CI: 34, 60),<br />p&lt;0.001</td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left" colspan="4"><span class="Bold">Components of events contributing to Total VTE</span></td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Proximal DVT</td>       <td class="Rrule" align="center">9 (1.1%)</td>       <td class="Rrule" align="center">19 (2.2%)</td>       <td class="Rrule" align="center"></td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Distal DVT</td>       <td class="Rrule" align="center">74 (9.1%)</td>       <td class="Rrule" align="center">154 (17.7%)</td>       <td class="Rrule" align="center"></td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Non-fatal PE</td>       <td class="Rrule" align="center">0</td>       <td class="Rrule" align="center">4 (0.5%)</td>       <td class="Rrule" align="center"></td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left">&nbsp;&nbsp;Death (any cause)</td>       <td class="Rrule" align="center">0</td>       <td class="Rrule" align="center">2 (0.2%)</td>       <td class="Rrule" align="center"></td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Number of Patients</span></td>       <td class="Rrule" align="center"><span class="Bold">N = 895</span></td>       <td class="Rrule" align="center"><span class="Bold">N = 917</span></td>       <td class="Rrule" align="center"></td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Major VTE</span><a class="Sup" href="#footnote-25" name="footnote-reference-25">†</a></td>       <td class="Rrule" align="center">9 (1.0%)</td>       <td class="Rrule" align="center">23 (2.5%)</td>       <td class="Rrule" align="center">60% (95% CI: 14, 81), p = 0.024</td>       </tr>       <tr class="Botrule">        <td class="Lrule Rrule" align="left"><span class="Bold">Number of Patients</span></td>       <td class="Rrule" align="center"><span class="Bold">N = 1206</span></td>       <td class="Rrule" align="center"><span class="Bold">N = 1226</span></td>       <td class="Rrule" align="center"></td>       </tr>       <tr class="Last">        <td class="Lrule Rrule" align="left"><span class="Bold">Symptomatic VTE</span></td>       <td class="Rrule" align="center">8 (0.7%)</td>       <td class="Rrule" align="center">24 (2.0%)</td>       <td class="Rrule" align="center"></td>       </tr>      </tbody>     </table>   </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">16 HOW SUPPLIED/STORAGE AND HANDLING</a> <div class="Section toggle-content closed" data-sectioncode="34069-5">   <a name="S16"></a>  <a name="section-14"></a>   <p></p>    <p class="First">XARELTO (rivaroxaban) Tablets are available in the strengths and packages listed below:</p>   <ul>    <li>10 mg tablets are round, light red, biconvex film-coated tablets marked with a triangle pointing down above a &quot;10&quot; on one side, and &quot;Xa&quot; on the other side. The tablets are supplied in the packages listed:    <table class="Noautorules" width="90%">      <colgroup>      <col align="left" valign="top" width="40%" />       <col align="left" valign="top" width="60%" />      </colgroup>     <tbody class="Headless">       <tr>        <td align="left">NDC 50458-580-30</td>       <td align="left">Bottle containing 30 tablets</td>       </tr>       <tr>        <td align="left">NDC 50458-580-10</td>       <td align="left">Blister package containing 100 tablets (10 blister cards containing 10 tablets each)</td>       </tr>      </tbody>     </table> </li>    <li>15 mg tablets are round, red, biconvex film-coated tablets with a triangle pointing down above a &quot;15&quot; marked on one side and &quot;Xa&quot; on the other side. The tablets are supplied in the packages listed:    <table class="Noautorules" width="90%">      <colgroup>      <col align="left" valign="top" width="40%" />       <col align="left" valign="top" width="60%" />      </colgroup>     <tbody class="Headless">       <tr>        <td align="left">NDC 50458-578-30</td>       <td align="left">Bottle containing 30 tablets</td>       </tr>       <tr>        <td align="left">NDC 50458-578-90</td>       <td align="left">Bottle containing 90 tablets</td>       </tr>       <tr>        <td align="left">NDC 50458-578-10</td>       <td align="left">Blister package containing 100 tablets (10 blister cards containing 10 tablets each)</td>       </tr>      </tbody>     </table> </li>    <li>20 mg tablets are triangle-shaped, dark red film-coated tablets with a triangle pointing down above a &quot;20&quot; marked on one side and &quot;Xa&quot; on the other side. The tablets are supplied in the packages listed:    <table class="Noautorules" width="90%">      <colgroup>      <col align="left" valign="top" width="40%" />       <col align="left" valign="top" width="60%" />      </colgroup>     <tbody class="Headless">       <tr>        <td align="left">NDC 50458-579-30</td>       <td align="left">Bottle containing 30 tablets</td>       </tr>       <tr>        <td align="left">NDC 50458-579-90</td>       <td align="left">Bottle containing 90 tablets</td>       </tr>       <tr>        <td align="left">NDC 50458-579-10</td>       <td align="left">Blister package containing 100 tablets (10 blister cards containing 10 tablets each)</td>       </tr>      </tbody>     </table> </li>    <li>Starter Pack for treatment of deep vein thrombosis and treatment of pulmonary embolism:    <table class="Noautorules" width="90%">      <colgroup>      <col align="left" valign="top" width="40%" />       <col align="left" valign="top" width="60%" />      </colgroup>     <tbody class="Headless">       <tr>        <td align="left">NDC 50458-584-51</td>       <td align="left">30-day starter blister pack containing 51 tablets: 42 tablets of 15 mg and 9 tablets of 20 mg</td>       </tr>      </tbody>     </table> </li>   </ul>   <div class="Section" data-sectioncode="44425-7">    <a name="section-14.1"></a>    <p></p>    <p class="First">Store at 25&deg;C (77&deg;F) or room temperature; excursions permitted to 15&deg;–30&deg;C (59&deg;–86&deg;F) [see USP Controlled Room Temperature].</p>    <p>Keep out of the reach of children.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">17 PATIENT COUNSELING INFORMATION</a> <div class="Section toggle-content closed" data-sectioncode="34076-0">   <a name="S17"></a>  <a name="section-15"></a>   <p></p>    <p class="First"> <span class="Italics">See FDA-approved patient labeling (<a href="#MED">Medication Guide</a>).</span> </p>   <div class="Section" data-sectioncode="42229-5">    <a name="S17.1"></a>   <a name="section-15.1"></a>    <p></p>    <h2>17.1 Instructions for Patient Use</h2>    <ul class="Disc">     <li>Advise patients to take XARELTO only as directed.</li>     <li>Remind patients to not discontinue XARELTO without first talking to their healthcare professional.</li>     <li>Advise patients with atrial fibrillation to take XARELTO once daily with the evening meal.</li>     <li>Advise patients with DVT and/or PE to take XARELTO 15 mg or 20 mg tablets with food at approximately the same time every day <span class="Italics">[see <a href="#s2.4">Dosage and Administration (2.4)</a>]</span>.</li>     <li>Advise patients who cannot swallow the tablet whole to crush XARELTO and combine with a small amount of applesauce followed by food <span class="Italics">[see <a href="#S2.8">Dosage and Administration (2.8)</a>]</span>.</li>     <li>For patients requiring an NG tube or gastric feeding tube, instruct the patient or caregiver to crush the XARELTO tablet and mix it with a small amount of water before administering via the tube <span class="Italics">[see <a href="#S2.8">Dosage and Administration (2.8)</a>]</span>.</li>     <li>If a dose is missed, advise the patient to take XARELTO as soon as possible on the same day and continue on the following day with their recommended daily dose regimen.</li>    </ul>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S17.2"></a>   <a name="section-15.2"></a>    <p></p>    <h2>17.2 Bleeding Risks</h2>    <ul class="Disc">     <li>Advise patients to report any unusual bleeding or bruising to their physician. Inform patients that it might take them longer than usual to stop bleeding, and that they may bruise and/or bleed more easily when they are treated with XARELTO <span class="Italics">[see <a href="#s5.2">Warnings and Precautions (5.2)</a>]</span>.</li>     <li>If patients have had neuraxial anesthesia or spinal puncture, and particularly, if they are taking concomitant NSAIDs or platelet inhibitors, advise patients to watch for signs and symptoms of spinal or epidural hematoma, such as back pain, tingling, numbness (especially in the lower limbs), muscle weakness, and stool or urine incontinence. If any of these symptoms occur, advise the patient to contact his or her physician immediately <span class="Italics">[see <a href="#box">Boxed Warning</a>]</span>.</li>    </ul>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S17.3"></a>   <a name="section-15.3"></a>    <p></p>    <h2>17.3 Invasive or Surgical Procedures</h2>    <p class="First">Instruct patients to inform their healthcare professional that they are taking XARELTO before any invasive procedure (including dental procedures) is scheduled.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S17.4"></a>   <a name="section-15.4"></a>    <p></p>    <h2>17.4 Concomitant Medication and Herbals</h2>    <p class="First">Advise patients to inform their physicians and dentists if they are taking, or plan to take, any prescription or over-the-counter drugs or herbals, so their healthcare professionals can evaluate potential interactions <span class="Italics">[see <a href="#s7">Drug Interactions (7)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S17.5"></a>   <a name="section-15.5"></a>    <p></p>    <h2>17.5 Pregnancy and Pregnancy-Related Hemorrhage</h2>    <ul class="Disc">     <li>Advise patients to inform their physician immediately if they become pregnant or intend to become pregnant during treatment with XARELTO<span class="Italics"> [see <a href="#s8.1">Use in Specific Populations (8.1)</a>]</span>.</li>     <li>Advise pregnant women receiving XARELTO to immediately report to their physician any bleeding or symptoms of blood loss <span class="Italics">[see <a href="#s5.7">Warnings and Precautions (5.7)</a>]</span>.</li>    </ul>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S17.6"></a>   <a name="section-15.6"></a>    <p></p>    <h2>17.6 Nursing</h2>    <p class="First">Advise patients to discuss with their physician if they are nursing or intend to nurse during anticoagulant treatment <span class="Italics">[see <a href="#s8.3">Use in Specific Populations (8.3)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="section-15.7"></a>    <p></p>    <h2>17.7 Females of Reproductive Potential</h2>    <p class="First">Advise patients who can become pregnant to discuss pregnancy planning with their physician <span class="Italics">[see <a href="#s8.6">Use in Specific Populations (8.6)</a>]</span>.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">SPL UNCLASSIFIED SECTION</a> <div class="Section toggle-content closed" data-sectioncode="42229-5">   <a name="section-16"></a>   <p></p>   <p class="First">Active Ingredient Made in Germany</p>   <p>Finished Product Manufactured by:<br />Janssen Ortho, LLC<br />Gurabo, PR 00778</p>   <p>or <br />Bayer Pharma AG <br />51368 Leverkusen, Germany</p>   <p>Manufactured for:<br />Janssen Pharmaceuticals, Inc.<br />Titusville, NJ 08560</p>   <p>Licensed from:<br />Bayer HealthCare AG<br />51368 Leverkusen, Germany</p>   <p>&copy; Janssen Pharmaceuticals, Inc. 2011</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">MEDICATION GUIDE</a> <div class="Section toggle-content closed" data-sectioncode="42231-1">   <a name="MED"></a>  <a name="section-17"></a>   <p></p>   <p class="First"> <span class="Bold">MEDICATION GUIDE<br />XARELTO<span class="Sup">&reg;</span> (zah-REL-toe)<br />(rivaroxaban)<br />tablets</span> </p>   <p>Read this Medication Guide before you start taking XARELTO and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking with your doctor about your medical condition or your treatment.</p>   <p> <a name="important"></a><span class="Bold">What is the most important information I should know about XARELTO?</span> </p>   <ul class="Disc">    <li> <span class="Bold">For people taking XARELTO for atrial fibrillation</span>:<p class="First">People with atrial fibrillation (an irregular heart beat) are at an increased risk of forming a blood clot in the heart, which can travel to the brain, causing a stroke, or to other parts of the body. XARELTO lowers your chance of having a stroke by helping to prevent clots from forming. If you stop taking XARELTO, you may have increased risk of forming a clot in your blood.</p> <p> <span class="Bold">Do not stop taking XARELTO without talking to the doctor who prescribes it for you. Stopping XARELTO increases your risk of having a stroke.</span> </p> <p>If you have to stop taking XARELTO, your doctor may prescribe another blood thinner medicine to prevent a blood clot from forming.</p> </li>    <li> <span class="Bold">XARELTO can cause bleeding</span> which can be serious, and rarely may lead to death. This is because XARELTO is a blood thinner medicine that reduces blood clotting. While you take XARELTO you are likely to bruise more easily and it may take longer for bleeding to stop.<p class="First">You may have a higher risk of bleeding if you take XARELTO and take other medicines that increase your risk of bleeding, including:</p>     <ul class="Disc">      <li>aspirin or aspirin containing products</li>      <li>non-steroidal anti-inflammatory drugs (NSAIDs)</li>      <li>warfarin sodium (Coumadin<span class="Sup">&reg;</span>, Jantoven<span class="Sup">&reg;</span>)</li>      <li>any medicine that contains heparin</li>      <li>clopidogrel (Plavix<span class="Sup">&reg;</span>)</li>      <li>other medicines to prevent or treat blood clots</li>     </ul> <p>Tell your doctor if you take any of these medicines. Ask your doctor or pharmacist if you are not sure if your medicine is one listed above.</p> <p> <span class="Bold">Call your doctor or get medical help right away if you develop any of these signs or symptoms of bleeding:</span> </p>     <ul class="Disc">      <li>unexpected bleeding or bleeding that lasts a long time, such as:      <ul class="Circle">        <li>nose bleeds that happen often</li>        <li>unusual bleeding from the gums</li>        <li>menstrual bleeding that is heavier than normal or vaginal bleeding</li>       </ul> </li>      <li>bleeding that is severe or you cannot control</li>      <li>red, pink or brown urine</li>      <li>bright red or black stools (looks like tar)</li>      <li>cough up blood or blood clots</li>      <li>vomit blood or your vomit looks like &quot;coffee grounds&quot;</li>      <li>headaches, feeling dizzy or weak</li>      <li>pain, swelling, or new drainage at wound sites</li>     </ul> </li>    <li> <span class="Bold">Spinal or epidural blood clots (hematoma).</span> People who take a blood thinner medicine (anticoagulant) like XARELTO, and have medicine injected into their spinal and epidural area, or have a spinal puncture have a risk of forming a blood clot that can cause long-term or permanent loss of the ability to move (paralysis). Your risk of developing a spinal or epidural blood clot is higher if:    <ul class="Circle">      <li>a thin tube called an epidural catheter is placed in your back to give you certain medicine</li>      <li>you take NSAIDs or a medicine to prevent blood from clotting</li>      <li>you have a history of difficult or repeated epidural or spinal punctures</li>      <li>you have a history of problems with your spine or have had surgery on your spine</li>     </ul> </li>   </ul>   <p>If you take XARELTO and receive spinal anesthesia or have a spinal puncture, your doctor should watch you closely for symptoms of spinal or epidural blood clots. Tell your doctor right away if you have back pain, tingling, numbness, muscle weakness (especially in your legs and feet), loss of control of the bowels or bladder (incontinence).</p>   <ul class="Disc">    <li> <span class="Bold">XARELTO is not for patients with artificial heart valves.</span> </li>   </ul>   <p> <span class="Bold">See &quot;<a href="#sideeffects">What are the possible side effects of XARELTO?</a>&quot; for more information about side effects.</span> </p>   <p> <span class="Bold">What is XARELTO?</span> </p>   <ul class="Disc">    <li>XARELTO is a prescription medicine used to:    <ul class="Circle">      <li>reduce the risk of stroke and blood clots in people who have a medical condition called atrial fibrillation. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to the formation of blood clots, which can travel to the brain, causing a stroke, or to other parts of the body.</li>      <li>treat blood clots in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism) and reduce the risk of them occurring again</li>      <li>reduce the risk of forming a blood clot in the legs and lungs of people who have just had hip or knee replacement surgery</li>     </ul> </li>   </ul>   <p>It is not known if XARELTO is safe and effective in children.</p>   <p> <span class="Bold">Who should not take XARELTO?</span> </p>   <p> <span class="Bold">Do not take XARELTO if you:</span> </p>   <ul class="Disc">    <li>currently have certain types of abnormal bleeding. Talk to your doctor before taking XARELTO if you currently have unusual bleeding.</li>    <li>are allergic to rivaroxaban or any of the ingredients in XARELTO. See the end of this leaflet for a complete list of ingredients in XARELTO.</li>   </ul>   <p> <span class="Bold">What should I tell my doctor before taking XARELTO?</span> </p>   <p>Before you take XARELTO, tell your doctor if you:</p>   <ul class="Disc">    <li>have ever had bleeding problems</li>    <li>have liver or kidney problems</li>    <li>have any other medical condition</li>    <li>are pregnant or plan to become pregnant. It is not known if XARELTO will harm your unborn baby. Tell your doctor right away if you become pregnant while taking XARELTO. If you take XARELTO during pregnancy tell your doctor right away if you have any bleeding or symptoms of blood loss.</li>    <li>are breastfeeding or plan to breastfeed. It is not known if XARELTO passes into your breast milk. You and your doctor should decide if you will take XARELTO or breastfeed.</li>   </ul>   <p>Tell all of your doctors and dentists that you are taking XARELTO. They should talk to the doctor who prescribed XARELTO for you before you have any surgery, medical or dental procedure.</p>   <p> <span class="Bold">Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements.</span> Some of your other medicines may affect the way XARELTO works. Certain medicines may increase your risk of bleeding. See <span class="Bold">&quot;<a href="#important">What is the most important information I should know about XARELTO?</a>&quot;</span> </p>   <p>Especially tell your doctor if you take:</p>   <ul class="Disc">    <li>ketoconazole (Nizoral<span class="Sup">&reg;</span>)</li>    <li>itraconazole (Onmel<span class="Sup">™</span>, Sporanox<span class="Sup">&reg;</span>)</li>    <li>ritonavir (Norvir<span class="Sup">&reg;</span>)</li>    <li>lopinavir/ritonavir (Kaletra<span class="Sup">&reg;</span>)</li>    <li>indinavir (Crixivan<span class="Sup">&reg;</span>)</li>    <li>carbamazepine (Carbatrol<span class="Sup">&reg;</span>, Equetro<span class="Sup">&reg;</span>, Tegretol<span class="Sup">&reg;</span>, Tegretol<span class="Sup">&reg;</span>-XR, Teril™, Epitol<span class="Sup">&reg;</span>)</li>    <li>phenytoin (Dilantin-125<span class="Sup">&reg;</span>, Dilantin<span class="Sup">&reg;</span>)</li>    <li>phenobarbital (Solfoton<span class="Sup">™</span>)</li>    <li>rifampin (Rifater<span class="Sup">&reg;</span>, Rifamate<span class="Sup">&reg;</span>, Rimactane<span class="Sup">&reg;</span>, Rifadin<span class="Sup">&reg;</span>)</li>    <li>St. John's wort (Hypericum perforatum)</li>   </ul>   <p>Ask your doctor if you are not sure if your medicine is one listed above.</p>   <p>Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.</p>   <p> <span class="Bold">How should I take XARELTO?</span> </p>   <ul class="Disc">    <li>Take XARELTO exactly as prescribed by your doctor.</li>    <li>Do not change your dose or stop taking XARELTO unless your doctor tells you to.</li>    <li>Your doctor will tell you how much XARELTO to take and when to take it.</li>    <li>Your doctor may change your dose if needed.</li>    <li>If you take XARELTO for:    <ul class="Circle">      <li> <span class="Bold">atrial fibrillation:</span>       <ul class="Square">        <li>Take XARELTO 1 time a day with your evening meal.</li>        <li>If you miss a dose of XARELTO, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time.</li>       </ul> </li>      <li> <span class="Bold">blood clots in the veins of your legs or lungs:</span>       <ul class="Square">        <li>Take XARELTO once or twice a day as prescribed by your doctor.</li>        <li>Take XARELTO with food at the same time each day.</li>        <li>If you miss a dose of XARELTO:         <ul class="Disc">          <li> <span class="Bold">and take XARELTO 2 times a day:</span> Take XARELTO as soon as you remember on the same day. You may take 2 doses at the same time to make up for the missed dose. Take your next dose at your regularly scheduled time.</li>          <li> <span class="Bold">and take XARELTO 1 time a day:</span> Take XARELTO as soon as you remember on the same day. Take your next dose at your regularly scheduled time.</li>         </ul> </li>       </ul> </li>      <li> <span class="Bold">hip or knee replacement surgery:</span>       <ul class="Square">        <li>Take XARELTO 1 time a day with or without food.</li>        <li>If you miss a dose of XARELTO, take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time.</li>       </ul> </li>     </ul> </li>    <li>If you have difficulty swallowing the tablet whole, talk to your doctor about other ways to take XARELTO.</li>    <li>Your doctor will decide how long you should take XARELTO. Do not stop taking XARELTO without talking with your doctor first.</li>    <li>Your doctor may stop XARELTO for a short time before any surgery, medical or dental procedure. Your doctor will tell you when to start taking XARELTO again after your surgery or procedure.</li>    <li>Do not run out of XARELTO. Refill your prescription of XARELTO before you run out. When leaving the hospital following a hip or knee replacement, be sure that you will have XARELTO available to avoid missing any doses.</li>    <li>If you take too much XARELTO, go to the nearest hospital emergency room or call your doctor right away.</li>   </ul>   <p> <a name="sideeffects"></a><span class="Bold">What are the possible side effects of XARELTO?</span> </p>   <ul class="Disc">    <li> <span class="Bold">See &quot;<a href="#important">What is the most important information I should know about XARELTO?</a>&quot;</span> </li>   </ul>   <p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p>   <p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>   <p> <span class="Bold">How should I store XARELTO?</span> </p>   <ul class="Disc">    <li>Store XARELTO at room temperature between 68&deg;F to 77&deg;F (20&deg; to 25&deg;C).</li>   </ul>   <p> <span class="Bold">Keep XARELTO and all medicines out of the reach of children.</span> </p>   <p> <span class="Bold">General information about XARELTO.</span> </p>   <p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use XARELTO for a condition for which it was not prescribed. Do not give XARELTO to other people, even if they have the same condition. It may harm them.</p>   <p>This Medication Guide summarizes the most important information about XARELTO. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about XARELTO that is written for health professionals.</p>   <p>For more information call 1-800-526-7736 or go to www.XARELTO-US.com.</p>   <p> <span class="Bold">What are the ingredients in XARELTO?</span> </p>   <p>Active ingredient: rivaroxaban</p>   <p>Inactive ingredients: croscarmellose sodium, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate.</p>   <p>The proprietary film coating mixture for XARELTO 10 mg tablets is Opadry<span class="Sup">&reg;</span> Pink and contains: ferric oxide red, hypromellose, polyethylene glycol 3350, and titanium dioxide.</p>   <p>The proprietary film coating mixture for XARELTO 15 mg tablets is Opadry<span class="Sup">&reg;</span> Red and contains: ferric oxide red, hypromellose, polyethylene glycol 3350, and titanium dioxide.</p>   <p>The proprietary film coating mixture for XARELTO 20 mg tablets is Opadry<span class="Sup">&reg;</span> II Dark Red and contains: ferric oxide red, polyethylene glycol 3350, polyvinyl alcohol (partially hydrolyzed), talc, and titanium dioxide.</p>   <p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>   <p>Finished Product Manufactured by:<br />Janssen Ortho, LLC<br />Gurabo, PR 00778</p>   <p>or</p>   <p>Bayer Pharma AG <br />51368 Leverkusen, Germany</p>   <p>Manufactured for:<br />Janssen Pharmaceuticals, Inc.<br />Titusville, NJ 08560</p>   <p>Licensed from:<br />Bayer HealthCare AG<br />51368 Leverkusen, Germany</p>   <p>Revised: December 2014</p>   <p>&copy; Janssen Pharmaceuticals, Inc. 2011</p>   <p>Trademarks are property of their respective owners.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Label</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="section-18"></a>   <p></p>    <p class="First"> <span class="Bold">NDC</span> 50458-580-30<br /> <span class="Bold">30 Tablets</span> </p>   <p> <span class="Bold">Xarelto<span class="Sup">&reg;</span> <br />(rivaroxaban)<br />Tablets<br />10 mg</span> </p>   <p> <span class="Bold">Rx only</span> </p>   <p>janssen</p>   <div class="Figure">    <img src="image.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610&name=xarelto%2D06%2Ejpg" alt="PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Label" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL - 15 mg Tablet Bottle Label</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="section-19"></a>   <p></p>    <p class="First"> <span class="Bold">NDC</span> 50458-<span class="Bold">578</span>-30<br /> <span class="Bold">30 Tablets</span> </p>   <p> <span class="Bold">Xarelto<span class="Sup">&reg;</span> <br />(rivaroxaban)<br />Tablets<br />15 mg</span> </p>   <p> <span class="Bold">Dispense the accompanying<br />Medication Guide to each patient.</span> </p>   <p>janssen</p>   <p> <span class="Bold">Rx only</span> </p>   <div class="Figure">    <img src="image.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610&name=xarelto%2D07%2Ejpg" alt="PRINCIPAL DISPLAY PANEL - 15 mg Tablet Bottle Label" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL - 20 mg Tablet Bottle Label</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="section-20"></a>   <p></p>    <p class="First"> <span class="Bold">NDC</span> 50458-<span class="Bold">579</span>-30<br /> <span class="Bold">30 Tablets</span> </p>   <p> <span class="Bold">Xarelto<span class="Sup">&reg;</span> <br />(rivaroxaban)<br />Tablets<br />20 mg</span> </p>   <p> <span class="Bold">Dispense the accompanying<br />Medication Guide to each patient.</span> </p>   <p>janssen</p>   <p> <span class="Bold">Rx only</span> </p>   <div class="Figure">    <img src="image.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610&name=xarelto%2D08%2Ejpg" alt="PRINCIPAL DISPLAY PANEL - 20 mg Tablet Bottle Label" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">PRINCIPAL DISPLAY PANEL - Kit Carton</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="section-21"></a>   <p></p>    <p class="First"> <span class="Bold">Xarelto<span class="Sup">&reg;</span></span> <br />(rivaroxaban) Tablets</p>   <p>NDC 50458-584-51<br /> <span class="Bold">Rx only</span> </p>   <p> <span class="Bold">Please see full Prescribing Information, including<br />BOXED WARNINGS, and Medication Guide inside.</span> </p>   <p> <span class="Bold">Starter Pack<br />for treatment of deep vein thrombosis and treatment of pulmonary embolism</span> </p>   <p> <span class="Bold">Days 1-21<br />15 mg </span>per tablet, <span class="Bold">twice</span> daily<br /> <span class="Bold">42 tablets</span> </p>   <p> <span class="Bold">Days 22-30<br />20 mg </span>per tablet, <span class="Bold">once</span> daily<br /> <span class="Bold">9 tablets</span> </p>   <p> <span class="Bold">First 30-day supply</span> </p>   <p> <span class="Bold">LIFT HERE TO OPEN</span> </p>   <div class="Figure">    <img src="image.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610&name=xarelto%2D09%2Ejpg" alt="PRINCIPAL DISPLAY PANEL - Kit Carton" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">INGREDIENTS AND APPEARANCE</a> <div class="DataElementsTables toggle-content">   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>XARELTO&nbsp; </strong> <br /> <span class="contentTableReg">rivaroxaban tablet, film coated</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:50458-580</td>          </tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">ORAL</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>rivaroxaban</strong> (UNII: 9NDF7JZ4M3) (rivaroxaban - UNII:9NDF7JZ4M3)</td>          <td class="formItem">rivaroxaban</td>          <td class="formItem">10&nbsp;mg</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>cellulose, microcrystalline</strong> (UNII: OP1R32D61U)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>croscarmellose sodium</strong> (UNII: M28OL1HH48)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>hypromelloses</strong> (UNII: 3NXW29V3WO)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>lactose monohydrate</strong> (UNII: EWQ57Q8I5X)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>magnesium stearate</strong> (UNII: 70097M6I30)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>sodium lauryl sulfate</strong> (UNII: 368GB5141J)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>polyethylene glycol 3350</strong> (UNII: G2M7P15E5P)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>titanium dioxide</strong> (UNII: 15FIX9V2JP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>ferric oxide red</strong> (UNII: 1K09F3G675)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Characteristics</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Color</td>          <td class="formItem">RED (light red)</td>          <td class="formLabel">Score</td>          <td class="formItem">no score</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Shape</td>          <td class="formItem">ROUND (biconvex)</td>          <td class="formLabel">Size</td>          <td class="formItem">6mm</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Flavor</td>          <td class="formItem"></td>          <td class="formLabel">Imprint Code</td>          <td class="formItem">10;Xa</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Contains</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:50458-580-10</td>          <td class="formItem">10 in 1 CARTON</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem"></td>          <td class="formItem">10 in 1 BLISTER PACK; Type 0: Not a Combination Product</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">2</th>          <td class="formItem">NDC:50458-580-30</td>          <td class="formItem">30 in 1 BOTTLE; Type 0: Not a Combination Product</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA022406</td>          <td class="formItem">07/01/2011</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>XARELTO&nbsp; </strong> <br /> <span class="contentTableReg">rivaroxaban tablet, film coated</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:50458-578</td>          </tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">ORAL</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>rivaroxaban</strong> (UNII: 9NDF7JZ4M3) (rivaroxaban - UNII:9NDF7JZ4M3)</td>          <td class="formItem">rivaroxaban</td>          <td class="formItem">15&nbsp;mg</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>cellulose, microcrystalline</strong> (UNII: OP1R32D61U)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>croscarmellose sodium</strong> (UNII: M28OL1HH48)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>hypromelloses</strong> (UNII: 3NXW29V3WO)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>lactose monohydrate</strong> (UNII: EWQ57Q8I5X)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>magnesium stearate</strong> (UNII: 70097M6I30)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>sodium lauryl sulfate</strong> (UNII: 368GB5141J)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>polyethylene glycol 3350</strong> (UNII: G2M7P15E5P)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>titanium dioxide</strong> (UNII: 15FIX9V2JP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>ferric oxide red</strong> (UNII: 1K09F3G675)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Characteristics</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Color</td>          <td class="formItem">RED</td>          <td class="formLabel">Score</td>          <td class="formItem">no score</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Shape</td>          <td class="formItem">ROUND (biconvex)</td>          <td class="formLabel">Size</td>          <td class="formItem">6mm</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Flavor</td>          <td class="formItem"></td>          <td class="formLabel">Imprint Code</td>          <td class="formItem">15;Xa</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Contains</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:50458-578-10</td>          <td class="formItem">10 in 1 CARTON</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem"></td>          <td class="formItem">10 in 1 BLISTER PACK; Type 0: Not a Combination Product</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">2</th>          <td class="formItem">NDC:50458-578-30</td>          <td class="formItem">30 in 1 BOTTLE; Type 0: Not a Combination Product</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">3</th>          <td class="formItem">NDC:50458-578-90</td>          <td class="formItem">90 in 1 BOTTLE; Type 0: Not a Combination Product</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">4</th>          <td class="formItem">NDC:50458-578-14</td>          <td class="formItem">14 in 1 BOTTLE; Type 0: Not a Combination Product</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA202439</td>          <td class="formItem">11/04/2011</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>XARELTO&nbsp; </strong> <br /> <span class="contentTableReg">rivaroxaban tablet, film coated</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:50458-579</td>          </tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">ORAL</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>rivaroxaban</strong> (UNII: 9NDF7JZ4M3) (rivaroxaban - UNII:9NDF7JZ4M3)</td>          <td class="formItem">rivaroxaban</td>          <td class="formItem">20&nbsp;mg</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>cellulose, microcrystalline</strong> (UNII: OP1R32D61U)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>croscarmellose sodium</strong> (UNII: M28OL1HH48)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>hypromelloses</strong> (UNII: 3NXW29V3WO)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>lactose monohydrate</strong> (UNII: EWQ57Q8I5X)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>magnesium stearate</strong> (UNII: 70097M6I30)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>sodium lauryl sulfate</strong> (UNII: 368GB5141J)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>polyethylene glycol 3350</strong> (UNII: G2M7P15E5P)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>titanium dioxide</strong> (UNII: 15FIX9V2JP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>ferric oxide red</strong> (UNII: 1K09F3G675)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Characteristics</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Color</td>          <td class="formItem">RED (dark red)</td>          <td class="formLabel">Score</td>          <td class="formItem">no score</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Shape</td>          <td class="formItem">TRIANGLE</td>          <td class="formLabel">Size</td>          <td class="formItem">7mm</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Flavor</td>          <td class="formItem"></td>          <td class="formLabel">Imprint Code</td>          <td class="formItem">20;Xa</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Contains</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:50458-579-10</td>          <td class="formItem">10 in 1 CARTON</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem"></td>          <td class="formItem">10 in 1 BLISTER PACK; Type 0: Not a Combination Product</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">2</th>          <td class="formItem">NDC:50458-579-30</td>          <td class="formItem">30 in 1 BOTTLE; Type 0: Not a Combination Product</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">3</th>          <td class="formItem">NDC:50458-579-90</td>          <td class="formItem">90 in 1 BOTTLE; Type 0: Not a Combination Product</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">4</th>          <td class="formItem">NDC:50458-579-99</td>          <td class="formItem">1 in 1 CARTON</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">4</th>          <td class="formItem"></td>          <td class="formItem">5 in 1 BOTTLE; Type 0: Not a Combination Product</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA202439</td>          <td class="formItem">11/05/2011</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>XARELTO&nbsp; </strong> <br /> <span class="contentTableReg">rivaroxaban kit</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:50458-584</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:50458-584-51</td>          <td class="formItem">1 in 1 CARTON</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Quantity of Parts</td>          </tr>          <tr>           <th class="formTitle" width="5" scope="col">Part&nbsp;#</th>          <th class="formTitle" scope="col">Package Quantity</th>          <th class="formTitle" scope="col">Total Product Quantity</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem" width="5"><strong>Part 1</strong></td>          <td class="formItem">1 BLISTER PACK</td>          <td class="formItem">42&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem" width="5"><strong>Part 2</strong></td>          <td class="formItem">1 BLISTER PACK</td>          <td class="formItem">9&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table cellpadding="5" cellspacing="0" width="100%">         <tbody>         <tr>           <td class="contentTableTitle">Part 1 of 2</td>          </tr>          <tr>           <td class="contentTableTitle"><strong>XARELTO&nbsp; </strong> <br /> <span class="contentTableReg">rivaroxaban tablet, film coated</span></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt"></tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">ORAL</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>rivaroxaban</strong> (UNII: 9NDF7JZ4M3) (rivaroxaban - UNII:9NDF7JZ4M3)</td>          <td class="formItem">rivaroxaban</td>          <td class="formItem">15&nbsp;mg</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>cellulose, microcrystalline</strong> (UNII: OP1R32D61U)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>croscarmellose sodium</strong> (UNII: M28OL1HH48)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>hypromelloses</strong> (UNII: 3NXW29V3WO)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>lactose monohydrate</strong> (UNII: EWQ57Q8I5X)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>magnesium stearate</strong> (UNII: 70097M6I30)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>sodium lauryl sulfate</strong> (UNII: 368GB5141J)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>polyethylene glycol 3350</strong> (UNII: G2M7P15E5P)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>titanium dioxide</strong> (UNII: 15FIX9V2JP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>ferric oxide red</strong> (UNII: 1K09F3G675)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Characteristics</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Color</td>          <td class="formItem">RED</td>          <td class="formLabel">Score</td>          <td class="formItem">no score</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Shape</td>          <td class="formItem">ROUND (biconvex)</td>          <td class="formLabel">Size</td>          <td class="formItem">6mm</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Flavor</td>          <td class="formItem"></td>          <td class="formLabel">Imprint Code</td>          <td class="formItem">15;Xa</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Contains</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem"></td>          <td class="formItem">42 in 1 BLISTER PACK; Type 1: Convenience Kit of Co-Package</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA022406</td>          <td class="formItem">09/16/2014</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table cellpadding="5" cellspacing="0" width="100%">         <tbody>         <tr>           <td class="contentTableTitle">Part 2 of 2</td>          </tr>          <tr>           <td class="contentTableTitle"><strong>XARELTO&nbsp; </strong> <br /> <span class="contentTableReg">rivaroxaban tablet, film coated</span></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt"></tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">ORAL</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>rivaroxaban</strong> (UNII: 9NDF7JZ4M3) (rivaroxaban - UNII:9NDF7JZ4M3)</td>          <td class="formItem">rivaroxaban</td>          <td class="formItem">20&nbsp;mg</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>cellulose, microcrystalline</strong> (UNII: OP1R32D61U)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>croscarmellose sodium</strong> (UNII: M28OL1HH48)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>hypromelloses</strong> (UNII: 3NXW29V3WO)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>lactose monohydrate</strong> (UNII: EWQ57Q8I5X)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>magnesium stearate</strong> (UNII: 70097M6I30)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>sodium lauryl sulfate</strong> (UNII: 368GB5141J)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>polyethylene glycol 3350</strong> (UNII: G2M7P15E5P)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>titanium dioxide</strong> (UNII: 15FIX9V2JP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>ferric oxide red</strong> (UNII: 1K09F3G675)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>polyvinyl alcohol</strong> (UNII: 532B59J990)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>talc</strong> (UNII: 7SEV7J4R1U)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Characteristics</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Color</td>          <td class="formItem">RED (dark red)</td>          <td class="formLabel">Score</td>          <td class="formItem">no score</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Shape</td>          <td class="formItem">TRIANGLE</td>          <td class="formLabel">Size</td>          <td class="formItem">7mm</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Flavor</td>          <td class="formItem"></td>          <td class="formLabel">Imprint Code</td>          <td class="formItem">20;Xa</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Contains</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem"></td>          <td class="formItem">9 in 1 BLISTER PACK; Type 1: Convenience Kit of Co-Package</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA022406</td>          <td class="formItem">09/16/2014</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA022406</td>          <td class="formItem">09/16/2014</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Labeler -&nbsp;</span>Janssen Pharmaceuticals, Inc. (063137772) </td>      </tr>     </tbody>   </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td>      </tr>      <tr>       <th class="formTitle" scope="col">Name</th>      <th class="formTitle" scope="col">Address</th>      <th class="formTitle" scope="col">ID/FEI</th>      <th class="formTitle" scope="col">Business Operations</th>      </tr>      <tr class="formTableRowAlt">       <td class="formItem">Bayer Pharma AG</td>      <td class="formItem"></td>      <td class="formItem">341081414</td>      <td class="formItem">MANUFACTURE(50458-580, 50458-578, 50458-579, 50458-584)</td>      </tr>     </tbody>   </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td>      </tr>      <tr>       <th class="formTitle" scope="col">Name</th>      <th class="formTitle" scope="col">Address</th>      <th class="formTitle" scope="col">ID/FEI</th>      <th class="formTitle" scope="col">Business Operations</th>      </tr>      <tr class="formTableRowAlt">       <td class="formItem">Janssen Ortho LLC</td>      <td class="formItem"></td>      <td class="formItem">805887986</td>      <td class="formItem">MANUFACTURE(50458-580, 50458-578, 50458-579, 50458-584) , ANALYSIS(50458-580, 50458-578, 50458-579, 50458-584)</td>      </tr>     </tbody>   </table>  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li>                                            </ul>                                        <div class="control-nav">                                            <a class="open-all" href="#">View All Sections</a><a class="close-all" href="#">Close All Sections</a>                                        </div>                                        </div>                                    </div>                        </article>                       <div class="articlefooternav">                       <h2>Find additional resources</h2> <strong>(also available in the <a href="#leftmenu">left menu</a>)</strong>                                              <h3>Safety</h3>                       <p>                                                            <a href="#boxedwarning" target="_blank">Boxed Warnings</a>,                                                                                                                     <a href="/www.accessdata.fda.gov/scripts/medwatch/ " target="_blank">Report Adverse Events</a>,                                 <a href="http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety Recalls</a>,                                 <a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22rivaroxaban%22+%29" target="_blank">Presence in Breast Milk</a>                                                   </p>                       <h3>Related Resources</h3>                       <p>                                                                                          <a href="http://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&query=rivaroxaban" target="_blank">Medline Plus</a>,                                                       <a href="/www.clinicaltrials.gov/ct/search?submit=Search&term=rivaroxaban" target="_blank">Clinical Trials</a>,                            <a href="#pubmed-menu" id="pubmed-bottom">PubMed</a>,                            <a href="http://www.drugbank.ca/search?utf8=%E2%9C%93&query=rivaroxaban&search_type=drugs&button=" target="_blank">Biochemical Data Summary</a>                                                  </p>                       <h3>More Info on this Drug</h3>                       <p>                            <a href="#modal-label-archives" class="modal-open">View Label Archives</a>,                             <a href="#modal-rx-norm" class="modal-open">RxNorm</a>,                             <a href="#modal-label-rss" class="modal-open">Get Label RSS Feed</a>                        </p>                    </div>                </div>                                <div class="divider"></div>            </div>        </div>        <!-- Label Archives Modal --><div class="mfp-hide modal" id="modal-label-archives">        <div class="modal-wrapper">        <header><h2>View Label Archives for this drug</h2></header>        <div class="top">        							    	    																																			    																	    	    	                             		       	                                                                                                           <h3 class="long-title">XARELTO- rivaroxaban tablet, film coated <br>XARELTO- rivaroxaban   <br></h3>            <h4>Number of versions: 14</h4>        </div>        <div class="modal-content">                <table class="modal">                    <tbody><tr>                        <th>Published Date</th>                        <th>Version</th>                               <th>Files</th>                    </tr>                                        <tr>                        <td>Jan 21, 2015</td>                        <td>							                                16                             							(current)                         </td>                              <td>                        								                                                            <a class="view-link" href="dailymed/drugInfo.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610" title="View this Label">view</a><span class="sep"> | </span>                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=163314">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Dec 12, 2014</td>                        <td>							                                15                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=159660">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Sep 23, 2014</td>                        <td>							                                14                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=151665">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Sep 15, 2014</td>                        <td>							                                13                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=151066">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Mar 12, 2014</td>                        <td>							                                11                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=133419">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Feb 27, 2014</td>                        <td>							                                10                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=132351">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Jan 17, 2014</td>                        <td>							                                9                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=129360">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Jan 9, 2014</td>                        <td>							                                8                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=128793">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Aug 16, 2013</td>                        <td>							                                7                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=117071">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Mar 7, 2013</td>                        <td>							                                6                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=101988">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Nov 20, 2012</td>                        <td>							                                5                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=93991">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Dec 14, 2011</td>                        <td>							                                4                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=69257">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Nov 21, 2011</td>                        <td>							                                2                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=67609">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Jul 12, 2011</td>                        <td>							                                1                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=58646">download</a>                                                    </td>                    </tr>                                    </tbody></table>        </div>        </div></div>        <!-- RxNorm Modal --><div class="mfp-hide modal" id="modal-rx-norm">        <div class="modal-wrapper">        <header><h2>RxNorm</h2></header>        <div class="top">            <h3 class="long-title">XARELTO- rivaroxaban tablet, film coated <br>XARELTO- rivaroxaban   <br></h3>        </div>        <div class="modal-content">        							    	    																																			    																	    	    	                             		       	                                                                                               			                            <table class="modal">                    <tbody><tr>                        <th></th>                        <th>RxCUI</th>                               <th>RxNorm NAME</th>                        <th>RxTTY</th>                    </tr>                                                                                                    <tr class="psn-rxtty">                                                                    <td>1</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1114198">1114198</a></td>                              <td>rivaroxaban 10 MG Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>2</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1114198">1114198</a></td>                              <td>rivaroxaban 10 MG Oral Tablet</td>                        <td>SCD</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>3</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1114202">1114202</a></td>                              <td>Xarelto 10 MG Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>4</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1114202">1114202</a></td>                              <td>rivaroxaban 10 MG Oral Tablet [Xarelto]</td>                        <td>SBD</td>                    </tr>                   	                                                    <tr>                                                                    <td>5</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1114202">1114202</a></td>                              <td>Xarelto 10 MG Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>6</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1232082">1232082</a></td>                              <td>rivaroxaban 15 MG Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>7</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1232082">1232082</a></td>                              <td>rivaroxaban 15 MG Oral Tablet</td>                        <td>SCD</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>8</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1232084">1232084</a></td>                              <td>Xarelto 15 MG Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>9</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1232084">1232084</a></td>                              <td>rivaroxaban 15 MG Oral Tablet [Xarelto]</td>                        <td>SBD</td>                    </tr>                   	                                                    <tr>                                                                    <td>10</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1232084">1232084</a></td>                              <td>Xarelto 15 MG Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>11</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1232086">1232086</a></td>                              <td>rivaroxaban 20 MG Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>12</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1232086">1232086</a></td>                              <td>rivaroxaban 20 MG Oral Tablet</td>                        <td>SCD</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>13</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1232088">1232088</a></td>                              <td>Xarelto 20 MG Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>14</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1232088">1232088</a></td>                              <td>rivaroxaban 20 MG Oral Tablet [Xarelto]</td>                        <td>SBD</td>                    </tr>                   	                                                    <tr>                                                                    <td>15</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1232088">1232088</a></td>                              <td>Xarelto 20 MG Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>16</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1549682">1549682</a></td>                              <td>rivaroxaban 30-Day Starter Pack (42-15 MG Oral Tablets & 9-20 MG Oral Tablets)</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>17</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1549682">1549682</a></td>                              <td>{42 (rivaroxaban 15 MG Oral Tablet) / 9 (rivaroxaban 20 MG Oral Tablet) } Pack</td>                        <td>GPCK</td>                    </tr>                   	                                                    <tr>                                                                    <td>18</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1549682">1549682</a></td>                              <td>rivaroxaban 30-Day Starter Pack (42-15 MG Oral Tablets & 9-20 MG Oral Tablets)</td>                        <td>SY</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>19</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1549683">1549683</a></td>                              <td>Xarelto Starter Pack, 30-Day</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>20</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1549683">1549683</a></td>                              <td>{42 (rivaroxaban 15 MG Oral Tablet [Xarelto]) / 9 (rivaroxaban 20 MG Oral Tablet [Xarelto]) } Pack [Xarelto Kit]</td>                        <td>BPCK</td>                    </tr>                   	                                                    <tr>                                                                    <td>21</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=1549683">1549683</a></td>                              <td>Xarelto 30-Day Starter Pack Kit</td>                        <td>SY</td>                    </tr>                   	                </tbody></table>                    </div>        </div></div><!-- Label RSS Modal --><div class="mfp-hide modal" id="modal-label-rss">        <header><h2>Get Label RSS Feed for this Drug</h2></header>        <div class="top">            <h3 class="long-title">XARELTO- rivaroxaban tablet, film coated <br>XARELTO- rivaroxaban   <br></h3>        </div>        <div class="modal-content">            <h4>To receive this label RSS feed</h4>            <p>Copy the URL below and paste it into your RSS Reader application.			<p><a href="https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610" target="_blank">https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610</a></p>            <h4>To receive all DailyMed Updates for the last seven days</h4>            <p>Copy the URL below and paste it into your RSS Reader application.</p>            <p><a href="https://dailymed.nlm.nih.gov/dailymed/rss.cfm" target="_blank">https://dailymed.nlm.nih.gov/dailymed/rss.cfm</a></p>            <h4>What will I get with the DailyMed RSS feed?</h4>            <p>DailyMed will deliver notification of updates and additions to Drug Label information currently shown on this site through its RSS feed.</p>            <p>DailyMed will deliver this notification to your desktop, Web browser, or e-mail depending on the RSS Reader you select to use. To view updated drug label links, paste the RSS feed address (URL) shown below into a RSS reader, or use a browser which supports RSS feeds, such as Safari for Mac OS X.</p>            <h4>How to discontinue the RSS feed</h4>            <p>If you no longer wish to have this DailyMed RSS service, simply delete the copied URL from your RSS Reader.</p>            <a href="dailymed/rss-updates.cfm" class="rss-icon"></a> <a href="dailymed/rss-updates.cfm">More about getting RSS News & Updates from DailyMed</a>        </div></div>    <!-- this div is only for jQuery --><div class="search-results">    <div class="filter-drop"></div></div><div class="webview"></div><div class="hide-on-mobile"></div>    <div class="mobilenav no-js">        <ul>            <li><a href="dailymed/index.cfm">Home</a></li>            <li>News                <ul>                    <li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>                    <li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>                </ul>            </li>            <li>Search                <ul>                    <li><a href="dailymed/advanced-search.cfm">Advanced Search</a></li>                    	                    <li><a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>	                    <li><a href="dailymed/archives/index.cfm">Labels Archives</a></li>                                                            <li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID Tool</a></li>                </ul>            </li>                            <li><a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a></li>                <li>NLM SPL Resources                    <ul>                        <li><a href="dailymed/spl-resources.cfm">Download Data</a>                            <ul>                                <li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>                                <li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Index Files</a></li>                                <li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>                            </ul>                        </li>                        <li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>                        <li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>                    </ul>                </li>                <li>Application Development Support                    <ul>                        <li><a href="dailymed/app-support.cfm">Resources</a>                            <ul>                                <li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>                                <li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>                            </ul>                        </li>                    </ul>                </li>                        <li><a href="dailymed/help.cfm">Help</a></li>                                </ul>    </div>    <footer class="mainFooter">        <div class="container">            <div class="three columns">             <div class="nihnlmlogoprint"><img src="/dailymed/images/nihnlmlogoprint.png" alt="NIH NLM Logo"></div>                <a href="/www.nlm.nih.gov/" class="logo" title="National Library of Medicine | National Institutes of Health"><img src="/dailymed/images/footer-logo.png" width="109" height="37" alt="National Library of Medicine | National Institutes of Health" title="National Library of Medicine | National Institutes of Health" /></a>            </div>                        <div id="share" class="thirteen columns">                <div class="footer-links">                    <ul class="primary">                        <li><a href="dailymed/about-dailymed.cfm" title="About DailyMed">About DailyMed</a><span>|</span></li>                        <li><a href="dailymed/contact-us.cfm" title="Contact Us">Contact Us</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/copyright.html" title="Copyright" target="_blank" rel="bookmark">Copyright</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/privacy.html" title="Privacy" target="_blank" rel="bookmark">Privacy</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/accessibility.html" title="Web Accessibility" target="_blank" rel="bookmark">Web Accessibility</a><span>|</span></li>                        <li><a href="/www.hon.ch/HONcode/Conduct.html?HONConduct393117" target="_blank" title="HONCode Certification">DailyMed is HONCode Certified</a></li>                    </ul>                    <ul class="secondary">                        <li><a href="http://www.nih.gov/" title="National Institutes of Health" target="_blank" rel="bookmark">National Institutes of Health</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/" title="U.S. National Library of Medicine" target="_blank" rel="bookmark">U.S. National Library of Medicine</a><span>|</span></li>                        <li><a href="http://www.hhs.gov/" title="Health &amp; Human Services" target="_blank" rel="bookmark">Health &amp; Human Services</a></li>                    </ul>                    <ul class="secondary mobile">                        <li><a href="http://www.nih.gov/" title="National Institutes of Health" target="_blank" rel="bookmark">NIH</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/" title="U.S. National Library of Medicine" target="_blank" rel="bookmark">NLM</a><span>|</span></li>                        <li><a href="http://www.hhs.gov/" title="Health &amp; Human Services" target="_blank" rel="bookmark">Health &amp; Human Services</a></li>                    </ul>                    <div class="social">                        Share                         <!-- AddThis Button BEGIN -->                        <noscript>: JavaScript needed for Sharing tools</noscript>                        <div class="addthis_toolbox addthis_default_style addthis_16x16_style">							                                                            	                                	            			        	                                                            <a class="email-share" href="mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AXARELTO%2D%20Rivaroxaban%20Tablet%2C%20Film%20Coated%20XARELTO%2D%20Rivaroxaban%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3D10db92f9%2D2300%2D4a80%2D836b%2D673e1ae91610%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E" title="Share by Email"></a>                            <a class="addthis_button_facebook"></a>                            <a class="addthis_button_twitter"></a>                            <a class="at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share" href="/www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed" target="_blank" style="width: 16px; height: 16px">                                <span style="left: -9999px; position: absolute;">Bookmark &amp; Share</span>                                <img style="width:17px; margin-top: -2px;" src="/dailymed/images/addthis-image.jpg" alt="Bookmark &amp; Share">                            </a>                        </div>                                                <!-- AddThis Button END -->                    </div>                                    </div>            </div>        </div>                <div class="divider"></div>    </footer>    <div class="divider"></div></div><div class="to-top"></div><!-- this div is only for jQuery --><div class="search-results">    <div class="filter-drop"></div></div><div class="webview"></div> <div class="hide-on-mobile"></div><!-- START OF SmartSource Data Collector TAG --><!-- Copyright (c) 1996-2012 Webtrends Inc.  All rights reserved. --><!-- Version: 9.4.0 --><!-- Tag Builder Version: 3.3  --><!-- Created: 1/25/2012 11:57:33 PM --><script type="text/javascript" src="/dailymed/scripts/webtrends.min.js"></script><!-- ----------------------------------------------------------------------------------- --><!-- Warning: The two script blocks below must remain inline. Moving them to an external --><!-- JavaScript include file can cause serious problems with cross-domain tracking.      --><!-- ----------------------------------------------------------------------------------- --><script type="text/javascript">//<![CDATA[var _tag=new WebTrends();_tag.dcsGetId();//]]></script><script type="text/javascript">//<![CDATA[_tag.dcsCustom=function(){// Add custom parameters here.//_tag.DCSext.param_name=param_value;_tag.DCSext.dcsid=_tag.dcsid}_tag.trackAllEvents=true;_tag.dcsCollect();//]]></script><noscript><div><img alt="DCSIMG" id="DCSIMG" width="1" height="1" src="//wtsdc.nlm.nih.gov/dcsm7fmt310000o265ioub7ib_2b7v/njs.gif?dcsuri=/nojavascript&amp;WT.js=No&amp;WT.tv=9.4.0&amp;dcssip=dailymed.nlm.nih.gov&amp;dcsid=dcsm7fmt310000o265ioub7ib_2b7v"/></div></noscript><!-- END OF SmartSource Data Collector TAG --><script type="text/javascript">    setTimeout(function(){var a=document.createElement("script");    var b=document.getElementsByTagName("script")[0];    a.src=document.location.protocol+"//dnn506yrbagrg.cloudfront.net/pages/scripts/0027/2050.js?"+Math.floor(new Date().getTime()/3600000);    a.async=true;a.type="text/javascript";b.parentNode.insertBefore(a,b)}, 1);</script><script type="text/javascript">    function getParameterByName(name) {        name = name.replace(/[\[]/, "\\[").replace(/[\]]/, "\\]");        var regex = new RegExp("[\\?&]" + name + "=([^&#]*)"),            results = regex.exec(location.search);        return results === null ? "" : decodeURIComponent(results[1].replace(/\+/g, " "));    }    /* Tracking label type on search pages */    function CE_READY() {        if(!getParameterByName('labeltype')){           CE2.set(1, "No Label Type");        }        else{            var labeltype = getParameterByName('labeltype');            if(labeltype == 'all'){                CE2.set(1, "All");            }            else if(labeltype == 'human'){                CE2.set(1, "Human");            }            else if(labeltype == 'animal'){                CE2.set(1, "Animal");            }            else{                CE2.set(1, "Unknown");            }        }    }</script>                    <!-- DAP Universal Analytics -->    <script language="javascript" id="_fed_an_ua_tag" src="/dailymed/scripts/Universal-Federated-Analytics-Min.2.0.js?agency=HHS&subagency=NIH&enhlink=true&dclink=true"></script>    <script src="/dailymed/scripts/preview-text.min.js"></script></body></html>    